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DISSERTATION ABSTRACT 
 
Ashley Noël Lamm 
 
Doctor of Philosophy 
 
Department of Chemistry 
 
September 2012 
 
Title: Fundamental Chemistry of 1,2-Dihyro-1,2-Azaborines 
 
 
Benzene and its derivatives are ubiquitous in chemical research, with applications 
ranging from material science to biomedical research. 1,2-Dihydro-1,2-azaborine is a 
benzene mimic which replaces a CC bond with a BN bond.  The basic science and 
applications of 1,2-azaborines is relatively underdeveloped.  This thesis expands the 
fundamental understanding of 1,2-azaborines.  Chapter I describes the air and moisture 
stability of 1,2-azaborines.  Chapter II introduces nucleophilic aromatic substitution 
reactions that the parent 1,2-dihydro-1,2-azaborine will undergo.  Chapter III discusses a 
trimerization reaction that 1,2-dihydro-1,2-azaborine can perform, which is unique from 
benzene.  Chapter IV examines a novel protection free synthesis of 1,2-azaborines, which 
provides a more direct route to functionalized 1,2-azaborines.    Chapter V discusses the 
novel deprotection of the N-silicon using an amide, giving one of the first 1,2-azaborine 
pharmaceutical mimics. Finally, chapter VI summarized miscellaneous contributions I 
have made to the basic science of 1,2-azaborines.    
 This dissertation includes previously published and unpublished co-authored 
material.   
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CHAPTER I 
 
STRUCTURE REACTIVITY RELATIONSHIP OF 1,2-DIHYDRO-1,2-AZABORINES 
 
1.1. General Overview 
 This chapter describes the synthesis and stability of 1,2-dihydro-1,2-
azborines to oxygen and water. 1,2-Azaborines are water stable and their ability to 
withstand oxidative degradation is dependent on both the boron and the C(3) substituents.   
This chapter contains unpublished and published material: Lamm, A. N.; Liu, S.-Y. Mol. 
Bio. Syt 2009, 5, 1303-1305. All of the lab work was performed by me.  Professor Shih-
Yuan Liu provided editorial assistance and scientific guidance in this chapter.   
 
1.2. Introduction  
Benzene and its derivatives (arenes) play important roles in fundamental biomedical 
research and drug discovery. For instance, many small molecule blockbuster 
pharmaceuticals contain the arene structural motif. Three arene-based amino acids (i.e., 
tryptophan, phenylalanine, and tyrosine) serve as the molecular building blocks of life. 
Furthermore, the interactions of arenes with cations1 and other arenes2 have been shown 
to be vital in biological systems. 1,2-Dihydro-1,2-azaborines (abbreviated as 1,2-
azaborines, Figure 1.1) are a class of boron-containing heterocycles that are isoelectronic 
and isostructural with arenes.3 The broad utility of arenes4 combined with the unique 
elemental features of boron,5 and the potential of expanding the diversity of arene 
structures through CC/BN isosterism6 make 1,2-azaborines attractive targets for 
investigation.  
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C
C
B
N
Isostructural
Isoelectronic
arene1,2-azaborine  
Figure 1.1. Structural similarity between arenes and 1,2-azaborines 
 
Our research group has begun to study monocyclic 1,2-azaborines as arene 
mimics in materials and biomedical research. To this end, we have developed a general 
method for the synthesis of B-substituted 1,2-azaborines7 and shown through X-ray 
structural studies that 1,2-azaborines possess delocalized structures consistent with 
aromaticity.8 Recently, we prepared the parent compound of the family of 1,2- 
azaborines.9 However, in order to unleash the full potential of 1,2-azaborines in 
biomedical applications, the stability of these BN heterocycles need to be studied under 
conditions in which most biological systems operate, i.e., in air and water.   
In this communication, we report the air and moisture stability of 1,2-azaborines 
as a function of the boron and C(3) substituents. We demonstrate that 1,2-azaborines are 
in general compatible with water and that their stabilities toward air depend on the ring 
substituents.  
 
1.3. Synthesis and Stability of Reference Compounds 
We selected the tert-butyl group as the N-substituent for this initial structure–
activity relationship study because of the availability of the heterocyclic precursor 1 
(Scheme 1.1). We previously reported the synthesis of 1 via ring closing metathesis.8 
Dehydrogenation of 1 furnished the aromatic intermediate 2. Subsequent electrophilic 
  
 
3 
aromatic substitution of 2 with elemental bromine produced the C(3)-brominated 1,2-
azaborine precursor 3.10  
 
Scheme 1.1. Synthesis of 1,2-azaborine precursors 
 
 
We then prepared a set of B-substituted 1,2-azaborines via nucleophilic 
displacement of the B–Cl bond in 2 and 3.7 As can be seen from Table 1.1, alkyl- (entries 
1, and 6), aryl- (entries 2 and 7), H- (entries 3 and 8), alkynyl- (entries 4 and 9), and 
heteroatom-containing (entries 5  and 10) groups can be readily introduced at boron to 
investigate their impact on the air and moisture stability of the resulting 1,2-azaborine 
structures. To provide an additional functional group at the C(3) position other than H 
and Br we synthesized compound 6a by treating 1,2-azaborine 4a with N-
chlorosuccinimide (NCS) (Scheme 1.2).  
The stability of substituted 1,2-azaborines toward oxygen was determined by the 
following standardized procedure: a 0.1 M solution of 1,2-azaborine in benzene-d6 was 
exposed to 2.5 mL of oxygen gas in a sealed J. Young NMR tube, and the reaction 
progress was monitored over time by 1H NMR at 50 ºC. As can be seen from Figure 1.2 
and Table 1.2 (entries 1–6), the stability of 1,2-azaborines (C(3) substitutent X = H) 
toward oxygen is dependent on the boron substituent. While B-nBu substituted 1,2-
azaborine 4a (Table 1.2, entry 1) decomposes readily (only 46% remaining starting 
material after 4h), the B-alkynyl derivative 4d (Table 1.2, entry 4) is relatively stable 
  
 
4 
toward oxygen (92% starting material remaining). 1,2-Azaborines 4b (entry 2), 4c (entry 
3), and 4e (entry 5) display intermediate stability toward oxygen, whereas compound 2 
(entry 5) is almost as stable as heterocycle 4d under our experimental conditions.  
 
Table 1.1. Synthesis of B and C(3)-substituted 1,2-azaborines 
 
 
Scheme 1.2. Electrophilic aromatic substitution of the C(3) carbon of 1,2-azaborine  with 
NCS 
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Table 1.2 (entries 7–12) show similar scenarios for 1,2- azaborines bearing a C(3) 
substituent (X = Br), although the differences are less pronounced. The B-alkynyl-
substituted compound 5d (Table 1.2, entry 10) is very stable toward oxygen (98% 
material remaining after 4h) while the B-nBu derivative 5a (Table 1.2, entry 7) is the 
least stable among the C(3)- brominated series (60% material remaining). An effect of 
C(3) substitution is apparent from Table 1.2. With the exception of B-Cl substituted 
derivative, a significant enhancement in stability toward oxygen is observed when the 
C(3) position is substituted with Br compared to H (Table 1.2, entries 1–6 vs. 7–12). The 
replacement of Br with Cl at the C(3) position did not impact the rate of decomposition 
(entry 7 vs. 13).  
 
Table 1.2. Stability of 1,2-azaborines towards oxygen 
 
Unfortunately, we were unable to identify the structures of the decomposition 
products. Given that oxygen is an electrophilic species, we speculate that the 
decomposition is initiated by an attack of the oxygen molecule at the delocalized π 
electrons of 1,2-azaborines.11 This hypothesis is consistent with the observed stability 
  
 
6 
trend for the following compounds: B–nBu (4a, σp = –0.16) < B–Ph (4b, σp = –0.01) < 
B–H (4c, σp = 0) < B–CCPh (4d, σp = +0.16) ~ B–Cl (2, σp = +0.23),12 i.e., the more 
electron withdrawing the boron substituent, the more stable the resulting 1,2-azaborine is 
toward oxygen (Table 1.2, entries 1–5).a Calculations and experiments show that the C(3) 
position is nucleophilic in 1,2-azaborines. 9,10 We envisioned that placement of electron 
withdrawing halide substituents at this position could attenuate its nucleophilicity and 
thus lead to improved stability toward oxygen. With the exception of B-Cl substituted 
1,2-azaborines, our data in Table 1.2 (entries 1–4, and 6 vs. entries 7–10 and 12) is 
consistent with this hypothesis. 
It is worth noting that compound 4a and 5a are the only compounds containing 
benzylic-type protons, which might be susceptible to H atom abstractions. To gain more 
insight into the decomposition pathway, compounds 4f-4h were synthesized and 
subjected the standard oxygen stability conditions.   As can be seen from the 
decomposition of 4f and 4g (Table 1.3, entries 1 and 2) there does not seem to be a 
deuterium isotope effect. Compound 4h (entry 3), the bulkiest ortho-substituted 1,2-
azaborine to date, does not contain any benzylic H atom to abstract but decomposes 
readily (34% starting material).   The data suggests that the degradation does not proceed 
through a H atom abstraction mechanism.  The only 1,2-azaborines with  π-donating 
substituents are compounds 4e and 5e (σp = -.24), which are unusually stable to 
degradation. To further study the stability that π-donating substituents in 1,2-azaborines 
impart on oxygen degradation, compound 4i (entry 4) was synthesized. Once exposed to 
                                                
a However, compound 4e bearing the B-OEt group represents an exception to this trend. 
 
  
 
7 
oxygen 4i (σp = -0.83) decomposes readily (22% starting material). Very little material 
remains after 4 hours but based on the large negative σp (-0.83) it is more than 
anticipated; consistent with the hypothesis that π-donating substituents are more stable 
than σp predicts.   
 
 
Figure 1.2.  Decrease in 1,2-azaborine concentration with time when exposed to oxygen 
as a function of the boron substituent: 0.1 M 1,2-azaborine in benzene-d6 exposed to O2 
gas in a sealed tube monitored at 50 ºC.  Data points are an average of two runs. 
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Table 1.3. Synthesis and oxygen stability of 1,2-azaborines 
 
 We performed a simple Hammett analysis using the observed rate constants kobs 
for 4a–4i and 2. A plot of log (kobs(X)/kobs(H)) against the Hammett substituent parameter 
σp  shows a reasonable linear fit with a sensitivity constant ρ = –3.14 (Fig. 1.3).b The 
negative sign of ρ indicates that the rate determining step of the degradation of 1,2-
azaborines (with O2) is likely due to a positive charge forming in the heterocyclic ring.13 
An absolute value of |ρ| > 1 suggests that the reaction under study is more sensitive to 
substituents than the ionization of para-substituted benzoic acids. However, Fig. 1.3 also 
illustrates that the observed decomposition rate for the strongly π-donating B-OEt (4e)  
and B-NMe2 (4i) substituted 1,2-azaborines are inconsistent with the simple Hammett 
analysis, suggesting an overall more complex scenario with intricate interplay between 
                                                
b σp showed the best linear fit vs. σm. 
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inductive and resonance effects. The factors that contribute to the unexpected reactivity 
of heteroatom-substituted 1,2-azaborines toward oxygen are still unclear.  
 
Figure 1.3.  Hammett plot: log (kx/kH) versus substituent parameter σp.  
 
The stability of 1,2-azaborines toward water was studied as follows: to a 0.17 M 
solution of the 1,2-azaborine in DMSO was added two equivalents of degassed water. 
The reaction was monitored over time by 1H NMR at room temperature. Table 1.4 shows 
that the investigated 1,2-azaborines are generally stable toward water with less than 5% 
degradation after 4 h. The only exceptions are compounds 2 and 3, which hydrolyze 
readily in the presence of water due to the labile B–Cl bond. To push the water stability 
limits further for selected 1,2-azaborines, we determined that compounds 4a, 4c, and 4h 
do not show any decomposition (< 5% by 1H NMR) even in the presence of ten 
equivalents of water at room temperature after 12 h. 
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Table 1.4. Stability of 1,2-azaborine toward water  
 
 
1.4. Conclusion  
In summary, we have synthesized a series of B- and C(3)- substituted 1,2-
azaborines and studied their stability toward oxygen and water. We conclude that 1,2-
azaborines are generally water stable and that their ability to withstand oxidative 
degradation is dependent on both the boron and the C(3) substituents. Electron 
withdrawing groups on both positions enhance 1,2-azaborine’s air stability. Given the 
ubiquity and utility of arenes in biomedical research, our investigations provide initial 
structural guidelines for the development of 1,2-azaborines as arene mimics in 
biologically relevant applications.  
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1.5. Experimental 
General  
All oxygen- and moisture-sensitive manipulations were carried out under an inert 
atmosphere using either standard Schlenk techniques or a glove box. 
THF, Et2O, CH2Cl2, and pentane were purified by passing through a neutral alumina 
column under argon. Cyclohexene was dried over CaH2 and distilled under N2 prior to 
use. d6 dimethyl sulfoxide was refluxed with CaO, filtered with molecular sieves and 
dried over CaH2 and  vacuum distilled prior to use. 
Potassium hydride (Strem) was washed with pentane three times and pumped dry 
under vacuum prior to use. N-allyl-N-tert-butylamine was prepared according to an 
adapted procedure.14 All other chemicals and solvents were purchased (Aldrich or Strem) 
and used as received. 
Preparative TLC (1000 µm thickness) plates were purchased from Silicycle and 
heated to 120° C for 18 h in an oven before being brought into the glove box. 
11B NMR spectra were recorded on a Varian Unity/Inova 600 spectrometer at 
ambient temperature. 1H NMR spectra were recorded on a Varian Unity/Inova 300 or 
Varian Unity/Inova 500 spectrometer. 13C NMR spectra were recorded on a Varian 
Unity/Inova 300 or Varian Unity/Inova 500 spectrometer. All chemical shifts are 
externally referenced: 11B NMR to BF3•Et2O (δ 0). 
IR spectra were recorded on a Nicolet Magna 550 FT-IR instrument with OMNIC 
software. 
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Synthesis of BN Heterocycles 2 and 3 (Scheme 1.1) 
Compound 2: In a glove box, a 250 mL Schlenk flask containing a stir bar was 
charged with 18  (7.62 g, 44.5 mmol), Pd/C (0.994 g, 8.89 mmol), and cyclohexene (175 
mL). The vessel was sealed and heated to 80 °C for 16 h. The cooled reaction mixture 
was filtered and the resulting filtrate was cooled to –78 °C. A solution of 
phenylethynylmagnesium bromide (1.0 M solution in THF; 6.4 mL, 6.4 mmol) was then 
added. The mixture was allowed to warm to room temperature and was concentrated 
under reduced pressure. Vacuum distillation (52-55 °C, 50 mTorr) gave 1,2-azaborine 2 
as a clear, colorless liquid (4.77 g, 63 %). 
1H NMR (500 MHz, CD2Cl2): δ 7.63 (d, 3JHH = 6.9 Hz, 1H) 7.54 (dd, 3JHH = 10.3, 6.1 Hz, 
1H), 6.46 (dd, 3JHH = 9.4, 1.39 Hz, 1H), 6.30 (t, 3JHH = 5.9 Hz, 1H), 1.62 (s, 9H). 13C 
NMR (75 MHz, CD2Cl2): δ 143.9, 135.6, 129 (br), 110.0, 30.7. 11B NMR (192.5 MHz, 
CD2Cl2): δ 33.0. FTIR (thin film) 3076, 3042, 3011, 2979, 1605, 1517, 1441, 1390, 1370, 
1291, 1241, 1201, 1153, 1122, 1012, 742, 716, 680, 668, 628 cm–1. HRMS (EI) calcd for 
C8H13BNCl (M+) 169.08296, found 168.9888. 
 
Compound 3:  Br2 (1.01 g, 6.314 mmol in 5 mL CH2Cl2) was added slowly to a 0 
°C solution of 2 (1.00 g, 5.901 mmol in 15 mL CH2Cl2).  The resulting solution was 
stirred at 0 °C for 10 minutes and at room temperature for 4 hours.  The solvent was 
removed with reduced pressure and dissolved in pentane.  The suspension was then 
passed through an acrodisc and the resulting filtrate was concentrated under reduced 
pressure and purified via vacuum distillation (27-30 °C, 300 mTorr) gave 3 as a clear 
colorless liquid (1.08g, 68%).   
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1H NMR (300 MHz, CD2Cl2): δ 7.88 (d, 3JHH = 7.0 Hz, 1H) 7.63 (d, 3JHH = 7.0 Hz, 1H), 
6.18 (t, 3JHH = 7.0, 1.39 Hz, 1H), 1.71 (s, 9H). 13C NMR (125 MHz, CD2Cl2): δ 145.4, 
135.5, 126 (br), 109.4, 62.5, 30.6. 11B NMR (192.5 MHz, CD2Cl2): δ 32.1. FTIR (thin 
film) 2979, 1602, 1505, 1484, 1436, 1399, 1372, 1345, 1285, 1237, 1192, 1134, 1100, 
1050, 1010, 954, 759, 713, 669, 658 cm–1. HRMS (EI) calcd for C8H12BNBrCl (M+) 
246.99347, found 246.99153. 
 
Compound 4a: In a glove box, a vial was charged with a solution of 2 (0.117g, 
0.687 mmols in 10 mL Et2O) and cooled to –78 °C. BuMgCl (2.0 M in Et2O; 0.344 mL, 
0.687 mmol) was added to this stirring solution, and was allowed to warm to room 
temperature. After stirring for 8 h, approximately 75% of the solvent was removed. The 
crude material was subjected to silica gel chromatography using pentane as eluent, 
yielding 4a (0.102g, 78%) as a clear colorless oil.   
1H NMR (500 MHz, CD2Cl2): δ 7.56 (d, 3JHH = 7.2 Hz, 1H) 7.46 (dd, 3JHH = 6.2, 4.4 Hz, 
1H), 6.77 (d, 3JHH = 9.4 Hz, 1H), 6.16 (t, 3JHH = 5.6 Hz, 1H), 1.65 (s, 9H), 1.59 (m,  6H), 
1.02 (t, 3JHH = 7.3 Hz, 3H). 13C NMR (125 MHz, CD2Cl2): δ 141.0, 134.8, 131 (br), 
108.8, 59.9, 32.0, 30.8, 26.6, 22.6 (br), 14,2. 11B NMR (192.5 MHz, CD2Cl2): δ 39.4. 
FTIR (thin film) 3073, 3003, 2956, 2924, 2870, 2855, 1609, 1518, 1462, 1399, 1369, 
1296, 1240, 1204, 1153, 1144, 1094, 1045, 1009, 739, 692 cm–1. HRMS (EI) calcd for 
C12H22BN (M+) 191.18453, found 191.18377. 
 
Compound 4b: A vial was charged with a solution of 2 (0.250 g, 1.48 mmol in 
10 mL Et2O) and cooled to –78 °C. To this stirring solution phenylmagnesium bromide 
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(3.0 M solution in Et2O; 0.51 mL, 1.53 mmol) was added dropwise. Then the reaction 
was allowed to warm to room temperature and stirred for 10 h. Approximately 75% of 
the solvent was then removed under reduced pressure, and the remaining crude material 
was subjected to silica gel chromatography using pentane/CH2Cl2 as eluent. Pure 4b was 
obtained as a white crystalline solid (0.2572 g, 82%). 
1H NMR (500 MHz, CD2Cl2): δ 7.70 (d, 3JHH = 7.3 Hz, 1H) 7.54 (dd, 3JHH = 6.3, 4.2 Hz, 
1H), 7.42 (d, 3JHH = 6.8 Hz, 1H), 7.34 (t, 3JHH = 7.2 Hz, 2H), 7.28 (t, 3JHH = 7.3 Hz, 1H), 
6.56 (d, 3JHH = 1.3 Hz, 1H), 6.40 (t, 3JHH = 1.7 Hz, 1H), 1.50 (s, 9H). 13C NMR (125 
MHz, CD2Cl2): δ 141.3, 135.7, 133 (br), 131.6, 127.1, 126.1, 110.8, 61.0, 33.1. 11B NMR 
(192.5 MHz, CD2Cl2): δ 36.5. FTIR (thin film) 2971, 1605, 1516, 1447, 1391, 1366, 
1293, 1198, 1112, 969, 749, 702 cm–1. HRMS (EI) calcd for C14H18BN (M+) 211.15323, 
found 211.15280. 
 
Compound 4c: In a glovebox, a round bottom flask was charged with 2 (0.050 g, 
0.30 mmols) and 10 mL Et2O.  The flask was then cooled to -78 °C. Super Hydride (1.0 
M solution in THF, 0.30 mL, 0.30 mmols) was added dropwise to the stirring reaction 
flask. The mixture was allowed to warm to room temperature. After 10 h of stirring the 
mixture was passed through an acrodisc and concentrated under a stream of nitrogen. The 
crude material was subjected to silica gel chromatography using pentane as an eluent to 
afford 4c as a clear colorless liquid (0.033 g, 83%). 
1H NMR (500 MHz, CD2Cl2): δ 7.69 (d, 3JHH = 7.1 Hz, 1H) 7.68 (d, 3JHH = 6.8 Hz, 1H), 
7.61 (d, 3JHH = 6.1 Hz,1H), 6.91 (d, 3JHH = 9.5 Hz, 1H), 6.44 (t, 3JHH = 5.45 Hz, 1H), 5.32 
(q (br), 1JBH = 118 Hz, 1H), 1.61 (s, 9H). 13C NMR (125 MHz, CD2Cl2): 
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δ 141.9, 135.5, 130 (br), 111.5, 58.4, 32.0. 11B NMR (192.5 MHz, CD2Cl2): 
δ 30.7 (d,1JBH = 127 Hz). FTIR (thin film) 2978, 2560, 1606, 1515, 1464, 1397, 1369, 
1295, 1240, 1197, 1143, 1019, 954, 879, 797, 744, 714. HRMS (EI) calcd for C8H14BNO 
(M+) 135.12193 found 135.12164. 
 
Compound 4d: To a stirring solution of 2 (0.250 g, 1.50 mmol in 5 mL Et2O) at 
–78 °C was added phenylethynylmagnesium bromide (1.0 M solution in THF; 1.55 mL, 
1.55 mmol). The solution was allowed to warm to room temperature and stirred for 12 h. 
Approximately 75% of the solvent was removed, and the remaining mixture was passed 
through an acrodisc. This material was then subjected to silica gel chromatography using 
a mixture pentane/CH2Cl2 (9:1) as eluent to afford 4d as a light yellow crystalline solid 
(0.330 g, 93%).  
1H NMR (500 MHz, CD2Cl2): δ 7.68 (d, 3JHH = 7.3 Hz, 1H) 7.72 (d, 3JHH = 6.8 Hz, 1H), 
7.56 (m, 3H), 7.40 (m, 3H), 6.98 (d, 3JHH = 7.2 Hz, 1H), 6.36 (t, 3JHH = 7.2 Hz, 1H), 1.82 
(s, 9H). 13C NMR (125 MHz, CD2Cl2): δ 142.3, 135.6, 133 (br), 131.5, 128.6, 128.4, 
124.5, 110.7, 109.3, 104.4, 60.7, 31.4. 11B NMR (192.5 MHz, CD2Cl2): δ 26.8. FTIR 
(thin film) 2967, 2171, 1598, 1514, 1488, 1440, 1397, 1370, 1294, 1258, 1227, 1198, 
1173, 1160, 1128, 1089, 1070, 1044, 755, 743, 690 cm–1. HRMS (EI) calcd for C16H18BN 
(M+) 235.15323 found 235.15325. 
 
Compound 4e: In a glovebox, a round bottom flask was charged with 
triethylamine (0.12 mL, 0.840 mmols) and 5 mL THF, and EtOH (0.043 mL, 0.840 
mmols). The flask was then cooled to -78 °C. In a separate round bottom flask 2 (0.135 g, 
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0.803 mmols) and 10 mL THF were cooled to -78 °C.  The ethanol solution was slowly 
added to the 1,2-azaborine. The mixture was allowed to warm to room temperature. After 
10 h of stirring the mixture was passed through an acrodisc and concentrated under 
vacuum. The crude material was subjected to silica gel chromatography using pentane as 
and eluent to afford 4e as a yellow liquid (0.103 g, 72%). 
1H NMR (500 MHz, CD2Cl2): δ 7.48 (t, 3JHH = 6.6 Hz, 1H) 7.37 (d, 3JHH = 6.8 Hz, 1H), 
6.25 (d, 3JHH = 11.3 Hz, 1H), 5.86 (t, 3JHH = 5.9 Hz, 1H), 4.10 (q, 3JHH = 6.95 Hz, 2H), 
1.60 (s, 9H) 1.37 (t, 3JHH = 6.9 Hz, 3H). 13C NMR (125 MHz, CD2Cl2): 
δ 144.5, 135.1, 116 (br), 104.2, 60.5, 58.2, 30.4, 17.4. 11B NMR (192.5 MHz, CD2Cl2): 
δ 29.6. FTIR (thin film) 3076, 2973, 2197, 1652, 1635, 1609, 1576, 1538, 1521, 1487, 
1464, 1412, 1363, 1310, 1268, 1204, 1135, 1056, 1005, 832, 803, 769, 732, 708, 693, 
667. HRMS (EI) calcd for C8H14BNO (M+) 179.14815 found 179.14769. 
 
Compound 5a: In a glove box, a vial was charged with a solution of 3 (0.498g, 
2.02 mmols in 20 mL Et2O) and cooled to –78 °C. BuMgCl (2.0 M in Et2O; 1.01 mL, 
2.02 mmol) was added to this stirring solution, and was allowed to warm to room 
temperature. After stirring for 8 h, approximately 75% of the solvent was removed. The 
crude material was subjected to silica gel chromatography using pentane as eluent, 
yielding 5a (0.417g, 77%) as a clear colorless oil. 
1H NMR (500 MHz, CD2Cl2): δ 7.76 (d, 3JHH = 7.2 Hz, 1H) 7.58 (d, 3JHH = 7.2 Hz, 1H), 
6.06 (t, 3JHH = 7.2 Hz, 1H), 1.63 (s, 9H) 1.53 (m,  6H), 1.03 (t, 3JHH = 6.9 Hz, 3H). 13C 
NMR (125 MHz, CD2Cl2): δ 143.7, 135.0, 132 (br), 108.3, 61.2, 32.1, 28.3, 26.7, 22 (br) 
13.8. 11B NMR (192.5 MHz, CD2Cl2): δ 37.7. FTIR (thin film) 3133, 3074, 2958, 2856, 
  
 
17 
1605, 1505, 1464, 1398, 1351, 1285, 1237, 1195, 1161, 1122, 1085, 1063, 1035, 1010, 
950, 921, 888, 752, 725, 698, 672, 592 cm–1. HRMS (EI) calcd for C8H12BNBrCl (M+) 
269.09504, found 269.09397. 
 
Compound 5b: To a stirring solution of 3 (0.137 g, 0.549 mmol in 15 mL Et2O) 
at –78 °C was added phenylmagnesium bromide (3.0 M solution in Et2O; 0.219 mL, 
0.658 mmol). The solution was allowed to warm to room temperature and stirred for 10 
h. Approximately 75% of the solvent was removed, and the remaining mixture was 
passed through an acrodisc. This material was then subjected to silica gel 
chromatography using a mixture pentane/CH2Cl2 as eluent to afford 5b as a white 
crystalline solid (0.146 g, 92%).  
1H NMR (500 MHz, CD2Cl2): δ 7.94 (d, 3JHH = 7.3 Hz, 1H) 7.72 (d, 3JHH = 6.8 Hz, 1H), 
7.34 (m, 5H), 6.28 (t, 3JHH = 7.2 Hz, 1H), 1.47 (s, 9H). 13C NMR (125 MHz, CD2Cl2): 
δ 143.7, 135.7, C3 ipso not observed, 132.2, 127.3, 126.8, 110.4, C ipso not observed, 
62.3, 33.9. 11B NMR (192.5 MHz, CD2Cl2): δ 35.9. FTIR (thin film) 2963, 1605, 1506, 
1428, 1369, 1349, 1260, 1193, 1121, 1013, 755, 703, 692 cm–1. HRMS (EI) calcd for 
C14H17BNBr (M+) 289.06374, found 289.06254. 
 
Compound 5c: In a glovebox, a round bottom flask was charged with 3 (0.288 g, 
1.15 mmols) and 10 mL Et2O.  The flask was then cooled to -78 °C. Super Hydride (1.0 
Mol solution in THF, 1.17 mL, 1.15 mmols) was added dropwise to the stirring reaction 
flask. The mixture was allowed to warm to room temperature. After 10 h of stirring the 
mixture was passed through an acrodisc and concentrated under vacuum. The crude 
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material was subjected to silica gel chromatography using pentane as an eluent to afford 
5c as a clear colorless liquid (0.200 g, 81%). 
1H NMR (500 MHz, CD2Cl2): δ 7.79 (d, 3JHH = 6.9 Hz, 1H) 7.65 (d, 3JHH = 6.9 Hz, 1H), 
6.33 (t, 3JHH = 7.05 Hz, 1H), 5.41 (q (br), 1JBH = 150 Hz, 1H), 1.58 (s, 9H). 13C NMR 
(125 MHz, CD2Cl2): 142.8, 134.7, 129 (br), 111.3, 59.1, 31.8. 11B NMR (192.5 MHz, 
CD2Cl2): δ 31.5 (d,1JBH = 137 Hz). FTIR (thin film) 2977, 2594, 1602, 1501, 1471, 1397, 
1373, 1347, 1286, 1214, 1192, 1038, 1018, 1003, 834, 763, 682, 646, 611. HRMS (EI) 
calcd for C8H14BNO (M+) 213.03244 found 213.02174. 
 
Compound 5d: To a stirring solution of 3 (0.373 g, 1.50 mmol in 5 mL Et2O) at 
–78 °C was added phenylethynylmagnesium bromide (1.0 M solution in THF; 1.55 mL, 
1.55 mmol). The solution was allowed to warm to room temperature and stirred for 12 h. 
Approximately 75% of the solvent was removed, and the remaining mixture was passed 
through an acrodisc. This material was then subjected to silica gel chromatography using 
a mixture pentane/CH2Cl2 (9:1) as eluent to afford 5d as a white crystalline solid (0.349 
g, 74%).  
1H NMR (500 MHz, CD2Cl2): δ 7.91 (d, 3JHH = 7.1 Hz, 1H) 7.68 (d, 3JHH = 7.1 Hz, 1H), 
7.62 (m, 2H), 7.42 (m, 3H), 6.26 (t, 3JHH = 7.2 Hz, 1H), 1.84 (s, 9H). 13C NMR (125 
MHz, CD2Cl2): δ 143.8, 137 (br), 135.1, 131.7, 128.9, 128.6, 124.1, 112.6, 110.0, 93.3, 
61.7, 31.3. 11B NMR (192.5 MHz, CD2Cl2): δ 26.6. FTIR (thin film) 2976, 2181, 1597, 
1558 1503, 1489, 1457, 1437, 1370, 1357, 1194, 1027, 757, 690, 678. HRMS (EI) calcd 
for C16H17BNBr (M+) 313.06374 found 313.06374. 
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Compound 5e: In a glovebox, a round bottom flask was charged with 
triethylamine (0.12 mL, 0.840 mmols) and 5 mL THF, and EtOH (0.043 mL, 0.840 
mmols). The flask was then cooled to -20 °C. In a separate round bottom flask 3 (0.200 g, 
0.803 mmols) and 10 mL THF were cooled to -20 °C.  The azaborine was slowly added 
to the ethanol solution. The mixture was allowed to warm to room temperature. After 10 
h of stirring the mixture was passed through an acrodisc and concentrated under vacuum. 
The crude material was subjected to silica gel chromatography using pentane as and 
eluent to afford 5e as a yellow liquid (0.139 g, 65%). 
1H NMR (500 MHz, CD2Cl2): δ 7.73 (d, 3JHH = 7.2 Hz, 1H) 7.39 (d, 3JHH = 6.8 Hz, 1H), 
7.75 (t, 3JHH = 6.9 Hz, 1H), 4.55 (q, 3JHH = 6.9 Hz, 2H), 1.59 (s, 9H), 1.39 (t, 3JHH = 6.6 
Hz, 3H). 13C NMR (125 MHz, CD2Cl2): δ 147.5, 135.2, 116 (br), 103.9, 62.1, 59.4, 30.4, 
17.9. 11B NMR (192.5 MHz, CD2Cl2): δ 25.4. FTIR (thin film) 2977, 1606, 1504, 1410, 
1378, 1351, 1296, 1233, 1194, 1020, 954, 800, 714, 680. HRMS (EI) calcd for 
C10H17BBrNO (M+) 257.05866 found 257.0009. 
 
Compound 6a: Compound 4a (0.116 g, 0.607 mmols in 5 mL CH2Cl2) was 
added to a solution of N-chlorosuccinimide (0.283 g, 1.80 mmols in 20 mL CH2Cl2).  The 
reaction was stirred for 8 hours at room temperature, which turns a deep purple color.  
Approximately 75% of the solvent was removed at reduced pressure. The crude mixture 
was purified via column chromatography with pentane/ CH2Cl2 (7:1) yielding 6a as a 
yellow liquid (0.075g, 55%). 
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1H NMR (300 MHz, CD2Cl2): δ 7.74 (t, 3JHH = 7.0 Hz, 2H) 6.07 (t, 3JHH = 7.0, 1.39 Hz, 
1H), 1.62 (s, 9H), 1.55 (m, 6H), 0.97 (t, 3JHH = 6.9 Hz, 3H). 13C NMR (125 MHz, 
CD2Cl2): δ 140.9, 132.4, 130 (br), 107.3, 61.9, 32.1, 30.22, 26.7, 20 (br), 14.0. 11B NMR 
(192.5 MHz, CD2Cl2): δ 37.7. FTIR (thin film) 2959, 2926, 1695, 1652, 1607, 1456, 
1436, 1419, 1363, 1336, 1263, 1195, 763, 742 cm–1. HRMS (EI) calcd for C12H21BNCl 
(M+) 225.14556, found 225.14535. 
 
Oxygen Stability Studies (Table 1.2 and Table 1.3) 
General Procedure:  1,2-Azaborine (0.05211 mmols) was weighed into a vial, 
0.5 mL stock solution of 0.006 M hexamethyl benzene (HMB) in C6D6 was added to vial.  
The solution was then transferred to a J Young valve NMR tube and freeze-pump-thawed 
to remove all nitrogen.  2.5 mL pure oxygen was then introduced to the sample, capped 
and vigorously shaken.  Each compound was tested in duplicate.  
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Table 1.5. Compound 4a (Table 1.2, Entry 1): average kobs =52 x 10-6s-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.6. Compound 4b (Table 1.2, entry 2): average kobs =13 x 10-6s-1 
Compound 4b 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 99.2 99.7 
0.05 98.3 99.4 
0.10 97.5 97.5 
0.17 95.9 97.3 
0.25 93.7 96.2 
0.35 91.5 95.5 
0.47 90.1 94.4 
0.60 88.7 93.9 
0.75 86.8 92.7 
0.92 86.8 92.5 
1.10 84.9 91.3 
1.30 84.3 90.8 
1.52 83.7 90.2 
Compound 4a 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 96.0 97.9 
0.05 93.0 92.2 
0.10 89.6 88.8 
0.17 83.3 84.8 
0.25 82.2 81.2 
0.35 80.0 84.8 
0.47 78.4 75.4 
0.60 76.9 72.0 
0.75 76.4 68.8 
0.92 75.9 66.0 
1.10 74.1 62.9 
1.30 70.6 59.7 
1.52 69.0 56.9 
1.75 66.3 54.0 
2.00 63.8 50.5 
2.27 61.2 49.7 
2.55 58.8 48.7 
2.85 55.3 47.7 
3.17 53.3 47.3 
3.50 50.6 45.5 
3.85 47.6 44.8 
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1.75 83.1 89.9 
2.00 83.1 89.3 
2.27 82.5 88.1 
2.55 82.5 87.5 
2.85 81.9 87.3 
3.17 81.9 86.2 
3.50 81.4 86.0 
3.85 80.8 84.8 
 
 
Table 1.7. Compound 4c (Table 1.2, entry 3):  average kobs =9 x 10-6s-1 
 
Compound 4c 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 98.5 98.2 
0.05 98.5 98.2 
0.10 97.7 96.4 
0.17 97.0 96.4 
0.25 96.3 94.7 
0.35 95.6 94.7 
0.47 95.6 91.5 
0.60 94.2 91.5 
0.75 94.2 91.5 
0.92 92.9 90.0 
1.10 92.9 90.0 
1.30 91.5 90.0 
1.52 91.5 90.0 
1.75 90.9 90.0 
2.00 90.3 88.5 
2.27 89.7 88.5 
2.55 89.0 88.5 
2.85 88.4 87.1 
3.17 88.4 87.1 
3.50 87.2 85.7 
3.85 87.2 85.7 
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Table 1.8. Compound 4d (Table 1.2, entry 4): average kobs =5 x 10-6s-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.9. Compound 2 (Table 1.2, entry 5): average kobs =5 x 10-6s-1 
 
Compound 2 
Time (h) 
% SM 
remaining 
Trial 1 
% SM 
remaining 
Trial 2 
0 100.0 100.0 
0.02 99.3 99.7 
0.05 97.9 99.7 
0.10 96.5 99.4 
0.17 95.8 99.1 
0.25 95.1 98.5 
0.35 94.5 98.5 
0.47 94.5 97.7 
0.60 93.8 97.4 
0.75 93.8 97.4 
0.92 93.2 96.8 
1.10 93.2 96.8 
1.30 93.2 96.6 
Compound 4d 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 100.0 99.2 
0.05 100.0 99.2 
0.10 100.0 98.4 
0.17 100.0 98.4 
0.25 100.0 97.7 
0.35 98.7 96.9 
0.47 98.7 96.2 
0.60 98.7 96.2 
0.75 98.7 95.5 
0.92 98.7 95.5 
1.10 98.7 95.5 
1.30 97.4 94.8 
1.52 97.4 94.8 
1.75 97.4 94.1 
2.00 96.2 94.1 
2.27 96.2 93.4 
2.55 96.2 93.4 
2.85 95.0 92.7 
3.17 95.0 92.0 
3.50 95.0 91.4 
3.85 93.8 90.7 
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1.52 92.6 96.3 
1.75 92.6 96.0 
2.00 92.6 96.0 
2.27 92.6 95.7 
2.55 91.9 95.7 
2.85 91.9 94.9 
3.17 91.9 93.6 
3.50 91.3 91.6 
3.85 91.3 91.1 
 
 
 
Table 1.10. Compound 4e (Table 1.2, entry 6): average kobs = 11 x 10-6s-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound 4e 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 99.2 100.0 
0.05 99.2 100.0 
0.10 99.2 99.2 
0.17 99.2 99.2 
0.25 99.2 98.5 
0.35 98.3 98.5 
0.47 97.5 98.5 
0.60 96.7 98.5 
0.75 95.2 98.5 
0.92 94.4 97.0 
1.10 93.0 97.0 
1.30 92.2 96.2 
1.52 91.5 95.5 
1.75 90.2 94.8 
2.00 89.5 94.1 
2.27 87.5 93.4 
2.55 87.5 92.8 
2.85 86.9 91.4 
3.17 86.2 90.1 
3.50 85.6 88.9 
3.85 85.0 87.7 
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Table 1.11. Compound 5a (Table 1.2, entry 7) 
 
Compound 5a 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 99.4 99.5 
0.05 97.1 97.9 
0.10 96.0 96.4 
0.17 95.0 94.0 
0.25 93.4 92.1 
0.35 91.9 90.8 
0.47 90.4 89.5 
0.60 88.5 86.6 
0.75 86.3 83.5 
0.92 84.2 82.4 
1.10 82.1 81.3 
1.30 80.2 79.9 
1.52 77.6 77.9 
1.75 75.6 74.5 
2.00 73.0 71.1 
2.27 71.1 68.2 
2.55 68.8 65.2 
2.85 66.7 63.0 
3.17 64.2 62.3 
3.50 61.6 60.3 
3.85 59.4 59.7 
 
 
Table 1.12. Compound 5b (Table 1.2, entry 8) 
 
Compound 5b 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 99.7 99.7 
0.05 99.5 99.1 
0.10 99.5 99.1 
0.17 99.2 98.8 
0.25 98.9 98.8 
0.35 99.2 98.5 
0.47 98.6 98.2 
0.60 98.6 97.9 
0.75 98.6 97.9 
0.92 98.4 97.9 
1.10 98.4 97.4 
1.30 97.6 97.4 
1.52 97.3 96.5 
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1.75 97.3 96.2 
2.00 96.5 96.0 
2.27 96.0 95.7 
2.55 96.0 95.4 
2.85 94.3 94.9 
3.17 94.3 95.1 
3.50 93.8 94.6 
3.85 93.1 94.6 
 
 
Table 1.13. Compound 5c (Table 1.2, entry 9) 
Compound 5c 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 100.0 100.0 
0.05 100.0 99.4 
0.10 100.0 99.4 
0.17 100.0 99.4 
0.25 100.0 97.7 
0.35 100.0 97.7 
0.47 99.4 96.6 
0.60 98.8 95.5 
0.75 98.2 94.4 
0.92 98.2 93.9 
1.10 98.2 93.9 
1.30 98.2 93.9 
1.52 96.5 93.3 
1.75 95.9 93.3 
2.00 95.3 92.8 
2.27 94.3 92.8 
2.55 93.7 92.3 
2.85 92.7 91.8 
3.17 92.1 91.3 
3.50 91.6 90.8 
3.85 91.1 90.3 
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Table 1.14. Compound 5d (Table 1.2, entry 10) 
 
Compound 5d 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 99.5 99.5 
0.05 99.5 99.5 
0.10 99.5 99.5 
0.17 99.5 99.5 
0.25 99.5 99.2 
0.35 99.5 99.2 
0.47 99.5 99.2 
0.60 99.5 99.2 
0.75 99.5 99.2 
0.92 99.5 99.2 
1.10 99.1 98.9 
1.30 99.1 98.9 
1.52 99.1 98.9 
1.75 99.3 98.9 
2.00 99.1 98.7 
2.27 99.1 98.7 
2.55 98.8 98.7 
2.85 98.8 98.7 
3.17 98.8 98.4 
3.50 98.6 98.4 
3.85 98.4 98.4 
 
Table 1.15. Compound 3 (Table 1.2, entry 11) 
Compound 3 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 98.3 97.8 
0.05 96.7 97.1 
0.10 94.3 96.0 
0.17 92.8 95.4 
0.25 92.0 94.0 
0.35 91.3 93.0 
0.47 90.9 91.8 
0.60 90.6 91.1 
0.75 90.2 90.5 
0.92 90.2 90.5 
1.10 90.2 90.5 
1.30 89.5 89.9 
1.52 89.2 89.9 
1.75 88.2 89.0 
2.00 88.5 88.7 
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2.27 88.2 88.4 
2.55 86.5 88.1 
2.85 85.6 87.8 
3.17 84.6 87.5 
3.50 84.3 87.3 
3.85 84.0 87.0 
 
Table 1.16. Compound 5e (Table 1.2, entry 12) 
 
Compound 5e 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 99.7 99.8 
0.05 99.4 99.8 
0.10 99.4 99.6 
0.17 99.1 99.3 
0.25 99.1 99.3 
0.35 98.8 99.3 
0.47 98.8 99.3 
0.60 98.5 99.1 
0.75 97.9 99.1 
0.92 97.6 99.1 
1.10 97.6 98.9 
1.30 97.4 98.9 
1.52 97.1 98.7 
1.75 97.1 98.7 
2.00 96.2 98.4 
2.27 95.7 97.8 
2.55 94.3 97.4 
2.85 94.9 95.5 
3.17 94.6 94.7 
3.50 94.3 94.3 
3.85 94.3 93.7 
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Table 1.17. Compound 6a (Table 1.2, entry 13) 
Compound 6a 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 95.4 98.1 
0.05 94.5 97.5 
0.10 94.3 95.5 
0.17 92.7 93.3 
0.25 90.6 91.1 
0.35 90.4 90.1 
0.47 89.6 88.1 
0.60 89.2 87.1 
0.75 85.7 85.3 
0.92 84.1 82.8 
1.10 83.5 80.7 
1.30 80.8 79.7 
1.52 79.5 77.2 
1.75 77.6 75.9 
2.00 77.6 74.3 
2.27 72.8 73.1 
2.55 72.1 68.4 
2.85 70.9 65.3 
3.17 69.4 64.2 
3.50 66.7 62.0 
3.85 65.9 60.7 
 
 
Table 1.18. Compound 4f (Table 1.3, entry 1) 
Compound 4f 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 98.6 100.0 
0.05 98.3 100.0 
0.10 95.8 97.1 
0.17 94.4 94.3 
0.25 91.7 91.7 
0.35 88.4 89.2 
0.47 85.3 86.8 
0.60 82.0 84.6 
0.75 77.1 80.5 
0.92 73.1 76.7 
1.10 68.9 73.3 
1.30 63.8 68.8 
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1.52 59.2 64.7 
1.75 55.4 62.3 
2.00 51.8 60.0 
2.27 44.8 50.8 
2.55 40.6 47.1 
2.85 35.9 42.3 
3.17 31.9 38.4 
3.50 28.1 34.4 
3.85 24.3 30.3 
 
Table 1.19. Compound 4g (Table 1.3, entry 2) 
Compound 4g 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 97.6 98.2 
0.05 96.4 97.4 
0.10 95.3 97.0 
0.17 94.6 96.1 
0.25 91.7 94.1 
0.35 88.7 89.2 
0.47 85.3 86.2 
0.60 81.3 82.7 
0.75 77.6 79.2 
0.92 73.2 75.4 
1.10 69.0 71.8 
1.30 64.1 68.1 
1.52 59.7 64.2 
1.75 55.7 60.9 
2.00 51.7 57.4 
2.27 47.3 54.1 
2.55 43.9 50.7 
2.85 40.6 48.1 
3.17 37.0 42.4 
3.50 34.0 38.7 
3.85 31.1 35.0 
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Table 1.20. Compound 4h (Table 1.3, entry 3) 
Compound 4h 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 98.1 97.0 
0.05 97.5 93.1 
0.10 94.8 93.1 
0.17 91.5 91.0 
0.25 88.1 86.2 
0.35 85.2 84.8 
0.47 81.8 82.7 
0.60 78.1 77.1 
0.75 75.1 71.7 
0.92 71.0 69.2 
1.10 66.9 65.1 
1.30 63.0 62.1 
1.52 59.4 56.1 
1.75 55.6 53.1 
2.00 51.8 51.8 
2.27 48.5 47.5 
2.55 44.7 45.8 
2.85 41.1 42.6 
3.17 37.8 41.4 
3.50 34.6 38.2 
3.85 31.5 37.2 
 
 
Table 1.21. Compound 4i (Table 1.3, entry 4) 
Compound 4i 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 89.6 95.3 
0.05 87.4 93.5 
0.10 84.8 88.2 
0.17 82.4 83.5 
0.25 78.9 78.2 
0.35 76.6 74.6 
0.47 74.8 73.8 
0.60 72.1 68.1 
0.75 69.3 63.6 
0.92 66.3 61.1 
1.10 63.5 57.8 
  
 
32 
1.30 58.5 54.9 
1.52 53.8 51.0 
1.75 49.2 47.0 
2.00 44.0 40.7 
2.27 38.7 38.7 
2.55 33.8 31.1 
2.85 32.0 28.2 
3.17 29.9 24.0 
3.50 24.8 21.8 
3.85 22.4 19.7 
 
Water Stability Studies (Table 1.4) 
General Procedure for H2O Studies: Azaborine (0.05211 mmols) was weighed 
into vial, 0.3 mL DMSO, TMS as an internal standard was added.  The solution was then 
transferred to a norell screw cap NMR tube and sealed. Degased D2O (2 µL, 0.208 
mmols) was added and vigorously shaken.  Each compound was tested in duplicate.  
 
Table 1.22. Compound 4a (Table 1.4, entry 1) 
 
Compound 4a 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 100.0 100.0 
0.05 100.0 100.0 
0.10 100.0 100.0 
0.17 100.0 100.0 
0.25 100.0 100.0 
0.35 100.0 100.0 
0.47 100.0 100.0 
0.60 100.0 100.0 
0.75 100.0 99.4 
0.92 100.0 99.4 
1.30 100.0 100.0 
1.70 100.0 100.0 
2.18 100.0 100.0 
2.75 96.2 100.0 
3.48 96.2 99.4 
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Table 1.23. Compound 4b (Table 1.4, entry 2) 
 
Compound 4b 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 97.0 100.0 
0.05 98.8 99.8 
0.10 100.0 100.0 
0.17 100.0 100.0 
0.25 100.0 98.6 
0.35 100.0 98.8 
0.47 100.0 97.8 
0.60 100.0 99.0 
0.75 100.0 99.0 
0.92 100.0 99.2 
1.30 100.0 99.2 
1.70 100.0 99.0 
2.18 100.0 98.2 
2.75 100.0 97.8 
3.48 100.0 97.1 
 
 
Table 1.24. Compound 4c (Table 1.4, entry 3) 
Compound 4c 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 96.5 100.0 
0.05 98.9 99.8 
0.10 96.7 99.6 
0.17 97.4 99.6 
0.25 98.9 99.4 
0.35 100.0 99.2 
0.47 99.8 99.2 
0.60 97.8 99.0 
0.75 96.7 99.0 
0.92 95.6 98.8 
1.30 96.5 98.6 
1.70 98.0 98.6 
2.18 95.6 98.4 
2.75 95.6 98.2 
3.48 95.6 98.2 
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Table 1.25. Compound 4d (Table 1.4, entry 4) 
Compound 4d 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 98.0 99.8 
0.05 97.6 98.9 
0.10 100.0 99.7 
0.17 100.2 98.1 
0.25 96.5 98.7 
0.35 100.0 98.4 
0.47 97.0 98.1 
0.60 97.0 97.4 
0.75 98.1 97.2 
0.92 100.0 98.7 
1.30 99.0 96.8 
1.70 96.2 99.0 
2.18 98.3 96.7 
2.75 98.3 96.7 
3.48 97.0 96.4 
 
 
Table 1.26. Compound 4e (Table 1.4, entry 5) 
 
Compound 4e 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 100.0 99.3 
0.05 99.0 99.2 
0.10 98.3 100.0 
0.17 99.9 99.5 
0.25 99.9 98.4 
0.35 98.6 99.9 
0.47 98.2 99.5 
0.60 97.5 99.0 
0.75 97.4 99.5 
0.92 97.3 98.8 
1.30 97.8 98.1 
1.70 97.8 97.8 
2.18 97.3 97.5 
2.75 97.4 97.5 
3.48 97.4 97.5 
 
 
Compound 2 (Table 1.4, entry 6) reacted rapidly with water to furnish B-OR containing 
1,2-azaborines. 
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Table 1.27. Compound 5a (Table 1.4, entry 7) 
 
Compound 5a 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 99.2 100.0 
0.05 99.5 99.9 
0.10 99.7 99.9 
0.17 98.7 99.9 
0.25 98.8 100.0 
0.35 98.7 99.9 
0.47 99.2 99.8 
0.60 98.2 99.8 
0.75 98.4 99.7 
0.92 97.5 99.6 
1.30 97.5 99.5 
1.70 98.6 99.5 
2.18 98.9 99.6 
2.75 98.9 99.5 
3.48 98.9 99.4 
 
 
 
Table 1.28. Compound 5b (Table 1.4, entry 8) 
 
Compound 5b 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 100.0 99.5 
0.05 100.0 100.9 
0.10 99.5 99.1 
0.17 99.5 99.5 
0.25 99.5 100.0 
0.35 98.9 100.9 
0.47 98.9 100.0 
0.60 98.9 100.0 
0.75 97.4 99.5 
0.92 98.9 99.5 
1.30 95.4 100.0 
1.70 96.4 99.1 
2.18 98.4 99.5 
2.75 95.4 98.6 
3.48 97.9 99.5 
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Table 1.29. Compound 5c (Table 1.4, entry 9) 
 
Compound 5c 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 100.0 96.9 
0.05 100.0 97.4 
0.10 99.4 97.4 
0.17 100.0 97.6 
0.25 100.0 98.9 
0.35 99.0 98.5 
0.47 100.0 100.0 
0.60 100.0 99.3 
0.75 100.0 100.0 
0.92 99.1 100.0 
1.30 99.7 100.0 
1.70 99.6 98.4 
2.18 100.0 98.2 
2.75 97.9 96.6 
3.48 96.4 96.6 
 
Table 1.30. Compound 5d (Table 1.4, entry 10) 
 
Compound 5d 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 97.2 99.0 
0.05 99.0 99.1 
0.10 96.9 98.5 
0.17 96.9 98.3 
0.25 96.9 97.8 
0.35 95.6 98.5 
0.47 95.3 97.6 
0.60 95.9 98.0 
0.75 100.4 97.2 
0.92 100.4 96.9 
1.30 99.1 98.1 
1.70 97.0 96.3 
2.18 99.8 96.1 
2.75 98.9 96.1 
3.48 96.9 96.1 
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Table 1.31. Compound 5e  (Table 1.4, entry 11) 
 
Compound 5e 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 98.2 100.3 
0.05 96.7 99.7 
0.10 96.7 99.4 
0.17 97.4 99.6 
0.25 99.5 99.1 
0.35 99.3 99.7 
0.47 98.4 98.4 
0.60 99.3 98.5 
0.75 98.6 97.8 
0.92 98.9 98.3 
1.30 99.4 98.6 
1.70 96.8 98.0 
2.18 97.0 97.9 
2.75 96.6 97.5 
3.48 96.0 97.8 
 
 
Table 1.32. Compound 6a (Table 1.4, entry 12) 
 
Compound 6a 
Time (h) Trial 1 Trial 2 
0 100.0 100.0 
0.02 99.6 97.0 
0.05 99.6 98.8 
0.10 100.0 100.0 
0.17 99.9 100.0 
0.25 98.9 100.0 
0.35 100.0 100.0 
0.47 99.9 100.0 
0.60 99.4 100.0 
0.75 99.8 99.9 
0.92 99.2 100.0 
1.30 98.5 100.0 
1.70 98.2 100.0 
2.18 97.9 100.0 
2.75 97.8 100.0 
3.48 97.7 100.0 
 
Compound 3 (Table 1.4, entry 13) reacted rapidly with water to furnish B-OR containing 
1,2-azaborines.  
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Procedure with 10 equivalents of H2O and prolonged reaction time: 1,2-
Azaborine (0.052 mmols) was weighed into vial, 0.3 mL DMSO and  degassed D2O (10 
µL, 1.04 mmols) was added.  TMS was used as an internal standard.  The solution was 
then transferred to a norell screw cap NMR tube and sealed.  Compounds 4a, 4c and 4e 
were each tested.  
Table 1.33. Compounds 4a, 4c and 4e 
 
Time (h) 4a 4c 4e 
0 100.0 100.0 100.0 
0.02 100.0 100.0 100.0 
0.05 100.0 100.0 100.0 
0.10 100.0 100.0 100.0 
0.17 100.0 100.0 100.0 
0.25 99.7 100.0 100.0 
0.35 100.0 100.0 100.0 
0.47 99.5 100.0 100.0 
0.60 99.7 100.0 100.0 
0.75 100.0 100.0 100.0 
0.92 100.3 100.0 100.0 
1.10 100.0 100.0 100.0 
1.30 100.0 100.9 98.9 
1.52 100.3 100.0 98.9 
1.75 100.0 100.0 98.9 
2.00 99.5 100.0 98.9 
2.27 100.0 100.0 98.9 
2.55 100.0 100.0 98.9 
2.85 101.4 100.0 100.0 
3.17 101.4 100.9 100.0 
3.50 101.4 100.9 98.9 
3.85 100.3 100.9 98.9 
4.22 100.0 100.9 100.0 
4.60 99.7 99.1 98.9 
5.00 99.5 100.9 98.9 
5.42 99.5 100.0 101.1 
5.85 100.0 100.9 100.0 
6.30 99.5 100.9 100.0 
6.77 99.5 100.0 100.0 
7.25 99.5 100.0 100.0 
7.75 98.9 100.0 100.0 
8.27 99.2 101.9 101.1 
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8.80 98.9 100.0 100.0 
9.35 98.9 100.0 100.0 
9.92 100.3 100.0 98.9 
10.50 100.0 100.9 100.0 
11.10 100.0 101.9 100.0 
11.72 98.7 100.0 101.1 
12.35 98.4 99.1 98.9 
 
 
1.6. Bridge from Chapter I to Chapter II 
Chapter I of this dissertation defined the stability of 1,2-azaborines in water and 
oxygen. Chapters II focuses on  a specific class of reactivity for the parent 1,2-dihydro-
1,2-azaborine.    
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CHAPTER II 
 
NUCLEOPHILIC AROMATIC SUBSTITUTION OF 1,2-DIHYDRO-1,2-AZABORINE 
 
2.1. General Overview 
 This chapter describes the chemistry and reaction mechanisms of nucleophiles 
with 1,2-dihydro-1,2-azaborine.   1,2-Dihydro-1,2-azaborine will undergo nucleophilic 
aromatic substitutions through two distinct mechanisms which is dependent upon the 
nature of the nucleophile.  This chapter contains previously published material: Lamm, 
A. N.; Garner, E. B. III; Dixon, D. A.; Liu, S.-Y.  Angew. Chem. Int. Ed. 2011, 	  50, 8157-
8160.  I preformed all of the lab work, Edward Garner and David Dixon provided 
computational data and Shih-Yuan Liu provided editorial assistance and scientific 
guidance.   
 
2.2. Nucleophilic Aromatic Substitution Introduction 
1,2-Dihydro-1,2-azaborine (1) is a benzene isostere in which a C=C unit of  
benzene is replaced with an isoelectronic B-N unit (Figure 2.1).1,2  As part of our program 
to develop the basic science and applications of 1,2-azaborine heterocycles,3-6 we have 
focused on expanding the scope of synthetically accessible 1,2-azaborines and 
investigating the aromatic character of this family of heterocycles.  
 
 
Figure 2.1. Structural similarity between 1 and benzene 
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Among the four commonly investigated criteria for aromaticity (structure, 
magnetism, energy, and reactivity), we have determined that 1,2-azaborines exhibit 
delocalized bonding,7 have appropriate predicted NICS (-7.27 ppm; nucleus-independent 
chemical shift) values,8 and have an experimentally determined resonance stabilization 
energy of 16.6 kcalmol-1,9 which is consistent with significant aromatic character. With 
regard to the reactivity criterion, Ashe and co-workers have demonstrated that substituted 
1,2-azaborines undergo electrophilic aromatic substitution reactions.10 
The parent 1,2-dihydro-1,2-azaborine (1) has recently been isolated.8 However, 
there have been no reactivity studies performed on 1 to date. We are particularly 
interested in investigating the reactivity of parent 1 for two reasons: 1) to explore the 
fundamental reactivity differences between 1 and benzene, and 2) to develop new 
synthetic methods to access novel 1,2-azaborine derivatives. Herein we report that 1 
readily undergoes nucleophilic aromatic substitution (SNAr) reactions to furnish new 1,2-
azaborine compounds. We also present evidence that the substitution involves an addition 
elimination mechanism consistent with SNAr.  
 
2.3. Nucleophilic Aromatic Substitution Reaction Substrate Scope and Reaction 
Mechanism 
In our initial investigation, we discovered that when 1 was treated with 1 
equivalent of nBuLi in Et2O followed by 4 equivalents of trimethylsilyl chloride, the 
substituted heterocycle 2 was formed in 17% yield (Table 1.1, entry 1). A dramatic 
increase in product yield was observed when 2 equivalents of the nucleophile were used 
  
 
42 
(entry 2). However, an additional increase in the amount of nucleophile used led to a 
substantial decrease in product yield (entry 3). A survey of solvents revealed that Et2O is 
the solvent of choice among etheral and hydrocarbon solvents (entries 4–7 versus entry 
2).We also determined that the optimal temperature for performing this substitution 
reaction is -30 oC; increasing or lowering the reaction temperature resulted in diminished 
yield of 2 (entries 8 and 9 versus entry 2).  
 
Table 2.1. Optimization survey of SNAr reaction 
 
 
The formation of compound 2 is consistent with a nucleophilic aromatic 
substitution in which the hydride on boron is serving as a leaving group. The ease with 
which this substitution occurs (i.e., at -30 oC) is distinct from the reactivity of benzene. 
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The corresponding substitution reaction with benzene typically requires a stronger 
nucleophile (e.g., tBuLi) and much harsher conditions (e.g., reflux in decalin at 165 oC 
for 20 h).11, 12  
Having established the optimal reaction conditions for this new substitution 
reaction, we then sought to expand its substrate scope. As can be seen from Table 2.2, 
oxygen-based nucleophiles are suitable for this reaction, including sodium tert-butyloxide 
(entry 1) and potassium allyloxide (entry 2). Carbon nucleophiles are very effective 
reaction partners. Hindered branched (entry 3), less-hindered linear (entry 4) 
 
Table 2.2. Substrate scope of SNAr reactiona 
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sp3-hybridized organolithium reagents, as well as sp2-hybridized phenyllithium (entry 5) 
furnish the desired substituted products in high yield. Grignard reagents also give the 
corresponding products in moderate to good yield (entries 6 and 7). Noteworthy is the 
synthesis of B-N styrene13 (entry 6) and a novel B-N tolan derivative (entry 7). The scope 
with respect to the electrophile at the nitrogen position includes H, TMS, Me, and Bn 
(entries 4, 8–10).  
Scheme 2.1 illustrates four possible mechanistic scenarios for the observed 
substitution reaction. Mechanism 1 involves a simple displacement of the B-H bond with 
the nucleophile (via intermediate A) with subsequent intermolecular deprotonation by the 
released metal hydride and quenching with the electrophile. In Mechanism 2, 
intermediate A releases H2 in an intramolecular fashion to generate intermediate B, 
which is then quenched with the electrophile. In Mechanisms 3 and 4, 1 equivalent of the 
nucleophile serves first as a base to remove the N-H proton to produce C. Subsequently 
in Mechanism 3, the second equivalent of the nucleophile displaces the B-H bond (via a 
“di-anion”) to produce intermediate B. Alternatively, intermediate C can eliminate a 
hydride to yield a “benzyne”-type 1,2-azaborine14 which then reacts with the nucleophile 
to produce B (Mechanism 4).  
In our mechanistic studies we initially focused on the reaction of 1 with nBuLi 
and TMSCl. To test the role of the NH group, we synthesized the N-benzyl-protected 1,2-
azaborine 3 [Scheme 2.2, Eq. (1)], which was then subjected to the SNAr reaction 
conditions (1 and 2 equivalents of nBuLi and subsequent quenching with TMSCl). 
Interestingly, the substituted product 4 was not formed [Scheme 2.2, Eq. (1)].c This 
                                                
c Similarly, no reaction occurred when 3 was reacted with Na-OtBu as the nucleophile. For more details, 
see Experimental section. 
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experimental observation is inconsistent with Mechanism 1, which should be largely 
independent of the nature of the N substituent. We determined that 2 equivalents of 
nucleophile are necessary to achieve a high yield of 2 [Scheme 2.2, Eq. (2) versus (3)]. 
This result is incompatible with Mechanism 2, which requires only 1 equivalent of the 
nucleophile. Furthermore, when 1 was treated with 2 equivalents of nBuLi, a fine white 
powder precipitated out of solution [Scheme 2.2, Eq. (4)]. IR analysis of this powder 
indicates formation of LiH.15,16 The observation of LiH is again inconsistent with 
Mechanism 2.  
 
Scheme 2.1. Possible reaction pathways of the substitution reaction  
 
Whereas the experiments illustrated in Scheme 2.2, equations (1)–(4) are 
inconsistent with the proposed Mechanisms 1 and 2, they are in agreement with 
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Mechanisms 3 and 4. We were not successful in trapping the “benzyne”-type 1,2-
azaborine intermediate using a number of trapping agents.d Therefore, we used 
calculations to help determine the most likely mechanism for the SNAr reaction. The 
computationally determined energy diagram (Figure 2.2) at the G3MP217 plus COSMO18 
level indicates that the formation of the “benzyne”- type 1,2-azaborine is a high-energy 
process. In contrast, the formation of the “di-anion” intermediate is energetically very 
favorable. Based on all of the available data, we believe that Mechanism 3 is the most 
likely mechanism for the conversion of 1 into 2. 
 
Scheme 2.2. Reactions for mechanism elucidation 
 
                                                
d  Benzyl azide, anthracene, furan, and cyclopentadiene were used as trapping agents. See the Experimental 
for more details. 
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Figure 2.2. Calculated free energies in Et2O (G3 MP2 + COSMO solvation model at the 
B3LYP DZVP2 level of theory, see Experimental) of the proposed intermediates in the 
SNAr reaction at 298K.  
 
The pKa value of the N-H proton in 1,2-azaborines has been determined to be 
approximately 26.19 Alkoxide nucleophiles are not basic enough to deprotonate the N-H 
of 1. Consequently, Mechanisms 3 and 4 cannot be used to explain the SNAr reactivity 
with alkoxide nucleophiles (Table 2.2, entries 1 and 2). To investigate the mechanism for 
oxygen based nucleophiles, we focused on the reaction of 1 with NaOtBu and TMSCl. In 
this case, we determined that 1 equivalent of nucleophile is sufficient to furnish the 
substituted product 5 in comparable yield as when 2 equivalents of nucleophile were used 
[Scheme 2.3, Eq. (5) versus Table 2.2, entry 1]. Furthermore, the addition of NaOtBu to 1 
results in release of significant amount of gas consistent with H2 formation. Mechanisms 
1 and 2 are both consistent with these observations, the difference being whether H2 is 
released in an intramolecular fashion (Mechanism 2) or intermolecularly through the 
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formation of NaH (Mechanism 1). To address this, we added NaH to compound 6 
followed by addition of TMSCl [Scheme 2.3, Eq. (6)]; the starting material 6 was the 
only observed species of this reaction by NMR spectroscopy. If Mechanism 1 were 
operating, we would expect formation of 5. Based on these observations, we conclude 
that substitution reactions of 1 with alkoxide nucleophiles are most consistent with 
Mechanism 2.  
 
Scheme 2.3. Mechanism elucidation for oxygen nucleophiles 
 
2.4. Conclusion 
In summary, we have presented the first reactivity study of 1,2-dihydro-1,2- 
azaborine (1). We demonstrated that 1 can readily undergo nucleophilic aromatic 
substitution reactions under mild reaction conditions, a reactivity pattern that is distinct 
from its isostere benzene. This new reactivity allows access to novel 1,2-azaborine 
structures, including a BN-tolan derivative. By using a combined experimental and 
computational approach, we determined the most likely substitution mechanisms of 1 
with both carbon- and oxygen-based nucleophiles. Current efforts are directed at utilizing 
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this reactivity for incorporating 1,2-azaborines into biologically relevant and materials 
related molecules. 
2.5. Experimental 
General 
All oxygen- and moisture-sensitive manipulations were carried out under an inert 
atmosphere using either standard Schlenk techniques or a glove box. 
THF, Et2O, CH2Cl2, toluene and pentane were purified by passing through a neutral 
alumina column under argon. 
1,2-Dihydro-1,2-azaborine,8 benzylallylamine20 and triallylborane21 were 
prepared according to adapted procedures. All other chemicals and solvents were 
purchased (Aldrich, Acros, TCI or Strem) and used as received. 
Silica gel (230-400 mesh) was heated under vacuum in a 200 °C sand bath for 12 
hours. Flash chromatography was performed with this silica gel under an inert 
atmosphere. Preparative TLC (1000 µm thickness) plates were purchased from Silicycle 
and heated to 120° C for 18 h in an oven before usage under inert conditions. 
11B NMR spectra were recorded on a Varian Unity/Inova 600 or a Varian 
Unity/Inova 300 spectrometer at ambient temperature. 1H NMR spectra were recorded on 
a Varian Unity/Inova 300 or Varian Unity/Inova 500 spectrometer. 13C NMR spectra 
were recorded on a Varian Unity/Inova 300 or Varian Unity/Inova 500 spectrometer. All 
chemical shifts are externally referenced: 11B NMR to BF3•Et2O (δ 0). 
IR spectra were recorded on a Nicolet Magna 550 FT-IR instrument with OMNIC 
software. 
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High-resolution mass spectroscopy data were obtained at the Mass Spectroscopy 
Facilities and Services Core of the Environmental Health Sciences Center at Oregon State 
University. Financial support for this facility has been furnished in part by the National 
Institute of Environmental Health Sciences, NIH (P30 ES00210). 
 
Nucleophilic Aromatic Substitution Reaction: Optimization Survey (Table 2.1) 
Yields in Table 2.1 were determined by GC analysis of the reaction mixture 
versus pentadecane as a calibrated internal standard.  
General Procedure:  In a glove box, a 4 mL vial was charged with a solution of 
1 and solvent. The vessel was sealed and cooled.  n-BuLi (1.6 M in hexane) was added to 
the vessel and reacted for 3 h. Cold trimethylsiyl chloride was slowly added to the 
reaction mixture and allowed to react for 1 h, then warmed to room temperature and 
reacted an additional hour.   At the conclusion of the reaction, pentadecane was added to 
the vial.  The mixture was then passed through a silica gel plug with copious washing 
using ether. An aliquot of the resulting solution was subjected to GC analysis.  All GC 
yields have been corrected for response factors. 
 
Entry 1: The general procedure was followed, using 1 (18 mg, 0.226 mmol), 
BuLi (0.139 mL, 0.226 mmol), Et2O (1.0 mL) TMSCl (10 mg, 0.902 mmol) and cooled 
to   ̶  30 °C. GC analysis indicated the formation of 2 in 21% yield. 
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Entry 2: The general procedure was followed, using 1 (20 mg, 0.256 mmol), 
BuLi (0.315 mL, 0.510 mmol), Et2O (1.0 mL) TMSCl (11 mg, 1.02 mmol) and cooled 
to   ̶  30 °C. GC analysis indicated the formation of 2 in 97% yield. 
 
Entry 3: The general procedure was followed, using 1 (20 mg, 0.253 mmol), 
BuLi (0.468 mL, 0.760 mmol), Et2O (1.0 mL) TMSCl (17 mg, 1.52 mmol) and cooled 
to   ̶  30 °C. GC analysis indicated the formation of 2 in 73% yield. 
 
Entry 4: The general procedure was followed, using 1 (21 mg, 0.267 mmol), 
BuLi (0.329 mL, 0.535 mmol), THF (1.0 mL) TMSCl (12 mg, 1.10 mmol) and cooled 
to   ̶  30 °C. GC analysis indicated the formation of 2 in 67% yield. 
 
Entry 5: The general procedure was followed, using 1 (17 mg, 0.214 mmol), 
BuLi (0.264 mL, 0.428 mmol), pentane (1.0 mL) TMSCl (9.3 mg, 0.856 mmol) and 
cooled to   ̶  30 °C. GC analysis indicated the formation of 2in 12% yield. 
 
Entry 6: The general procedure was followed, using 1 (19 mg, 0.242 mmol), 
BuLi (0.298 mL, 0.484 mmol), toluene (1.0 mL) TMSCl (11 mg, 0.968 mmol) and cooled 
to   ̶  30 °C. GC analysis indicated the formation of 2 in 55% yield. 
 
Entry 7: The general procedure was followed, using 1 (19 mg, 0.242 mmol), 
BuLi (0.298 mL, 0.484 mmol), DME (1.0 mL) TMSCl (10 mg, 0.968 mmol) and cooled 
to   ̶  30 °C. GC analysis indicated the formation of 2 in 89% yield. 
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Entry 8: The general procedure was followed, using 1 (17 mg, 0.214 mmol), 
BuLi (0.264 mL, 0.428 mmol), Et2O (1.0 mL) TMSCl (9.3 mg, 0.856 mmol) and reacted 
at 25 °C. GC analysis indicated the formation of 2 in 46 % yield. 
 
Entry 9: The general procedure was followed, using 1 (17 mg, 0.214 mmol), 
BuLi (0.264 mL, 0.428 mmol), Et2O (1.0 mL) TMSCl (9.3 mg, 0.856 mmol) and cooled 
to  ̶  78 °C. GC analysis indicated the formation of 2 in 80 % yield. 
 
Synthesis of BN-Sustituted 1,2,-dihydro-1,2-azaborines (Table 2.2): 
Entry 1: In a glove box, a 4 mL vial was charged with a solution of 1 (0.019 g, 
0.24 mmol) and ether (1 mL). The vessel was sealed and cooled to  ̶  30 °C.  NaOtBu 
(0.047 g, 0.48 mmol) was added to the vessel and reacted for 3 h. Cold HCl (2.0 M in 
Et2O; 0.241 mL, 0.48 mmol) was slowly added to the reaction mixture and reacted for 1 h 
at  ̶  30 °C, then warmed to room temperature and  reacted an additional hour.  The 
mixture was concentrated under reduced pressure and the crude mixture was subjected to 
silica gel chromatography using pentane/ Et2O (3:1) as eluent, yielding the desired 
compound (0.025g, 68%) as a crystalline white solid. 
1H NMR (300 MHz, C6D6): δ 7.94 (d, 3JHH = 6.7, 1H), 7.63 (dd, 3JHH = 6.2, 5.3 Hz, 1H), 
6.94 (d, 3JHH = 11.7 Hz, 1H), 6.26 (t, 3JHH = 7.0 Hz, 1H), 3.50 (s, 1H), 1.09 (s, 9H). 13C 
NMR (125 MHz, C6D6): δ 145.9, 135.0, 129 (br), 105.6, 66.2, 30.9. 11B NMR (96.3 
MHz, C6D6): δ 27.7. FTIR (thin film) 3384, 2974, 1719, 1616, 1558, 1528, 1506, 1460, 
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1429, 1364, 1314, 1224, 1991, 1151, 1084, 738 cm–1. HRMS (EI) calcd for C8H14BNO 
(M+) 151.11685, found 151.11798. 
 
Entry 2: In a glove box, a 4 mL vial was charged with a solution of 1 (0.020 g, 
0.25 mmol)  and ether (1 mL). The vessel was sealed and cooled to  ̶  30 °C.  Allyl 
alcohol (0.030 g, 0.52 mmol) was placed in a separate vial with ether (1 mL).  KH (0.020 
g, 0.50 mmol) was added to the alcohol and reacted at 25 °C  for 1 h then cooled to  ̶  30 
°C.  The cold 1 was added dropwise to the salt solution and reacted for 3 h. Cold HCl (2.5 
M in Et2O; 0.200 mL, 0.50 mmol) was slowly added to the reaction mixture and reacted 
for 1 h at  ̶  30 °C, then allowed to warm to room temperature and  reacted an additional 
hour.  The mixture was concentrated under reduced pressure and the crude mixture was 
subjected to silica gel chromatography using pentane/ Et2O (3:1) as eluent, yielding the 
desired compound (0.026g, 79%) as a white solid. 
1H NMR (300 MHz, C6D6): δ 7.53 (m, 1H) 6.34 (d, 3JHH =  10.6Hz, 2H), 6.25 (s, 1H), 
5.85 (m, 1H), 5.78 (t, 3JHH = 6.4 Hz, 1H), 5.31 (dd, 3JHH = 16.7, 1.5 Hz, 1H), 5.05 (dd, 
3JHH = 10.55, 1.7 Hz, 1H), 4.32  (m, 2H). 13C NMR (125 MHz, C6D6): 
δ 146.9, 137.4, 134.4, 130 (br), 115.1, 106.6, 66.2. 11B NMR (96.3 MHz, C6D6): δ 28.9. 
FTIR (thin film) 3411, 3326, 2927, 2869, 1616, 1536, 1460, 1432, 1294, 1265, 1240, 
1159, 1087, 1033, 919, 738 cm–1. HRMS (EI) calcd for C7H10BNO (M+) 135.08554, 
found 135.08511. 
 
Entry 3: In a glove box, a 4 mL vial was charged with a solution of 1 (0.021 g, 
0.27 mmol),  and ether (1 mL). The vessel was sealed and cooled to  ̶  30 °C.  t-BuLi (1.6 
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M in Et2O, 0.334 mL, 0.53 mmol) was added to the vessel and reacted for 3 h. Cold HCl 
(2.0 M in Et2O; 0.267 mL, 0.53 mmol) was slowly added to the reaction mixture and 
reacted for 1 h at  ̶  30 °C, then allowed to warm to room temperature and allowed to react 
an additional hour.  The mixture was concentrated under reduced pressure and the crude 
reaction mixture was subjected to silica gel chromatography using pentane as eluent, 
yielding 5 (0.031g, 85%) as a clear colorless oil. 
1H NMR (300 MHz, C6D6): δ 7.61 (dd, 3JHH = 6.5, 4.5 Hz, 1H), 7.12 (s, 1H), 6.99 (d, 
3JHH = 11.3 Hz, 1H), 6.58 (t, 3JHH = 7.0 Hz, 1H), 6.09 (t, 3JHH = 6.5 Hz, 1H), 1.10 (s, 9H). 
13C NMR (125 MHz, C6D6): δ 144.0, 133.0, 131 (br), 110.0, Cipso not observed, 29.2. 11B 
NMR (96.3 MHz, C6D6): δ 38.7. FTIR (thin film) 3417, 2928, 2855, 1618, 1538, 1474, 
1459, 1420, 1092, 1059, 726 cm–1. HRMS (EI) calcd for C8H14BN (M+) 136.1298, found 
136.1293. 
 
Entry 4: In a glove box, a 4 mL vial was charged with a solution of 1 (0.024 g, 
0.31 mmol), and ether (1 mL). The vessel was sealed and cooled to  ̶  30 °C.  n-BuLi (1.6 
M in Et2O; 0.381 mL, 0.62 mmol) was added to the vessel and reacted for 3 h. Cold HCl 
(2.0 M in Et2O; 0.309 mL, 0.62 mmol) was slowly added to the reaction mixture and 
reacted for 1 h at  ̶  30 °C, then allowed to warm to room temperature and  reacted an 
additional hour.  The mixture was concentrated under reduced pressure and the crude 
mixture was subjected to silica gel chromatography using pentane as eluent, yielding the 
desired compound (0.034g, 80%) as a clear colorless oil. 
1H NMR (300 MHz, C6D6): δ 7.56 (dd, 3JHH = 6.4, 4.7 Hz, 1H) 6.93 (d, 3JHH = 11.1 Hz, 
1H), 6.72 (s, 1H), 6.56 (t, 3JHH = 6.7 Hz, 1H), 6.05 (t, 3JHH = 6.4 Hz, 1H), 1.43 (m, 4H), 
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1.13 (m, 2H), 0.96 (t, 3JHH = 7.0 Hz, 3H). 13C NMR (125 MHz, C6D6): δ 143.9, 133.9, 
132 (br), 110.2, 29.5 26.5, 19 (br), 14.7. 11B NMR (96.3 MHz, C6D6): δ 37.4. FTIR (thin 
film) 3379, 3072, 3019, 2955, 1613, 1545, 1458, 1426, 1376, 1356, 1231, 1159, 1142, 
1124, 1092, 989, 892, 773, 723, 614 cm–1. HRMS (EI) calcd for C8H14BN (M+) 
135.12193, found 135.12244. 
 
Entry 5: In a glove box, a 4 mL vial was charged with a solution of 1 (0.021 g, 
0.26 mmol),  and ether (1 mL). The vessel was sealed and cooled to  ̶  30 °C.  PhLi (1.8 M 
in Et2O; 0.290 mL, 0.52 mmol) was added to the vessel and reacted for for 3 h. Cold HCl 
(2.0 M in Et2O; 0.209 mL, 0.52 mmol) was slowly added to the reaction mixture and 
reacted for 1 h at  ̶  30 °C, then allowed to warm to room temperature and  reacted an 
additional hour.  The mixture was concentrated under reduced pressure and the crude 
mixture was subjected to silica gel chromatography using pentane as eluent, yielding the 
desired compound (0.040g, 98%) as a white solid.  The NMR is consistent with previous 
synthesis.22 
1H NMR (300 MHz, C6D6): δ 7.67 (d, 3JHH = 7.9 Hz, 2 H) 7.46 (d, 3JHH = 7.0Hz, 2H), 
7.35 (m,  2H), 7.23 (m, 2H), 6.63 (t, 3JHH = 6.4 Hz, 1H), 6.17 (t, 3JHH = 6.4 Hz,  1H). 13C 
NMR (125 MHz, C6D6): δ 144.7, 141.6, 133.9, 132.6,130 (br), 128.9, 110.8, Cipso not 
observed. 11B NMR (96.3 MHz, C6D6): δ 33.9.  
 
Entry 6: In a glove box, a 4 mL vial was charged with a solution of 1 (0.029 g, 
0.37 mmol), and ether (1 mL). The vessel was sealed and cooled to  ̶  30 °C.  
Vinylmagnesium bromide (1.0 M in Et2O; 0.735 mL, 0.74 mmol) was added to the vessel 
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and reacted for 3 h, upon addition bubbling occured. Cold HCl (2.0 M in Et2O; 0.367 mL, 
0.7.4 mmol) was slowly added to the reaction mixture and reacted for 1 h at  ̶  30 °C, then 
allowed to warm to room temperature and reacted an additional hour.  The mixture was 
concentrated under reduced pressure and the crude mixture was subjected to silica gel 
chromatography using pentane as eluent, yielding the desired compound (0.023g, 59%) 
as a clear colorless oil.  Characterization is consistent with previous work.13 
1H NMR (500 MHz, C6D6): δ 7.59 (dd, 3JHH = 6.4, 11 Hz, 1H) 7.11 ( t, 3JHH = 7.0  Hz, 
1H), 6.89 (s, 1H), 6.50 (t, 3JHH = 7.0  Hz, 1H) 6.40 (dd, 3JHH = 19.8, 13.4 Hz, 1H), 6.05 
(m, 2H), 5.93 (d, 3JHH = 13.4 Hz, 1H),  13C NMR (125 MHz, C6D6): δ 144.6, 138 (br), 
134.0, 130.0, 128 (br), 111.2. 11B NMR (96.3 MHz, C6D6): δ 32.2.  
 
Entry 7: In a glove box, a 4 mL vial was charged with a solution of 1 (0.021 g, 
0.26 mmol),  and ether (1 mL). The vessel was sealed and cooled to  ̶  30 °C.  
Phenylethynylmagnesium bromide (0.75 M solution in THF; 0.700 mL, 0.53 mmol) was 
added to the vessel and reacted for 3 h. Cold HCl (2.0 M in Et2O; 0.265 mL, 0.53 
mmol)was slowly added to the reaction mixture and reacted for 1 h at  ̶  30 °C, then 
allowed to warm to room temperature and  reacted an additional hour.  The mixture was 
concentrated under reduced pressure and the crude mixture was subjected to silica gel 
chromatography using pentane as eluent, yielding the desired compound (0.034 g, 73%) 
as a crystalline white solid. Characterization is consistent with previous work.23 
1H NMR (300 MHz, C6D6): δ 7.62 (dd, 3JHH = 8.2, 1.8Hz, 2H) 7.55 (dd, 3JHH =  2.9, 9.7 
Hz, 1H), 7.35 (s, 1H), 7.25 (d, 3JHH = 11.1 Hz, 1H), 7.02 (m, 3H), 6.41 (t, 3JHH = 7.0 Hz, 1 
H), 6.13 (dt, 3JHH = 1.8, 6.7 Hz, 1H). 13C NMR (125 MHz, C6D6): δ 145.2, 134.6, 132.7, 
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131 (br), 129.2, 128.9, 125.2, 111.8, 105.5, Cipso not observed. 11B NMR (96.3 MHz, 
C6D6): δ 26.1.  FTIR (thin film) 3380, 3049, 3027, 2178, 1605, 1593, 1568, 1537, 1486, 
1461, 1439, 1421, 1349, 1266, 1235, 1212, 1190, 1159, 1126, 1108, 1081, 1069, 1048, 
1025, 995, 917, 793, 759, 733, 692, 681 cm–1. HRMS (EI) calcd for C12H10BN (M
+) 
179.09063, found 179.09122. 
 
Entry 8: In a glove box, a 4 mL vial was charged with a solution of 1 (0.020, 0.26 
mmol), and ether (1 mL). The vessel was sealed and cooled to  ̶  30 °C.  n-BuLi (1.6 M in 
Et2O, 0.320 mL, 0.51 mmol) was added to the vessel and reacted for 3 h. Cold 
Trimethylsiyl chloride (0.111 g, 1.02 mmol in 0.5 mL Et2O) was slowly added to the 
reaction mixture and reacted for 1 h at  ̶  30 °C, then allowed to warm to room 
temperature and reacted an additional hour.  The mixture was concentrated under reduced 
pressure and the crude reaction mixture was subjected to silica gel chromatography using 
pentane as eluent, yielding the desired compound (0.472 g, 89%) as a clear colorless oil.  
1H NMR (500 MHz, C6D6): δ 7.59 (dd, 3JHH = 6.3, 4.8 Hz, 1H) 7.14 (d, 3JHH = 6.5  Hz, 
1H), 7.03 (d, 3JHH = 11.1 Hz, 1H), 6.22 (d t, 3JHH =1.18, 5.23 Hz, 1H), 1.71(m, 2H), 1.48 
(m, 2H), 1.38, (t, 3JHH = 8.3 Hz, 2H), 0.99 (t, 3JHH = 7.4  Hz, 3H), 0.17 (s, 9H). 13C NMR 
(125 MHz, C6D6): δ 143.2, 136.8, 130 (br), 111.3, 30.1, 26.4, 21 (br), 14.4, 1.5. 11B NMR 
(96.3 MHz, C6D6): δ 41.4. FTIR (thin film) 2958, 2872, 1608, 1508, 1448, 1401, 1286, 
1253, 1216, 1149, 1105, 1007, 991, 845, 765, 736, 685 cm–1. HRMS (EI) calcd for 
C11H22BNSi (M+) 207.16146, found 207.16073. 
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Entry 9: In a glove box, a 4 mL vial was charged with a solution of 1 (0.016 g, 
0.20 mmol), and ether (1 mL). The vessel was sealed and cooled to  ̶  30 °C.  n-BuLi (1.6 
M in Et2O, 0.243 mL, 0.40 mmol) was added to the vessel and reacted for 3 h. Cold MeI 
(0.056 g, 0.40 mmol in 0.5 mL in Et2O) was slowly added to the reaction mixture and 
reacted for 1 h at  ̶  30 °C, then allowed to warm to room temperature and  reacted an 
additional hour.  The mixture was concentrated under reduced pressure and the crude 
mixture was subjected to silica gel chromatography using pentane as eluent, yielding the 
desired compound (0.021g, 73%) as a clear colorless oil. 
1H NMR (300 MHz, C6D6): δ 7.56 (dd, 3JHH = 6.4, 4.7 Hz, 1H) 6.93 (d, 3JHH = 11.1 Hz, 
1H), 6.56 (t, 3JHH = 6.7 Hz, 1H), 6.05 (t, 3JHH = 6.4 Hz, 1H), 2.85(s, 3H), 1.43 (m, 4H), 
1.13 (m, 2H), 0.96 (t, 3JHH = 7.0 Hz, 3H). 13C NMR (125 MHz, C6D6): δ 141.9, 139.2, 
132 (br), 109.6, 40.0, 28.8 26.5, 19 (br), 14.7. 11B NMR (96.3 MHz, C6D6): δ 37.4. FTIR 
(thin film) 3379, 3072, 3019, 2955, 1613, 1545, 1458, 1426, 1376, 1356, 1231, 1159, 
1142, 1124, 1092, 989, 892, 773, 723, 614 cm–1. HRMS (EI) calcd for C9H16BN (M+) 
149.13758, found 149.13617. 
 
Entry 10: In a glove box, a 4 mL vial was charged with a solution of 1 (0.020 g, 
0.26 mmol),  and ether (1 mL). The vessel was sealed and cooled to  ̶  30 °C.  n-BuLi (1.6 
M in Et2O, 0.321 mL, 0.52 mmol) was added to the vessel and reacted for for 3 h. Cold 
Benzyl bromide (0.879 g, 0.52 mmol in 0.5 mL Et2O) was slowly added to the reaction 
mixture and reacted for 1 h at  ̶  30 °C, then allowed to warm to room temperature and  
reacted an additional hour.  The mixture was concentrated under reduced pressure and the 
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crude mixture was subjected to silica gel chromatography using pentane as eluent, 
yielding the desired compound (0.036g, 63%) as a clear colorless oil. 
1H NMR (500 MHz, C6D6): δ 7.59 (dd, 3JHH = 6.4, 4.4 Hz, 1H) 6.99 (m, 4H), 6.87 (m, 
2H), 6.75 (d, 3JHH = 6.8 Hz, 1H), 6.13 (dt, 3JHH = 1.5, 6.4Hz, 1H), 4.52 (s, 2H), 1.66 (m, 
2H), 1.41 (m, 2H), 1.24 (t, 3JHH =8.3, 2H), 0.95 (t, 3JHH = 7.3 Hz, 3H). 13C NMR (125 
MHz, C6D6): δ 142.9, 140.2, 139.5, 131 (br), 129.2, 127.6, 127.2, 111.0, 56.8, 29.8, 26.5, 
18 (br), 14.8. 11B NMR (96.3 MHz, C6D6): δ 38.5. FTIR (thin film) 3087, 3066, 3031, 
3002, 2954, 2922, 2869, 1612, 1515, 1496, 1453, 1406, 1375, 1354, 1339, 1298, 1224, 
1158, 1120, 1095, 1076, 1029, 1015, 731, 695 626 cm–1. HRMS (EI) calcd for C15H20BN 
(M+) 226.1767, found 126.1755. 
 
Synthesis of Compound 3 
 
Scheme 2.4. Synthesis of compound 3 
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3b 3c  
 
 Compound 3a:  A solution of BCl3 (1M in hexanes; 39 mL, 39 mmol) with 125 
mL of DCM was cooled to -78 °C in a round bottom flask under nitrogen.  Triallylborane 
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(2.60 g, 19.4 mmol in 50 mL DCM) was added dropwise.  The reaction flask was stirred at 
-78 °C for 2 h. A solution of allylbenzylamine (8.56 g, 58 mmol) and NEt3 (8.10 mL, 58 
mmol) in 100 mL pentane was added dropwise to the reaction flask and allowed to warm to 
R.T.  After 16 h of stirring, approximately three-fourths of the solvent was removed under 
vacuum, and 150 mL pentane was added to the reaction flask.  The reaction mixture was 
passed through a medium-porosity frit, and the filtrate was concentrated under reduced 
pressure.  Vacuum distillation (60 °C, 360 mT) provided 3a as a clear, colorless liquid 
(7.18 g, 53%). 
1H and 13C NMR were consistent with the formation of rotamers in a 1:1 ratio. 1H NMR 
(300 MHz, C6D6): δ 7.35-7.45 (m, 5H), 6.15 (m, 1H), 5.93 (m, 1H), 5.1-5.4 (m, 4H), 4.5-
4.6 (app br d, 2H), 3.8-3.95 (m, 2H), 2.28 (m, 2H). 13C NMR (125 MHz, C6D6): δ 138.3, 
137.0, 134.8, 134.7, 134.4, 134.3, 128.3, 128.5, 116.9, 116.8, 116.3, 116.1, 57.64, 56.3, 
51.9, 51.7, 50.8, 50.7, 49.9, 49.7, 28 (br), 26 (br). 11B NMR (192.5 MHz, CD2Cl2): δ 
38.6. FTIR (thin film) 3064, 3029, 2976, 2924, 1641, 1603, 1495, 1482, 1448, 1419, 
1385, 1359, 1256, 1149, 1112, 1079, 1029, 994, 921, 736, 698 cm–1. HRMS (EI) calcd 
for C13H17BNCl (M+) 233.10643, found 232.10685. 
 
 Compound 3b:  In a glove box, a solution of Grubbs 1st generation catalyst (0.246 
g, 0.308 mmol in 20 mL CH2Cl2) was added to a stirring solution of aminoborane 3a (7.18 
g, 30.8 mmol in 280 mL CH2Cl2).  The reaction was stirred at room temperature for 3 h, 
followed by the removal of solvent under vacuum.  The desired product was purified by 
vacuum distillation (bp 75°C at 210 mT) to furnish 3b as a clear, colorless liquid (5.13 g, 
81%). 
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1H NMR (300 MHz, C6D6): 1H NMR (500 MHz, C6D6): δ 7.08 (m, 5H), 4.95 (dd, 3JHH = 
10.3, 9.3 Hz, 1H), 4.80 (dd, , 3JHH = 17.1, 5.1 Hz 1H), 4.18 (s, 2H), 3.48 (d, , 3JHH = 5.4 
Hz 2H), 2.01 (d, , 3JHH = 7.3 Hz, 2H). 13C NMR (125 MHz, C6D6): δ 137.3, 133.2, 129.3, 
127.1, 116.9, 114.9, 51.8, 51.7, 50.7. 11B NMR (192.5 MHz, CD2Cl2): δ 38.1. FTIR (thin 
film) 3085, 3065, 3030, 2977, 2926, 2871, 1643, 1604, 1586, 1483, 1445, 1418, 1394, 
1359, 1341, 1309, 1254, 1231, 1184, 1110, 1079, 1029, 996, 923, 901, 818, 734, 699, 
662, 625, 559, 536, 516, 459 cm–1. HRMS (EI) calcd for C11H13BNCl (M+) 205.08296, 
found 205.08253. 
 
 Compound 3c:  In a glovebox, a Schlenk flask was charged with 3b (7.66 g, 37.3 
mmol), Pd/C (10 wt%; 7.93 g, 7.46 mmol), and cyclohexene (120 mL).  The flask was 
sealed and heated to 90 °C for 24 h.  The reaction mixture was passed through a frit and the 
resulting filtrate was concentrated under reduced pressure. Vacuum distillation ( bp 52°C at 
200 mT) provided 3c as a clear, colorless liquid (3.60 g, 48% yield). 
1H NMR (500 MHz, C6D6): δ 7.31 (dd, 3JHH = 6.8, 2.9 Hz, 1H) 6.98 (m, 3H), 6.90 (m, 
3H), 6.57 (d, 3JHH = 6.4 Hz, 1H), 5.92 (t, 3JHH = 6.8 Hz, 1H), 4.63 (s, 2H). 13C NMR (125 
MHz, C6D6): δ 145.2, 139.3, 138.9, 130 (br) 129.2, 128.2, 127.8, 111.6, 56.1. 11B NMR 
(96.3 MHz, C6D6): δ 32.8. FTIR (thin film) 3059, 3015, 2918, 1609, 1576, 1559, 1516, 
1496, 1453, 1437, 1399, 1344, 1300, 1261, 1234, 1136, 1074, 1028, 801, 741, 697, 672, 
648, 604 cm–1. HRMS (EI) calcd for C11H11BNCl (M+) 203.06731, found 203.06668. 
 
Compound 3:  In a glovebox, a round bottom flask was charged with 3c (3.00 g, 
15.0 mmols) and 10.0 mL Et2O. The flask was then cooled to –78 °C. Super Hydride (1.0 
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M solution in THF, 15 mL, 15.0 mmols) was added dropwise to the stirring reaction 
flask. The mixture was allowed to warm to room temperature. After 2 h of stirring, the 
mixture was passed through an acrodisc and concentrated reduced pressure. The crude 
material was subjected to silica gel chromatography using pentane as an eluent to afford 3 
as a clear colorless liquid (1.61g, 65%). 
1H NMR (300 MHz, C6D6): δ 7.58 (dd, 3JHH = 6.8, 3.9 Hz, 1H), 7.23 (d, 3JHH = 10.7 Hz, 
1H), 6.98 (m, 2H), 6.89 (d, 3JHH = 5.4 Hz, 2H), 6.79 (d, 3JHH = 6.2, 1H), 6.17 (t, 3JHH = 
5.4, 1H), 5.32 (q (br), 1JBH = 110 Hz, 1H), 4.55 (s, 2H). 13C NMR (125 MHz, C6D6): 
δ 143.3, 140.1, 138.8, 132 (br), 129.2, 127.9, 127.8, 113.0, 61.7. 11B NMR (96.3 MHz, 
C6D6): δ 33.4 (d, 1JBH = 120 Hz).. FTIR (thin film) 3065, 3031, 2963, 2520, 1605, 1576, 
1558, 1540, 1513, 1496, 1453, 1436, 1405, 1335, 1261, 1140, 1076, 1028, 973, 929, 879, 
801, 734, 696, 614, 598 cm–1. HRMS (EI) calcd for C11H12BN (M+) 169.10628, found 
169.10553. 
 
Attempted Synthesis of 4 from 3 
 
Scheme 2.5. Attempted synthesis of 4 from 3 
BH
N Ph 1. BuLi//
2. TMSCl
B
N Ph
Bu
3 4  
Compound 4: In a glove box, a 4 mL vial was charged with a solution of 3 (0.24 
g, 0.14 mmol in 1.0 mL Et2O).  The vessel was sealed and cooled to  ̶  30 °C.  n-BuLi 
(1.62 M, 0.090 mL, 0.14 mmol) was added to the vessel and reacted for 3 h. Cold TMSCl 
(0.031 g, 0.28 mmol) was slowly added to the mixture and reacted for 1 h at  ̶  30 °C, then 
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allowed to warm to room temperature and  reacted an additional hour.  The mixture was 
concentrated under reduced pressure, the crude mixture was subjected to silica gel 
chromatography using pentane as eluent, with no product isolated. 11B NMR of the crude 
reaction mixture indicated a non aromatic quaternary boron species. 
11B NMR (96.3 MHz, C6D6): δ−3.9.  
 
Compound 4: In a glove box, a 4 mL vial was charged with a solution of 3(0.26 
g, 0.16 mmol), with 1.0 mL ether. The vessel was sealed and cooled to  ̶  30 °C.  n-BuLi 
(1.62 M, 0.19 mL, 0.32 mmol) was added to the vessel and reacted for 3 h. Cold TMSCl 
(0.068 g, 0.64 mmol) was slowly added to the reaction mixture and reacted for 1 h at  ̶  30 
°C, then allowed to warm to room temperature and  reacted an additional hour.  The 
mixture was concentrated under reduced pressure and the crude mixture was subjected to 
silica gel chromatography using pentane as eluent with no product isolated.  NMR of the 
crude reaction mixture indicated a non aromatic quaternary boron species. 
11B NMR (96.3 MHz, C6D6): δ −4.2. 
 
Attempted Synthesis of Compound 4a from 3 
 
Scheme 2.6. Attempted synthesis of compound 4a from 3 
BH
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Compound 4a: In a glove box, a 4 mL vial was charged with a solution of 3 
(0.20 g,  0.12 mmol in 1 mL Et2O).  The vessel was sealed and cooled to  ̶  30 °C.  
NaOtBu (0.011 g, 0.12 mmol) was added to the vessel and reacted for 3 h. Cold TMSCl 
(0.026 g, 0.24 mmol) was slowly added to the mixture and reacted for 1 h at  ̶  30 °C, then 
allowed to warm to room temperature and  reacted an additional hour.  The mixture was 
concentrated under reduced pressure; the crude mixture was subjected to silica gel 
chromatography using pentane as eluent, yielding only quantative starting material.  
(NMR of the crude reaction mixture indicated only starting material.) 
1H NMR (300 MHz, C6D6): δ 7.58 (dd, 3JHH = 6.8, 3.9 Hz, 1H), 7.23 (d, 3JHH = 10.7 Hz, 
1H), 6.98 (m, 2H), 6.89 (d, 3JHH = 5.4 Hz, 2H), 6.79 (d, 3JHH = 6.2, 1H), 6.17 (t, 3JHH = 
5.4, 1H), 5.32 (q (br), 1JBH = 110 Hz, 1H), 4.55 (s, 2H). 11B NMR (96.3 MHz, C6D6): 
δ 33.4 (d, 1JBH = 120 Hz). 
 
Isolated Yield of Compound 2 with 1 equiv. of Nucleophile 
Compound 2: In a glove box, a 4 mL vial was charged with a solution of 1 
(0.019, 0.24 mmol), and ether (1 mL). The vessel was sealed and cooled to  ̶  30 °C.  n-
BuLi (1.6 M in Et2O, 0.148 mL, 0.24 mmol) was added to the vessel and reacted for 3 h. 
Cold Trimethylsiyl chloride (0.111 g, 1.02 mmol in 0.5 mL Et2O) was slowly added to 
the reaction mixture and reacted for 1 h at  ̶  30 °C, then allowed to warm to room 
temperature and reacted an additional hour.  The mixture was concentrated under reduced 
pressure and the crude reaction mixture was subjected to silica gel chromatography using 
pentane as eluent, yielding the desired compound (0.007 g, 14%) as a clear colorless oil.  
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1H NMR (500 MHz, C6D6): δ 7.59 (dd, 3JHH = 6.3, 4.8 Hz, 1H) 7.14 (d, 3JHH = 6.5  Hz, 
1H), 7.03 (d, 3JHH = 11.1 Hz, 1H), 6.22 (d t, 3JHH =1.18, 5.23 Hz, 1H), 1.71(m, 2H), 1.48 
(m, 2H), 1.38, (t, 3JHH = 8.3 Hz, 2H), 0.99 (t, 3JHH = 7.4  Hz, 3H), 0.17 (s, 9H). 13C NMR 
(125 MHz, C6D6): δ 143.2, 136.8, 130 (br), 111.3, 30.1, 26.4, 21 (br), 14.4, 1.5. 11B NMR 
(96.3 MHz, C6D6): δ 41.4. FTIR (thin film) 2958, 2872, 1608, 1508, 1448, 1401, 1286, 
1253, 1216, 1149, 1105, 1007, 991, 845, 765, 736, 685 cm–1. HRMS (EI) calcd for 
C11H22BNSi (M+) 207.16146, found 207.16073. 
 
Evidence of LiH Formation 
LiH:  In a glove box, a 4 mL vial was charged with a solution of 1 (0.020, 0.26 
mmol), and ether (1 mL). The vessel was sealed and cooled to  ̶  30 °C.  n-BuLi (1.6 M in 
Et2O, 0.320 mL, 0.51 mmol) was added to the vessel and reacted for 3 h.  The solution 
was decanted off of the white powder and washed with cold Et2O.  IR analysis of the 
insoluble powder indicates LiH formation. 
 
 
 
 
 
 
 
Figure 2.3. IR of experimentally isolated LiH and commercial LiH 
 
LiH 
Experimental 
  
 
66 
Evidence of Intermediate B Formation 
 Intermediate B: In a glove box, a 4 mL vial was charged with a solution of 1 
(0.022,  0.28 mmol), and ether (1 mL). The vessel was sealed and cooled to  ̶  30 °C.  n-
BuLi (1.6 M in Et2O, 0.320 mL, 0.51 mmol) was added to the vessel and reacted for 3 h.  
The powder was filtered off and the resulting solution was concentrated under reduced 
pressure to yield intermediate B (0.037 g, 93%) as a crystalline solid.  
1H NMR (300 MHz, THF-d8): δ 7.76 (d, 3JHH = 4.1, 1H) 7.18 (dd, 3JHH = 6.7, 2.9 Hz, 
1H), 6.14 (d, 3JHH = 10.6 Hz, 1H), 5.82 (t, 3JHH = 5.6 Hz, 1H), 1.56 (m, 2H), 1.45 (m, 2H), 
1.02 (m, 2H) 0.94 (m, 3H). 13C NMR (125 MHz, THF-d8): δ 148.8, 139.8, 123 (br), 
109.4, 32.6, 27.9, 24 (br), 15.1. 11B NMR (96.3 MHz, THF-d8): δ 38.6. FTIR (thin film) 
3019, 2955, 2917, 2852, 1559, 1496, 1459, 1432, 1386, 1263, 1151, 1124, 1094, 1027, 
940, 780, 769, 742, 640, 587 cm–1. HRMS (EI) calcd for C8H13BN (M+) 134.1147, found 
134.1195. 
 
 Attempted “Benzyne” Trapping Reactions 
General Procedure: In a glove box, a 4 mL vial was charged with a solution of 1 
(0.20 g, 0.25 mmol),  and ether (1 mL). The vessel was sealed and cooled to  ̶  30 °C.  n-
BuLi (1.6 M, 0.21 mL, 0.33 mmol) was added to a separate vessel and reacted for 1 h 
with tetramethylpiperidine (0.054 g, 0.38 mmol) at room temperature, then cooled to  ̶  30 
°C. The pre-cooled 1 was added to the LiTMP and reacted at  ̶  30 °C for 3 h.  A cold 
solution of benzyne trapping reagent (0.38 mmol) was slowly added to the reaction 
mixture and reacted for 1 h at  ̶  30 °C, then allowed to warm to room temperature and  
reacted an additional hour.  The mixture was concentrated under reduced pressure.  NMR 
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of the crude reaction mixture did not indicate the formation of the desired product.  
Benzyne traps: Benzyl azide,24 anthracene,25 furan,26 and cyclopentadiene27 
 
 
Calculations 
 Gas Phase: 
reaction coordinate
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Figure 2.4. Gas phase calculations for the nucleophilic aromatic substitution with butyl 
lithium.   
 
The first reaction is X + BuLi → Y + n-C4H10. 
The second reaction is Y + BuLi → di-anion as written. 
The third reaction is loss of LiH from the di-anion to give Z. The gas phase reaction 
enthalpies at 298 K were calculated using the ab initio G3MP2 method.28 The energy of 
the di-anion species is obtained by correcting the gas phase heat of reaction by the lattice 
energy, -UL estimated using the volume based thermodynamic (VBT) approach,29  which 
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relates the lattice energy, UL, to the ionic strength, I, of the lattice, and the inverse cube 
root of the formula unit volume, Vm. The expression for the lattice energy is 
 
UL = 2I(αVm -1/3 + β) (1) 
 
where α = 28.0 kcal-nm/mol and β = 12.4 kcal/mol. This approach has been used by us to 
model a number of different reacting processes.30 The value of the gas phase enthalpy for 
the second reaction is 104.7 kcal/mol and the lattice enthalpy correction is -115.9 
kcal/mol. 
 
Solution Models: The initial gas phase reaction energies were corrected for 
solvation effects for two  different solvents (diethyl ether (Et2O), ε =4.24, and 
tetrahydrofuran (THF), ε = 7.4257) to give free energies in solution at 298 K. The self 
consistent reaction field approach14 with the COSMO (Conductor-like Screening Model) 
parameterization15 as implemented in Gaussian09.16 The solvation calculations were 
done at the density functional theory level with the B3LYP exchange-correlation 
functional17 and the DZVP2 basis set.18 For Li, the van der Waals radius and alpha 
value where specified as 1.82 Å19 and 1.18 respectively. All parameters for the other 
atoms were set to their default values. The free energies of solvation are given in Table 
S1. 
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Table 2.3. Free energies of solvation (in kcal/mol at 298 K in Et2O and THF) 
 
Compound ΔGSolvation 
Et2O 
ΔGSolvation 
THF 
X -3.9 -4.5 
n-BuLi -7.8 -9.1 
Y -9.5 -10.9 
n-C4H10 -0.4 -0.5 
L -68.7 -75.1 
Li+ -90.4 -102.3 
LiH -29.0 -33.6 
Z -9.5 -11.1 
H -3.7 -4.3 
 
Table 2.4. The reaction free energies in solution (ΔGsolution = ΔGgas + ΔGSolvation, in 
kcal/mol at 298 K in Et2O and THF) 
 
Reaction ΔHgas ΔGgas ΔGSolvation 
Et2O 
ΔGSolution 
Et2O 
ΔGSolvation 
THF 
ΔGSolution 
THF 
1st -43.3 -42.6 1.8 -40.8 2.2 -40.4 
2nd bottom 104.7 108.0 -141.8 -33.8 -157.3 -49.3 
2nd top 90.8 80.6 -23.2 57.4 -27.0 53.6 
3rd bottom -111.1 -112.3 120.6 8.3 132.7 20.4 
3rd top -97.1 -84.9 2.0 -82.9 2.3 -82.6 
 
 
Figure 2.5. Calculated free energy diagram in Et2O solution 
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Oxygen Mechanism Reactions 
Compound 5: In a glove box, a 4 mL vial was charged with a solution of 1 
(0.024 g 0.26 mmol), in 1 mL Et2O. The vessel was sealed and cooled to  ̶  30 °C.  
NaOtBu (0.025 g, 0.26 mmol) was added to the vessel and reacted for 3 h, upon addition 
bubbling occurred. Cold TMSCl (0.056 g, 0.52 mmol) was slowly added to the reaction 
mixture and reacted for 1 h at  ̶  30 °C, then allowed to warm to room temperature and  
reacted an additional hour.  The mixture was concentrated under reduced pressure and the 
crude mixture was subjected to silica gel chromatography using pentane/Et2O (3:1) as 
eluent, yielding 5 (0.036 g, 63%) as a white solid. 
1H NMR (300 MHz, C6D6): δ 7.52 (dd, 3JHH = 5.3, 5.6 Hz, 1H) 7.02 (d, 3JHH = 6.2 Hz, 
1H), 6.33 (d, 3JHH = 11.7 Hz, 1H), 5.94 (t, 3JHH = 5.3 Hz, 1H), 1.33 (s, 9H), 0.27 (s, 9H). 
13C NMR (125 MHz, C6D6): δ 146.7, 135.1, 123 (br) 106.8, 31.0, 26.4, 1.8. 11B NMR 
(96.3 MHz, C6D6): δ 30.8. FTIR (thin film) 2977, 1616, 1534, 1460, 1431, 1387, 1266, 
1223, 1192, 1162, 1085, 907, 843, 739, 704 cm–1. HRMS (EI) calcd for C11H22BNOSi 
(M+) 223.15638, found 223.15601. 
 
 
Scheme 2.7. Attempted synthesis of 5 from 6  
B
NH
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Compound 13:  In a glove box, a 4 mL vial was charged with a solution of 3 
(0.15 g,  0.10 mmol in 1 mL Et2O).  The vessel was sealed and cooled to  ̶  30 °C.  NaH 
(0.003 g, 0.10 mmol) was added to the vessel and reacted for 3 h. Cold TMSCl (0.022 g, 
0.20 mmol) was slowly added to the mixture and reacted for 1 h at  ̶  30 °C, then allowed 
to warm to room temperature and  reacted an additional hour.  The mixture was 
concentrated under reduced pressure; the crude mixture was subjected to silica gel 
chromatography using pentane as eluent, yielding only starting material.   
1H NMR (300 MHz, C6D6): δ 7.52 (dd, 3JHH = 5.3, 5.6 Hz, 1H) 7.02 (d, 3JHH = 6.2 Hz, 
1H), 6.33 (d, 3JHH = 11.7 Hz, 1H), 5.94 (t, 3JHH = 5.3 Hz, 1H), 1.33 (s, 9H), 0.27 (s, 9H). 
13C NMR (125 MHz, C6D6): δ 146.7, 135.1, 123 (br) 106.8, 31.0, 26.4, 1.8. 11B NMR 
(96.3 MHz, C6D6): δ 30.8.  
 
2.6. Bridge from Chapter II to Chapter III 
Chapter II of this dissertation explored the nucleophilic aromatic substitution of 1,2-
dihydro-1,2-azaborine, the substrate scope and most likely mechanisms were discussed.  
Chapter III continues exploring the reactivity of 1,2-dihydro-1,2-azaborine, which in the 
presence of catalytic non-nucleophilic base will self-assemble into a BN-triphenylene.
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CHAPTER III 
TRIMERIZATION OF 1,2-DIHYDRO-1,2-AZABORINE 
 
3.1. General Overview 
 This chapter describes unpublished work.  1,2-Dihydro-1,2-azaborine undergoes a 
trimerization reaction in the presence of catalytic non-nucleophilic base.  The trimer can 
be used to regenerate the parent 1,2-dihydro-1,2-azaborine. I performed the bulk of the 
lab work, Adam Marwitz ran preliminary dehydrogenation experiments with a catalyst 
and some initial burette data.  Lev Zakharov provided the X-ray crystallography data. 
Tanya Mikulas, Edward Garner and David Dixon provided computational data. Shih-
Yuan Liu provided scientific guidance and editorial assistance for all the material in this 
chapter.   
 
3.2. Introduction 
Polycyclic aromatic hydrocarbons (PAH’s) have achieved widespread interest due 
to their potential utility in many optoelectronic devices.1  Triphenylene in particular has 
been explored in solar cell applications,2 organic field effect transistors,3 organic light 
emitting diodes4 as well as liquid crystals due to the unique mesogenic discotic crystals 
that many triphenylene derivatives form.5 Many exocyclic substituted derivatives have 
been extensively explored but modifying the triphenylene core remains a relatively 
unexplored area, including the incorporation of boron into these motifs (Figure 3.1).  
Dewar initially synthesized compound 1, which replaces select CC bonds with 
isoelectronic and isostructural BN bonds, through a hydroboration-oxidation sequence but 
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it required relatively harsh (≥ 300 °C) reaction conditions and only achieved 2.6% overall 
yield.6 Relatively little work has been done on this molecule presumably due to the low 
yield.  In 2006, Piers successfully synthesized B2N2-triphenylene mimics, such as 
compound 2, showing unique photophysical properties of these compounds relative to the 
all carbon analog.7 To our knowledge, these are the only examples of triphenylene cores 
that contain boron.   
 
 
Figure 3.1. Triphenylene, BN-triphenylene 1, B2N2-triphenylene 2 and the isosterism 
between benzene and 1,2-dihydro-1,2-azaborine 3 
 
Our research group explores the isosterism between 1,2-dihydro-1,2-azaborine  
and benzene.8   Dewar9 and White10 pioneered the synthesis of 1,2-azaborines in the 
1960’s but little work had been done in the field until recently when Ashe,11 Piers,12 
Paetzold,13 Yamaguchi,14 Perepichka15 and Liu16 have reinvigorated this area of 
chemistry.  Our group has been successful in the synthesis of compound 3 and discovered 
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that it will undergo nucleophilic aromatic substitutions, but very little reactivity studies 
have been performed on this molecule.17   During our initial investigation into the 
reactivity of the parent 1,2-dihydro-1,2-azaborine 3 we found that it will undergo 
dehydrogenative trimerization to form the BN-triphenylene 1.  Compound 3 readily 
undergoes a novel trimerization which has many features including 1) the formation of 
one discreet product, 2) efficient H2 release (the only bi-product) and 3) mild reaction 
conditions. This chapter provides in-depth analysis of this self-assembly along with 
fundamental chemistry, which could provide a route to novel functionalized BN-
triphenylenes.  
 
3.3. Synthesis and Functionalization of BN-Triphenylene 
During our initial investigation into the reactivity of 1,2-dihyrdo-1,2-azaborine  3 
we discovered that when 3 was treated with LiH at room temperature in THF, a 
crystalline solid was formed after a week.  Analysis of the crystals indicate the formation 
of 1 (Scheme 3.1).  We sought to optimize this reaction by heating 1 equivalent of LiH 
with 3. At 50 ºC the reaction was complete in 3 hours (Table 3.1, entry 1).  We 
determined that a catalytic amount of LiH can be used (entry 2) but elevated temperatures 
and prolonged reaction times are necessary.  We utilized a non-nucleophilic, soluble 
base, lithium tetramethylpiperidine (LiTMP) in a catalytic amount and found that it will 
readily form the desired product 1 (entry 3) at room temperature in 2 hours.  We next 
examined reagents that dehydrogenate ammonia borane, since the reaction proceeds via 
dehydrogenation of the BN bond. We screened acids18 (entry 4 and 5), and known 
dehydrogenation catalysts19 (entry 6-8) but detected no product formation. We examined 
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CoCl2 (entry 9), which has been shown to trimerize saturated cyclic BN-heterocycles, but 
product formation was not observed.20  Lastly, we attempted heating the reaction to 330 
ºC in hexadecane but even at these extreme temperatures product formation was not 
detected, rather unreacted starting material was recovered. 
  
Scheme 3.1. Synthesis and crystal structure of BN-triphenylene 1 
 
 
 
 
 
Figure 3.2 depicts two possible mechanisms for the observed self-assembly. In 
both mechanisms an equivalent of the base (TMP-) removes the N-H proton to produce 
intermediate A. In Mechanism 1, A acts as a nucleophile and reacts with an equivalent of 
3 releasing H2 to form intermediate B. Intermediate B then reacts with 3 producing 
another equivalent of H2 and intermediate C.  Intramolecular attack at boron from the 
anionic nitrogen followed by subsequent deprotonation of the base for a new molecule of 
starting material 1 and the final equivalent of H2. Alternatively, intermediate A can 
eliminate a hydride to yield a “benzyne”-type 1,2-azaborine21 which then reacts with 
itself to create trimer 1.  The hydride reacts with the protonated base (HTMP) to 
regenerate the catalyst (TMP) and give 3 equivalents of H2. Potentially, the BN 
“benzyne” could also react sequentially with 3 to produce 1.  
 
B
N
H
H
3
LiH, THF
168 h
N
B
N
B
N
B
1
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Table 3.1.  Optimization of the trimerization reaction 
 
 
  
Figure 3.2. Proposed mechanisms for the trimerization of 1,2-dihydro-1,2-azaborine 3 
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In our mechanistic studies we established that H2 is produced by the appearance 
of a peak at 4.54 ppm in the 1H NMR.22 Additionally, we monitored the release of H2 
using an automated gas burette and found that one equivalent of H2 is released per 
molecule of 3.23 To determine the reaction order, we varied the concentration of starting 
material 3 and determined a reaction order of 1.5 using initial-rate kinetic analysis.  
Derivation of the rate law based on the proposed reaction Mechanism 1 is shown in 
Figure 3.3, which accounts for the reaction order of 1.5 when the resting state of the 
reaction is between intermediate A and B. The computationally determined energy 
diagram (Figure 3.4) at the B3LYP/DZVP2 level indicates that the formation of the 
intermediate B is energetically very favorable, consistent with the reaction-order analysis.  
 
 
Figure 3.3. Derivation of the rate law based on the proposed reaction mechanism (Figure 
3.2)   
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Alternatively, the formation of the “benzyne”- type 1,2-azaborine is a high-energy 
process. Consequently, the formation of the “benzyne” is likely the rate-determining step, 
for any processes involving the benzyne intermediate including Mechanism 2. This 
would lead to a reaction order of 0 (assuming the resting state prior to the rate determine 
step is intermediate A). The reaction order analysis and the calculated high energy of the 
BN “benzyne” are inconsistent with Mechanism 2 or any process involving BN 
“benzyne.”  Based on all of the available data, we believe that Mechanism 1 is the most 
consistent mechanism for the conversion of 3 into 1. 
 
Figure 3.4. Calculated free energies of the proposed intermediates in THF (B3LYP 
DZVP2 + COSMO THF (ε =7.43) level of theory, see Experimental) in the trimerization 
reaction at 298K 
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We then focused on the reactivity of BN-triphenylene 1.  We treated 1.5 
equivalents of trisacetonitriletricarbonylchromium(0) with 1, which gave crystalline 
complex 5 (Scheme 3.2). This complex is analogous to the all-carbon triphenylene 
complex in which chromium preferentially binds to a peripheral ring.24 We then 
examined the regeneration of 1,2-dihydro-1,2-azaborine 3 from compound 1.  Upon 
addition of potassium hydroxide in THF/EtOH (1: 1) followed by an aqueous work up, 
compound 6 was isolated in 89% yield (Scheme 3.3). Addition of LiAlH4 followed by 
capric acid in dihexyl ether at 0 ºC yielded 1,2-dihydro-1,2-azaborine in 55% yield by 
vacuum transfer.  Dewar attempted a similar procedure and was unable to isolate 1,2-
dihydro-1,2-azaborine, presumably due to the lack of acidic work-up in his synthesis.6 He 
abandoned 1,2-azaborines because he believed them to be too “reactive and chemically 
unstable, prone to polymerization and other reactions.” The field of 1,2-azaborine 
chemistry potentially could have been significantly different had he altered the 
preparative reaction conditions.6 
 
Scheme 3.2.  Synthesis of chromium complexed BN-triphenylene 5 
B
N
N
B
N
B
B
N
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Scheme 3.3. Regeneration of 1,2-dihydro-1,2-azaborine 3 
B
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3.4. Conclusion 
 In summary, we have presented a novel procedure to catalytically dehydrogenate 
1,2-dihydro-1,2-azaborine 1.  We have presented evidence for our proposed mechanism 
and have shown that 1,2-dihydro-1,2-azaborine 3 can readily be regenerated from BN-
triphenylene 1. This novel reaction may be used to create functionalized BN-
triphenylenes. 
 
3.5. Experimental 
General 
All oxygen- and moisture-sensitive manipulations were carried out under an inert 
atmosphere using either standard Schlenk techniques or a glove box. 
THF, Et2O, CH2Cl2, toluene and pentane were purified by passing through a neutral 
alumina column under argon. 
1,2-Dihydro-1,2-azaborine,17 was prepared according to the literature procedure. 
All other chemicals and solvents were purchased (Aldrich, Acros, TCI or Strem) and 
used as received. 
Silica gel (230-400 mesh) was heated under vacuum in a 200 °C sand bath for 12 
hours. Flash chromatography was performed with this silica gel under an inert 
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atmosphere. Preparative TLC (1000 µm thickness) plates were purchased from Silicycle 
and heated to 120° C for 18 h in an oven before usage under inert conditions. 
11B NMR spectra were recorded on a Varian Unity/Inova 300 spectrometer at 
ambient temperature. 1H NMR spectra were recorded on a Varian Unity/Inova 300 or 
Varian Unity/Inova 500 spectrometer. 13C NMR spectra were recorded on a Varian 
Unity/Inova 300 or Varian Unity/Inova 500 spectrometer. All chemical shifts are 
externally referenced: 11B NMR to BF3•Et2O (δ 0). 
IR spectra were recorded on a Nicolet Magna 550 FT-IR instrument with OMNIC 
software. 
 
Synthesis of Compound 1 
Compound 1: A vial was charged with a solution of 3 (10.4 mg, 0.133 mmol) 
and THF (2 mL). LiH (1.0 mg, 0.12 mmol) was added to the vessel and reacted for 1 
week. Slow evaporation of the solvent yielded crystalline compound 1.  
 
Trimerization: Optimization Survey (Table 2.1) 
Yields in Table 3.1 were determined by GC analysis of the reaction mixture 
versus pentadecane as a calibrated internal standard.  
General Procedure:  In a glove box, a J-Young tube was charged with a solution 
of 3 and THF, unless otherwise stated. The catalyst was added to the J-Young tube and 
brought to the reaction temperature for the specified amount of time. The progress of the 
reaction was monitored by 11B NMR. At the conclusion of the reaction, pentadecane was 
added to the vial.  The mixture was then passed through a silica gel plug with copious 
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washing using ether. An aliquot of the resulting solution was subjected to GC analysis.  
All GC yields have been corrected for response factors. 
Entry 1: The general procedure was followed, using 3 (13 mg, 0.161 mmol), LiH 
(2.1 mg, 0.161 mmol), THF (0.5 mL) and heated to 50 °C for 3 hours. GC analysis 
indicated the formation of 1 in 99% yield. 
Entry 2: The general procedure was followed, using 3 (15 mg, 0.196 mmol), LiH 
( 0.2 mg, 0.020 mmol), THF (0.5 mL) and heated to 80 °C for 12 hours. GC analysis 
indicated the formation of 1 in 99% yield. 
Entry 3: The general procedure was followed, using 3 (14 mg, 0.18 mmol), 
LiTMP (18 μL, 1.0 M solution in THF 0.018 mmol), THF (0.5 mL) and stirred for 2 
hours at room temperature. GC analysis indicated the formation of 1 in 99% yield.  
Entry 4: The general procedure was followed, using 3 (13 mg, 0.171 mmol), 
BF3Et2O (24 mg, 0.171 mmol), THF (0.5 mL) and heated at 50 °C for 96 hours. GC 
analysis indicated no formation of 1. 
Entry 5: The general procedure was followed, using 3 (12 mg, 0.158 mmol), HCl 
(79 μL, 2.0 M solution in Et2O, 0.079 mmol), THF (0.5 mL) and heated at 50 °C for 96 
hours. GC analysis indicated no product formation. 
Entry 6: The general procedure was followed, using 3 (11 mg, 0.140 mmol), 
(RhClCOD)2 (7.1 mg, 0.014 mmol), THF (0.5 mL) and heated at 50 °C for 96 hours. GC 
analysis indicated no product formation. 
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Entry 7: The general procedure was followed, using 3 (13 mg, 0.161 mmol), 
Pd/C (1.7 mg, 0.016 mmol), Toluene (0.5 mL) and heated at 110 °C for 48 hours. GC 
analysis indicated no product formation.e 
Entry 8: The general procedure was followed, using 3 (12 mg, 0.153 mmol), Pt/C 
(3.0 mg, 0.015 mmol), THF (0.5 mL) and heated at 50 °C for 96 hours. GC analysis 
indicated no product formation. 
Entry 9: The general procedure was followed, using 3 (11 mg, 0.144 mmol), 
CoCl2 (1.9 mg, 0.014 mmol), THF (0.5 mL) and heated at 50 °C for 96 hours. GC 
analysis indicated no product formation. 
Entry 10: The general procedure was followed, using 3 (11 mg, 0.144 mmol), 
Hexadecane (0.5 mL) and heated at 330 °C for 24 hours. GC analysis indicated no 
product formation. 
Compound 1: Compound 3 (14 mg, 0.182 mmol) placed into a vial along with 1 
mL THF. LiTMP (18 μL, 1M in THF, 0.018 mmol) was added dropwise to the reaction. 
The mixture was stirred at room temperature for 2 hours, and then concentrated under 
reduced pressure.  The mixture was subjected to silica gel chromatography with pentane 
as eluent that yielded crystalline compound 1 (13 mg, 93%).   
1H NMR (300 MHz, CD2Cl2): 1H NMR (500 MHz, THF-d8): δ8.24 (d, 3JHH =6.7, 3H), 
7.80 (dd, 3JHH = 6.1, 5.3 Hz, 3H), 7.18 (d, 3JHH =11.5, 3H), 6.48 (t, 3JHH = 7.3 Hz, 3H). 
13C NMR (125 MHz, THF-d8): δ147.03, 136.51, 120 (br), 112.23. 11B NMR (96.3 MHz, 
THF-d8): δ 30.7. FTIR (thin film) 3584, 2925, 1614, 1524, 1453, 1410, 1316, 1262, 1019, 
                                                
e Reaction was also carried out at 50 °C in THF for 96 hours with no product formation. 
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800, 764, 739, 725, 701 cm–1. HRMS (EI) calcd for C12H12B3N3 (M+) 231.13104, found 
231.13091. 
 
Automated Gas Burette Measurements  
General Procedure: The automated gas burette used was based on the design 
reported by Sneddon.23
 
The burette system was purged of air by repeated 
evacuation/nitrogen cycles (3x). Compound 3 (100 mg, 1.27 mmol) was loaded into a 
two-neck, 100 mL flask and 0.5 mL THF. LiTMP (0.127 mL, 1M in THF, 0.127 mmol) 
was placed into an addition funnel with 3.50 mL THF. The reaction flask was attached to 
the burette apparatus under flowing N2. Once the system pressure equalized, the data 
collection program was started and the LiTMP was quickly added to the reaction flask.  
 
Figure 3.5. Automated burette measurement of H2 release catalyzed by LiTMP 
 
Reaction Order Experiments 
 General Procedure: In a glove box, a J-Young tube was charged with a solution 
of 3 and THF-d8. The catalyst was added to the J-Young tube and the progress of the 
reaction 1H NMR with hexamethylbenzene as an internal standard. 
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1.4 M: The general procedure was followed, using 3 (27.1 mg, 0.266 mmol), 
THF-d8 (0.25 mL) and LiTMP (27 µL, 1M solution in THF-d8, 0.027 mmol). kobs= 2.11 
x10-4.   
0.7 M:  The general procedure was followed, using 3 (13.6 mg, 0.172 mmol), 
THF-d8 (0.25 mL) and LiTMP (17 µL, 1M solution in THF-d8, 0.017 mmol). kobs= 1.42 
x10-4.   
0.35 M:  The general procedure was followed, using 3 (14.6 mg, 0.180 mmol), 
THF-d8 (0.50 mL) and LiTMP (18 µL, 1M solution in THF-d8, 0.018 mmol). kobs= 1.11 
x10-4.   
0.18 M:  The general procedure was followed, using 3 (15.0 mg, 0.19 mmol), 
THF-d8 (1.0 mL) and LiTMP (19 µL, 1M solution in THF-d8, 0.019 mmol). kobs=6.96 
x10-5.  
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Calculations and Rate Derivations:  
 
 
Mechanism 1:  
 
 
Figure 3.6. Solution phase (THF) calculations for the step-wise trimerization of 1,2-
dihydro-1,2-azaborine with LiTMP  
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 Derived Rate Law for Mechanism 1: 
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Mechanism 2: 
 
 
Figure 3.7. Solution phase calculations for the benzyne-type mechanism of the 
trimerization of 1,2-dihydro-1,2-azaborine  3 with LiTMP.   
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Reactivity Studies of Compound 1 
 Compound 5: Compound 1 (15.0 mg, 0.065 mmol) was placed into a vial with 2 
mL THF and trisacetonitriletricarbonylchromium(0) (25.1 mg, 0.098 mmol) and stirred 
overnight.  The mixture was concentrated under reduced pressure and the crude mixture 
was subjected to silica gel chromatography using pentane/Et2O as eluent, yielding the 
desired compound 5 (0.014g, 58%) as a orange powder. Slow evaporation from Et2O 
resulted in crystalline compound 5.  
1H NMR (300 MHz, CD2Cl2): 1H NMR (300 MHz, CD2Cl2): δ 8.25, (d, 3JHH = 6.4 Hz 
1H), 8.08 (d, 3JHH = 6.8 Hz, 1H), 7.91 (m, 2H), 7.10 (d, 3JHH = 11.7 Hz 1H), 7.01 (s, 1H), 
6.83 (d, 3JHH = 11.7 Hz 1H), 6.57 (m, 2H), 6.30 (t, 3JHH = 5.9 Hz 1H),  5.58 (t, 3JHH = 5.9 
Hz, 1H), 5.23 (d, 3JHH = 9.8 Hz 1H). 11B NMR (96.3 MHz, CD2Cl2): δ 29.6, 18.8.  
 Compound 6:  Compound 1 (61.1 mg, 0.264) was placed into a vial with 2 mL 
THF and 2 mL EtOH.  KOH (59.4 mg, 1.06 mmol) was added and stirred for 4 hours at 
room temperature.  The mixture was concentrated under reduced pressure followed by 
addition of 1 mL of H2O, which was subsequently extracted with Et2O. Yielding 
compound 6 (67.1, 89%) as a yellow liquid. 
 1H NMR (300 MHz, CD2Cl2): δ 7.62, (d, 3JHH = 7.6 Hz 1H), 7.17 (m, 2H), 6.43 (d, 3JHH 
= 11.7 Hz 1H), 6.05 (t 3JHH = 6.4 Hz, 1H), 11B NMR (96.3 MHz, CD2Cl2) δ 28.4. HRMS 
(EI) calcd. for C8H11N2B2O (M+) 173.1058, found 173.1063. 
Compound 3: A vial was charged with a solution of 6 (0.200 g, 1.15 mmol) and 
dihexyl ether (2 mL). The vessel was sealed and cooled to _30 °C.  LiAlH4 (0.044 g, 1.15 
mmol) was added to the vessel and reacted for 3 h. Capric Acid (0.398 g, 2.31 mmol) was 
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slowly added to the reaction mixture and reacted for 1 h at _30 °C, then allowed to warm 
to room temperature and  reacted an additional hour.  The mixture was passed through a 
plug of silica gel with dihexyl ether and subjected to vacuum transfer yielding the desired 
compound 4 (0.100 g, 55%) as a clear colorless liquid. Characterization is consistent with 
previous work. 
1H NMR (300 MHz, CD2Cl2): δ 8.44 (t, 1JNH = 57 Hz, 1H), 7.70 (t, 3JHH = 6.2 Hz, 1H), 
7.40 (t, 3JHH = 6.5 Hz, 1H), 6.92 (d, 3JHH = 10.7 Hz, 1H), 6.43 (t , 3JHH = 6.5 Hz, 1H), 4.9 
(br, q, 1JHH =128 Hz, 1 H). 11B NMR (96.3 MHz, CD2Cl2): δ 31.0 (1JBH = 130 Hz). 
 
3.6. Bridge from Chapter III to Chapter IV 
 Chapter III of this dissertation explored the trimerization of 1,2-dihydro-1,2-
azaborine, the reaction kinetics, rate law and most likely mechanisms. Several reactions 
involving compound 1 were discussed.  Chapter IV explores a protection free method to 
synthesize a variety of 1,2-azaborines. Reactivity studies on a BN-triphenylmethane 
mimic will be discussed. 
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CHAPTER IV 
NOVEL SYNTHETIC ROUTE TO 1,2-DIHYDRO-1,2-AZABORINES 
 
4.1. General Overview 
 This chapter describes unpublished work.  A novel protection free method to 
synthesize 1,2-dihydro-1,2-azaborines will be discussed. I performed most of the lab 
work; Eric Abbey developed the concept of protection free synthesis and the lab protocol 
for the boron-butoxide substituted 1,2-azaborine conversion into the more versatile B-Cl 
substituted 1,2-azaborine. Lev Zakharov provided the X-ray crystallography data. Eric 
Abbey and I wrote this manuscript. Shih-Yuan Liu provided scientific guidance and 
editorial assistance for all the material in this chapter.   
 
4.2. Introduction 
Substitution of the CC bond in arene scaffolds with a BN bond has provided new 
perspectives on concepts related to aromaticity, such as resonance stabilization,1 aromatic 
substitution reactions,2,3  and the structural consequences of π-bonding.4 BN-substitution  
tunes the electronic and reactivity profiles of established material and biological 
molecules. 1,2-Dihydro-1,2-azaborines (abbreviated as 1,2-azaborines) have attracted 
recent attention for their unique optical properties,5 favorable hydrogen storage 
parameters,6 and for examples of substitution into biological7 and pharmaceutical motifs.8 
Dewar9 and White10 were the pioneers of 1,2-azaborine chemistry, creating the first 
examples in the 1960’s. After a period of relative inactivity, many synthetic milestones 
have been reached in the past 20 years; notably the developments by Ashe,11 Piers,12 and 
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Liu.13 The full potential of this heterocycle has yet to be fully realized.  Significant 
synthetic hurdles must be overcome in order to allow more efficient construction of 1,2-
azaborine cores, and the ability to incorporate them into complex molecular scaffolds at 
will. 
In the past, chemists had to choose between 1,2-azaborine synthons containing 
labile groups on either nitrogen, such as Ashe’s N-TMS 1,2-azaborine 1,14 or boron such 
as our B-Cl 1,2-azaborine 28 (Figure 4.1). In both cases, the syntheses required that a 
non-labile group be attached to neighboring boron or nitrogen atoms, respectively. Our 
group recently synthesized the parent 1,2-dihydro-1,2-azaborine 4,15 from N-TBS B-Cl-
1,2-azaborine 3, which is the first example of a 1,2-azaborine that can be functionalized 
at both nitrogen and boron positions (Scheme 4.1). However, creating the parent 4 from 3 
requires four additional synthetic steps, one to install the B-H and three subsequent steps 
to remove the N-TBS protecting group. Fluoridic deprotection of N-TBS with 
HF·pyridine in the parent 1,2-azaborine synthesis proceeds in 76% yield, but requires 
complexation with stoichiometric chromium(0) in 71% yield, followed by a costly 
demetallation step with only a 10% isolated yield. The synthesis of precursor 3 also 
requires the use of stoichiometric organotin reagents, which are expensive and toxic.  
 
 
Figure 4.1. Previous 1,2-azaborine synthons 
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Scheme 4.1. Synthesis of the parent 1,2-dihydro-1,2-azaborine 4 
 
 
This chapter describes the protection-free synthesis of a new 1,2-azaborine 
synthon 8, which can be readily functionalized at boron and nitrogen. Reevaluation of our 
starting materials negates the need for an N-protecting group, resulting in a higher 
yielding, greenerf,16 and more cost-effective route to BN-substituted phenyl analogs that 
more accurately mimic their organic relatives. The new synthon 8 is available in three 
synthetic steps from commercially available materials.  
 
4.3. Protection Free Synthesis of 1,2-Dihydro-1,2-Azaborines 
By generating allylboron dichloride in-situ from the commercially available 
potassium allyltrifluoroborate, we eliminate the need for tin. Instead of keeping one of 
                                                
f The strategies of increasing atom economy, reducing derivatives such as protecting 
groups, and relying on catalytic methods when possible are consistent with three of the 
twelve principles of Green Chemistry. 
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the B-Cl bonds intact as in our previous syntheses, we quench both B-Cl bonds at once 
with allylamine to afford the much less reactive 9 in 61% yield (Scheme 4.2). By 
eliminating the reactive B-Cl bond, we negate the need for an N-protecting group. Ring-
closing metathesis with Schrock’s Mo catalyst allows access to heterocycle 10 in 88% 
yield with the N-H bond intact. Substitution of the B-allylamino fragment with n-butanol 
followed by Pd/C oxidation in cyclohexene and affords the chromatographable 8 in 40% 
yield. 
 
Scheme 4.2. Synthesis of synthon 8 
  
 
The azaborine synthon 8 allows for synthesis of the parent 1,2-azaborine 4 in 4 
steps instead of the 8 steps used in Marwitz’s original synthesis (Scheme 4.3). Treatment 
of 8 with LAH followed by solid NH4Cl in high-boiling dihexyl ether at _30 °C allows 
isolation of clean parent 4 via vacuum transfer in 22% yield (55% by 1H NMR.) Dewar’s 
original attempts at synthesizing 4 started with precursor 11 that is similar to our synthon 
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8. Dewar treated 11 with LAH, detecting parent 4 by mass spectrometry, but the material 
“resinified quickly”.17 He concluded that 1,2-azaborines are too reactive and ceased work 
on this scaffold. Had he used a protic workup, he would have probably succeeded in 
isolation of the parent 4 almost 50 years earlier. 
 
Scheme 4.3. Dewar’s attempted synthesis of 1,2-dihydro-1,2-azaborine 
 
 
The parent 4 can be derivatized to provide other simple benzenoid mimics 
containing a free N-H group using nucleophilic aromatic substitution reactions,3 but the 
starting material requires eight synthetic steps to create. Using the new synthon 8, many 
of the same BN analogs of important benzenoids can be accessed in five fewer steps if 8 
is substituted directly. This newfound economy provides access to many unprecedented 
BN isosteres of phenyl-based molecules containing a free N-H, the exploration of which 
was cost-prohibitive using existing protocols. 
The derivatization of 8 demonstrates the promise of this new route. Addition of 
vinylmagnesium bromide followed by acidic workup affords the previously reported BN 
  
 
96 
styrene analog 1218 in 53% yield (Scheme 4.4) Treatment with n-BuLi followed by acidic 
workup affords the B-nBu derivative 13 in 83% yield. As was previously demonstrated 
with the parent 1,2-azaborine 4, functionalization of both nitrogen and boron can be 
achieved in one step. The addition of MeLi to 8 installs a methyl group on boron, which 
can be quenched with TMSCl to afford the B-Me N-TMS derivative 14 in 63% yield or 
with MeI to afford the BN o-xylene analog 15 in 49% yield. 
 
Scheme 4.4. Derivatization of synthon 5 
 
 
Conditions: a) vinylMgBr, _30 °C Et2O; HCl, 53%; b) n-BuLi, _30 °C Et2O; HCl, 83%; c) 
MeLi, _30 °C Et2O; TMSCl, 63%; d) MeLi, _30 °C Et2O; MeI; 49% e) LAH, _30 °C 
Hex2O; NH4Cl, 22%; (55% by 1H NMR)  f) Ph2CHLi, _30 °C pentane; HCl, 75%; g) 
NaOPh, _30 °C, pentane, 66%; h) NaOCOBn, _30 °C pentane, 63%;  
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Other nucleophiles incapable of displacing the strong BO bond can still be added 
to 8. Pretreatment with of 8 with BCl3 generates a much more electrophilic boron center. 
In-situ generation of B-Cl N-H azaborine 16 at _30 °C allows less reactive nucleophiles to 
be added to 16 without the need to protect the nitrogen (Scheme 3.3). Treatment of 16 
with diphenylmethyl lithium followed by acidic workup affords the BN triphenylmethane 
analog 17 in 75% yield.  Heteroatoms such as oxygen can also be added to 16, the 
potassium salt of phenol readily adds to create a diphenyl ether mimic 18. The potassium 
salt of phenylacetic acid will also readily add to form the crystalline product 19.  
Exploration of the synthetic possibilities of 8 are just beginning, but the first glimpses 
into the reactivity demonstrate the wider range of substitution patterns made available by 
this intermediate.  
 
4.4. BN-Triphenylmethane  
Many fundamental aspects of incorporating a 1,2-azaborine have yet to be fully 
explored. The central carbon on triphenylmethane is significantly more acidic (pKa=30.6) 
than most hydrocarbons.19 BN-triphenylmethane 17 has the potential to be deprotonated 
at multiple sites (NH and CH). Our initial attempt to deprotonate compound 17 with KH 
(1 and 2 equivalents) only deprotonated the NH of the 1,2,-azaborine (pKa =26)20 leaving 
the central CH untouched.  We then tried a more soluble non-nucleophilic base LiTMP, 
the equivalents of LiTMP were varied from 1-5; even with 5 equivalents of LiTMP the 
methyne CH remains untouched. This indicates that the CH adjacent to boron in 17 has a 
higher pKa than triphenylmethane, which is readily deprotonated by LiTMP.  
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Further deprotonation could be hindered by the formation of the dianion  
therefore, we synthesized compound 20 replacing the NH with a methyl (Scheme 4.5). 
We were able to obtain x-ray quality crystals to unambiguously determine the structure.  
Compound 20 was subjected to 1 and 2 equivalents of LiTMP which did not deprotonate 
the methyne CH, reinforcing the fact that the pKa of the methyne CH is higher than 37 
for the BN-triphenylmethane mimics.  PhLi (pKa = 43) was also tested and resulted in 
addition to boron, not the desired deprotonation.  Bulkier t-BuLi was employed but 
resulted in a complex mixture of products. Unfortunately, the electrophilicity of boron 
inhibits the definitive pKa determination, but 1,2-azaborines seem to significantly raise 
the pKa of an adjacent X-H bond consistent with previous results.21   
 
Scheme 4.5. Synthesis of methyl substituted BN-triphenylmethane 20. ORTEP 
illustration of 20, with thermal ellipsoids drawn at the 35% level 
 
 
 
 
 
  
 
4.5. Conclusion  
This new method to easily-synthesize BN analogs of fundamentally interesting 
benzenoids, as well as more complex scaffolds desired for possible application, show 
promise. The synthetic economy gained by circumventing protection/deprotection 
protocols enables access to novel 1,2-azaborine structures. With less time and resources 
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required for the synthesis of 1,2-azaborine structures, efforts can be redirected towards 
studying the properties of these heterocycles and exploring possible applications derived 
thereof.   
 
4.6. Experimental 
General 
All oxygen- and moisture-sensitive manipulations were carried out under an inert 
atmosphere using either standard Schlenk techniques or a glove box. 
Et2O, CH2Cl2, THF and pentane were purified by passing through a neutral alumina 
column under argon. Acetonitrile was distilled from molecular sieves (3Å),  Potassium 
hydride was washed with pentane three times prior to use. 10% Pd/C was purchased from 
Strem and dried by heating under reduced pressure overnight. All other chemicals and 
solvents were purchased (Aldrich, TCI, or Strem) and used as received. 
11B NMR spectra were recorded on a Varian Unity/Inova 600 or a Varian Unity/Inova 
300 spectrometer at ambient temperature. 1H NMR spectra were recorded on a Varian 
Unity/Inova 300 or Varian Unity/Inova 600 spectrometer. 13C NMR spectra were 
recorded on a Varian Unity/Inova 300 or Varian Unity/Inova 500 spectrometer. All 
chemical shifts are externally referenced: 11B NMR to BF3Et2O (δ 0). 
IR spectra were recorded on a Nicolet Magna 550 FT-IR instrument with OMNIC 
software. High-resolution mass spectroscopy data were obtained at the Mass 
Spectroscopy Facilities and Services Core of the Environmental Health Sciences Center 
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at Oregon State University. Financial support for this facility has been furnished in part 
by the National Institute of Environmental Health Sciences, NIH (P30 ES00210). 
 
 
Synthesis 
Compound 9: In a 2 L round bottom flask (RBF) equipped with a reflux 
condenser fitted with a septum, and a stir bar, potassium allyltrifluoroborate (45.00 g, 
304.1 mmol) was suspended in acetonitrile (800 mL) under N2. Allylamine (113.7 mL, 
1.52 mol) was added quickly to the suspension while stirring under N2, followed by 
dropwise addition of TMSCl (115.8 mL, 912.3 mmol). The reaction was heated to reflux 
for 16 h, and cooled to room temperature. Approximately half the solvent was removed 
under reduced pressure and the mixture was filtered through a filter stick containing a 
glass frit. The remainder of the solvent was removed under reduced pressure and the 
crude product was purified by fractional vacuum distillation (55 °C, 350 mTorr) to afford 
the clear colorless product 9 (30.7 g, 61%). 
1H NMR (500 MHz, CDCl3): δ 5.77 (m, 2H), 4.97 (m, 4H), 4.84 (m, 2H), 3.39 (s br, 4H), 
2.48 (s br, 2H), 1.54 (d 3JHH = 7.6 Hz, 2H). 13C NMR (125 MHz, CD2Cl2): δ 140.4 (br), 
138.5, 113.8, 113.4, 45.1 (br), 22.5 (br). FTIR (thin film) 3424, 3021, 2977, 2851, 1659, 
1519, 1473, 1395, 998, 914, 669. HRMS (EI) calcd. for C9H16BN2 (M+) 163.14066, 
found 163.13923. 
 
Compound 10: In a 250 mL RBF equipped with a stir bar in a glove box, 9 (3.30 
g, 20.1 mmol) was dissolved in CH2Cl2 (80 mL.) Schrock’s Mo catalyst (462 mg, 0.600 
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mmol) was dissolved in CH2Cl2 (20 mL) and added quickly to the stirred solution, and 
reacted for 90 min under N2. The reaction was judged to be complete by 1H NMR, and 
the solvent was removed under reduced pressure. The crude mixture was purified by 
fractional vacuum distillation (45 °C, 400 mTorr) to afford 10 (2.40 g, 88%) as a clear 
colorless liquid.  
1H NMR (500 MHz, CDCl3): δ 5.89 (m, 1H), 5.77 (s br, 1H), 5.58 (m, 1H), 5.13 (app d 
3JHH =17.1 Hz, 1H), 5.01 (app d 3JHH = 11.2 Hz, 1H), 3.67 (s, 2H), 3.45 (m, 2H), 2.93 (s 
br, 1H), 2.42 (s br, 1H), 1.30 (s, 2H). 13C NMR (125 MHz, CD2Cl2): δ140.1, 126.1, 
125.9, 113.4, 44.1, 42.8, 12.0 (br). 11B NMR (96.3 MHz, CD2Cl2)δ 30.5. FTIR (thin film) 
3426, 3076, 2980, 2912, 2853, 1633, 1503, 1463, 1309, 1270, 995, 915. HRMS (EI) 
calcd. for C7H12N2B (M+) 135.10936, found 135.10942. 
 
Compound 8: A 100 mL Parr bomb equipped with a stir bar in a glove box was 
charged with a solution of 10 (1.00 g, 7.35 mmol) in CH2Cl2 (20 mL.) n-Butanol (545 
mg, 7.35 mmol) in CH2Cl2 (2 mL) was added dropwise to the solution while stirring 
vigorously. The reaction was stirred for 16 h, followed by solvent removal under reduced 
pressure. Cyclohexene (40 mL) followed by 10% Pd/C (1.56 g, 1.47 mmol) was added, 
and the vessel was sealed and heated to 60 °C for 24 h. After cooling to room 
temperature, the mixture was filtered through a glass frit and washed with CH2Cl2 (30 
mL.) The solvent was removed under reduced pressure and the crude product was 
purified with a short plug of silica (3:1 pentane/Et2O) to afford 8 (443 mg, 40%) as light 
yellow liquid. 
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 1H NMR (500 MHz, CD2Cl2): δ 7.54, (m, 1H), 7.05 (t 3JHH = 7.6 Hz, 1H), 6.89 (s br, 
1H), 6.29 (d 3JHH = 11.7 Hz, 1H), 5.91 (d 3JHH = 7.0 Hz, 1H), 3.95 (t 3JHH = 6.7 Hz, 2H), 
1.65 (m, 2H), 1.43 (m, 2H), 0.95 (m, 3H). 11B NMR (96.3 MHz, CD2Cl2) δ 29.1. FTIR 
(thin film) HRMS (EI) calcd. for C8H14NBO (M+) 151.11685, found 151.11686. 
 
Compound 12: In a glove box, a 4 mL vial was charged with a solution of 8 
(0.054 g, 0.35 mmol), and ether (1 mL). The vessel was sealed and cooled to _30 °C.  
Vinylmagnesium bromide (1.0 M in Et2O; 0.710 mL, 0.71 mmol) was added to the vessel 
and reacted for 3 h. Cold HCl (2.0 M in Et2O; 0.354 mL, 0.71 mmol) was slowly added 
to the reaction mixture and reacted for 1 h at  _30 °C, then allowed to warm to room 
temperature and reacted an additional hour.  The mixture was concentrated under reduced 
pressure and the crude mixture was subjected to silica gel chromatography using pentane 
as eluent, yielding 12 (0.023g, 62%) as a clear colorless oil.  Characterization is 
consistent with previous work.22 
1H NMR (300 MHz, CD2Cl2): δ 8.03 (s, 1H), 7.77 (dd, 3JHH = 6.4, 11 Hz, 1H) 7.39 ( t, 
3JHH = 7.0  Hz, 1H), 6.94 (d, 3JHH = 7.0  Hz, 1H) 6.48 (m, 1H), 6.37 (t, 3JHH = 19.8, 13.4 
Hz, 1H), 6.05(d, 3JHH = 12.4 Hz, 1H), 5.93 (d, 3JHH = 6.4 Hz, 1H), 11B NMR (96.3 MHz, 
CD2Cl2): δ 33.9.  
 
Compound 13: In a glove box, a 4 mL vial was charged with a solution of 8 
(0.047 g, 0.31 mmol) and ether (2 mL). The vessel was sealed and cooled to _30 °C.  
BuLi (2.5 M in hexane; 0.250 mL, 0.62 mmol) was added to the vessel and reacted for 3 
h. Cold HCl (2.0 M in Et2O; 0.241 mL, 0.48 mmol) was slowly added to the reaction 
  
 
103 
mixture and reacted for 1 h at  _30 °C, then allowed to warm to room temperature and 
reacted an additional hour.  The mixture was concentrated under reduced pressure and the 
crude mixture was subjected to silica gel chromatography using pentane as eluent, 
yielding the desired compound 13 (0.035g, 83%) as a clear colorless liquid. 
Characterization is consistent with previous work.3 
1H NMR (300 MHz, CD2Cl2): δ 7.81 (s, 1 H), 7.63 (dd, 3JHH = 6.4, 4.7 Hz, 1H), 7.16 (t, 
3JHH = 6.7 Hz, 1H), 6.63 (d, 3JHH = 11.1 Hz, 1H), 6.15 (t, 3JHH = 6.4 Hz, 1H), 1.43 (m, 
4H), 1.13 (m, 2H), 0.96 (t, 3JHH = 7.0 Hz, 3H). 11B NMR (96.3 MHz, CD2Cl2):  δ 38.3 
 
Compound 14: In a glove box, a 4 mL vial was charged with a solution of 8 
(0.051 g, 0.34 mmol) and ether (2 mL). The vessel was sealed and cooled to  _30 °C.  
MeLi (1.6 M in hexane; 0.420 mL, 0.67 mmol) was added to the vessel and reacted for 3 
h. Cold TMSCl (0.0731 mL, 0.67 mmol) was slowly added to the reaction mixture and 
reacted for 1 h at _30 °C, then allowed to warm to room temperature and reacted an 
additional hour.  The mixture was concentrated under reduced pressure and the crude 
mixture was subjected to silica gel chromatography using pentane as eluent, yielding the 
desired compound (0.035g, 63%) as a clear colorless liquid. 
1H NMR (300 MHz, CD2Cl2): δ 7.48 (dd, 3JHH = 6.4, 4.4 1H), 7.34 (d, 3JHH = 6.4 Hz, 
1H), 6.63 (d, 3JHH = 10.7 Hz, 1H), 6.24 (t, 3JHH = 6.4 Hz, 1H), 0.84 (s, 3H), 0.48 (s, 9H). 
13C NMR (125 MHz, CD2Cl2): δ 143.0, 137.8, 132 (br), 111.1 20 (br), 1.7. 11B NMR 
(96.3 MHz, CD2Cl2): δ40.4. FTIR (thin film) 3068, 3024, 2962, 1607, 1509, 1452, 1393, 
1310, 1268, 1256, 1202, 1150, 1084, 1017, 994, 884, 845, 760, 737, 629 cm–1. HRMS 
(EI) calcd for C8H16BNSi (M+) 165.1145, found 165.1144. 
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  Compound 15: In a glove box, a 4 mL vial was charged with a solution of 8 
(0.052 g, 0.34 mmol) and ether (2 mL). The vessel was sealed and cooled to _30 °C.  
MeLi (1.6 M in hexane; 0.430 mL, 0.68 mmol) was added to the vessel and reacted for 3 
h. Cold MeI (0.097 g, 0.68 mmol) was slowly added to the reaction mixture and reacted 
for 1 h at _30 °C, then allowed to warm to room temperature and reacted an additional 
hour.  The mixture was concentrated under reduced pressure and the crude mixture was 
subjected to silica gel chromatography using pentane as eluent, yielding the desired 
compound 15 (0.018g, 49%) as a clear colorless liquid. 
1H NMR (300 MHz, CD2Cl2): δ 7.47(dd, 3JHH = 6.2, 5.3, 1H), 7.19 (d, 3JHH = 6.5 Hz, 1H), 
6.63 (d, 3JHH = 10.8 Hz, 1H), 6.19 (t, 3JHH = 6.73 Hz, 1H), 3.51 (s, 3H), 1.31 (s, 3H). 11B 
NMR (96.3 MHz, CD2Cl2): ): δ 37.4. FTIR (thin film) 2964, 2951, 2939, 1610, 1517, 
1463, 1417, 1402, 1266,1123, 701, 626 cm–1. HRMS (EI) calcd for C6H11BN (M+) 
108.0985, found 108.0983. 
 
Compound 4: In a glove box, a 4 mL vial was charged with a solution of 8 
(0.154 g, 1.02 mmol) and dihexyl ether (2 mL). The vessel was sealed and cooled to _30 
°C.  LiAlH4 (0.020 g, 0.50 mmol) was added to the vessel and reacted for 3 h. 
Ammonium chloride (0.110, 2.04 mmol) was slowly added to the reaction mixture and 
reacted for 1 h at _30 °C, then allowed to warm to room temperature and  reacted an 
additional hour.  The mixture was passed through a plug of silica gel with dihexyl ether 
and subjected to vacuum transfer yielding the desired compound 4 (0.018 g, 22%) as a 
clear colorless liquid. Characterization is consistent with previous work.15 
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1H NMR (300 MHz, CD2Cl2): δ 8.44 (t, 1JNH = 57 Hz, 1H), 7.70 (t, 3JHH = 6.2 Hz, 1H), 
7.40 (t, 3JHH = 6.5 Hz, 1H), 6.92 (d, 3JHH = 10.7 Hz, 1H), 6.43 (t , 3JHH = 6.5 Hz, 1H), 4.9 
(br, q, 1JHH =128 Hz, 1 H). 11B NMR (96.3 MHz, CD2Cl2): δ 31.0 (1JBH = 130 Hz). 
 
Compound 17: In a glove box, a 4 mL vial was charged with a solution of 8 
(0.018 g, 0.12 mmol) and pentane (1 mL). The vessel was sealed and cooled to _30 °C.  
Diphenylmethane lithiate  (0.0.62 mL, 0.36 mmol) in 2 mL THF was added to the vessel 
and reacted for 3 h at – 30°C.  Cold HCl (2.0 M in Et2O; 0.180 mL, 0.36 mmol) was 
slowly added to the reaction mixture and reacted for 1 h at  _30 °C, then allowed to warm 
to room temperature and reacted an additional hour.  The mixture was concentrated under 
reduced pressure and the crude mixture was subjected to silica gel chromatography using 
pentane/CH2Cl2 as eluent, yielding the desired compound 17 (0.021g, 75%) as a solid. 
1H NMR (300 MHz, CD2Cl2): 1H NMR (300 MHz, CD2Cl2): δ7.72 (s, 1H), 7.59 (dd, 
3JHH = 6.8, 4.4 Hz, 1H), 7.24 (m, 11H), 6.63 (d, 3JHH = 11.7 Hz, 1H), 6.29 (t, 3JHH = 6.8 
Hz 1H), 4.33 (s, 1H). 13C NMR (125 MHz, CD2Cl2): δ 145.8, 144.3, 134.0, 130.1, 130 
(br), 129.0, 128.9, 128.3, 125.8, 110.7, 47 (br). 11B NMR (96.3 MHz, CD2Cl2): δ 36.9. 
FTIR (thin film) 3378, 3058, 3022, 2927, 1615, 1598, 1576, 1533, 1492, 1460, 1419, 
1154, 1154, 1072, 1030, 990, 789, 741, 722, 700, 608, 582 cm–1. HRMS (EI) calcd for 
C17H16BN (M+) 245.1376, found 245.1387. 
 
Compound 18: In a glove box, a round bottom flask was charged with a solution 
of 8 (0.150g, 0.99 mmol) and pentane (10 mL). The vessel was sealed and cooled to _30 
°C.  BCl3 (1 M, 0.60 mL, 0.60 mmol) was added to the cooled reaction solution slowly, 
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and reacted at – 30°C for 1 hour.  In a separate flask, potassium hydride (0.071 g, 1.8 
mmol) was added to a solution of phenol (0.90 g, 0.66 mmol in 15 mL THF) and reacted 
for 1 hr at room temperature.  The potassium salt was cooled to _30 °C and slowly added 
to the B-Cl solution, then allowed to warm to room temperature and reacted an additional 
hour.  The mixture was concentrated under reduced pressure and subjected to silica gel 
chromatography with pentane/Et2O as eluent yielding 18 (0.112g, 66%) as a crystalline 
solid. 
1H NMR (300 MHz, CD2Cl2): δ7.72 (s, 1H), 7.59 (dd, 3JHH = 6.8, 4.4 Hz, 1H), 7.24 (m, 
11H), 6.63 (d, 3JHH = 11.7 Hz, 1H), 6.29 (t, 3JHH = 6.8 Hz 1H), 4.33 (s, 1H). 13C NMR 
(125 MHz, CD2Cl2): δ 145.8, 144.3, 134.0, 130.1, 130 (br), 129.0, 128.9, 128.3, 125.8, 
110.7, 47 (br). 11B NMR (96.3 MHz, CD2Cl2): δ 36.9. FTIR (thin film) 3378, 3058, 3022, 
2927, 1615, 1598, 1576, 1533, 1492, 1460, 1419, 1154, 1154, 1072, 1030, 990, 789, 741, 
722, 700, 608, 582 cm–1. HRMS (EI) calcd for C10H11BNO (M+) 172.0934, found 
172.09251. 
 
Compound 19: In a glove box, a 4 mL vial was charged with a solution of 8 
(0.050g, 0.33 mmol) and pentane (2 mL). The vessel was sealed and cooled to _30 °C.  
BCl3 (1 M, 0.20 mL, 0.20 mmol) was added to the cooled reaction solution slowly, and 
reacted at – 30°C for 1 hour.  In a separate vial, potassium hydride (0.026 g, 0.66 mmol) 
was added to a solution of phenylacetic acid (0.90 g, 0.66 mmol in 3 mL THF) and 
reacted for 1 hr at room temperature.  The potassium salt was cooled to _30 °C and slowly 
added to the B-Cl solution, then allowed to warm to room temperature and reacted an 
additional hour.  The mixture was concentrated under reduced pressure.  The mixture was 
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dissolved in pentane and filtered through an across disc.  The solution was then reduced 
to ~1 mL pentane and recrystalized at _30 °C yielding the desired compound 19 (0.043g, 
63%) as a crystalline solid. 
1H NMR (300 MHz, CD2Cl2): δ 8.97 (s, 1H), 7.74 (dd, 3JHH = 6.9, 4.3 Hz, 1H), 7.33 (m, 
6H), 6.46 (d, 3JHH = 11.2 Hz, 1H), 6.25 (t, 3JHH = 6.4 Hz, 1H), 3.83 (s, 2H). 13C NMR 
(125 MHz, CD2Cl2): δ172.4 147.2, 132.6, 129.5, 129.4, 128.5, 127.0, 121 (br), 109.0, 
42.9. 11B NMR (96.3 MHz, CD2Cl2): δ 28.2. FTIR (thin film) 3394, 3031, 1958, 1702, 
1614, 1528, 1497, 1459, 1427, 1408, 1384, 1360, 1314, 1228, 1151, 1083, 801, 747, 701 
cm–1. HRMS (EI) calcd for C12H13BNO2 (M+) 214.1039, found 214.1044. 
 
Compound 20: In a glove box, a 4 mL vial was charged with a solution of 17 
(0.010 g, 0.041 mmol in 2 mL THF). The vessel was sealed and cooled to _30 °C.  
Lithium tetramethylpiperidine (1.0 M in THF; 0.049 mL, 0.049 mmol) was slowly added 
to the vessel and reacted for 15 minutes at – 30°C then allowed to warm to room 
temperature. The mixture was then cooled back to – 30°C and a solution of iodomethane 
(0.007 g, 0.049 mmols in 1 mL THF) was slowly added to the reaction mixture and 
reacted for 30 minutes at  _30 °C, then allowed to warm to room temperature and reacted 
an additional 2 hours.  The mixture was concentrated under reduced pressure and the 
crude mixture was subjected to silica gel chromatography using pentane as eluent, 
yielding the desired compound 20 (0.0092g, 87%) as a white powder. Crystals were 
grown from slow evaporation from Et2O.  
1H NMR (500 MHz, CD2Cl2): δ7.50 (dd, 3JHH =6.8, 4.4 Hz, 1H), 7.28 (t, 3JHH = 7.3 Hz, 
4H), 7.19 (m, 6 H), 6.36 (d, 3JHH = 11.2 Hz, 1H), 6.28 (t, 3JHH = 5.4 Hz 1H), 4.39 (s, 1H), 
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3.44 (s, 3H). 13C NMR (125 MHz, CD2Cl2): δ146.1, 143.1, 140.7, 131 br, 130.2, 128.8, 
125.5, 110.8, 45 br, 41.9. 11B NMR (96.3 MHz, CD2Cl2): δ 37.7. FTIR (thin film) 290.78, 
2851, 1606, 1448, 1436, 1400, 1386, 1306, 1260, 1084, 1029, 797 cm–1. HRMS (EI) 
calcd for C18H18BN (M+) 259.1532, found 259.15208. 
 
pKa Experiments 
KH: Compound  17 (10.5 mg, 0.048 mmol) and  hexamethylbenzene (1.0 mg, 
0.0062 mmol) as an internal standard were dissolved in THF-d8 (0.5 mL) and added to a 
J-Young tube containing KH (3.4 mg, 0.048 mmol.) The reaction was agitated for 10 
minutes at room temperature. 1 H NMR was taken of the solution, indicating 
deprotonation of the NH of the 1,2-azaborine.  Additional KH (3.4 mg, 0.048 mmol.) was 
added, with no change in the spectra.  
LiTMP: Compound  17 (8.3 mg, 0.034 mmol) and  hexamethylbenzene (1.0 mg, 
0.0062 mmol) as an internal standard were dissolved in THF-d8 (0.5 mL) and added to a 
J-Young tube. LiTMP(34 μL, 1M in THF, 0.034 mmol.) was added to the reaction and 
agitated for 10 minutes at room temperature. 1 H NMR was taken of the solution 
indicating deprotonation of the NH of the 1,2-azaborine. Additional LiTMP(34 μL, 1M 
in THF, 0.034 mmol.) was added, with no change in the spectra. Three additional 
equivalents were added sequentially with no change in the spectra (Figure 4.3).   
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Figure 4.2. LiTMP deprotonation experiment with compound 17 
 
LiTMP: Compound  20 (8.8 mg, 0.024 mmol) and  hexamethylbenzene (1.0 mg, 
0.0062 mmol) as an internal standard were dissolved in THF-d8 (0.5 mL) and added to a 
J-Young tube. LiTMP(24 μL, 1M in THF-d8, 0.024 mmol.) was added to the reaction and 
agitated for 10 minutes at room temperature. 1 H NMR was taken of the solution 
indicating no deprotonation of the central CH (Figure 4.4).  
 
 
e) 17 + 5 eq LiTMP 
d) 17 + 3 eq LiTMP 
c) 17 + 2 eq LiTMP 
b) 17 + 1 eq LiTMP 
a) 17 
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Figure 4.3. LiTMP deprotonation experiment with compound 20 
 
pKa control experiment: o-Tolyldiphenylmethane (14.3 mg, 0.055 mmol) and  
hexamethylbenzene (1.0 mg, 0.0062 mmol) as an internal standard were dissolved in 
THF-d8 (0.5 mL) and added to a J-Young tube. LiTMP(55 μL, 1M in THF, 0.055 mmol.) 
was added to the reaction and agitated for 2 hours at room temperature which turns a 
deep red. 1 H NMR was taken of the solution indicating full deprotonation of the central 
CH (Figure 4.5).  
 
 
20 + LiTMP 
20 
THF 
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Figure 4.4. LiTMP deprotonation experiment with o-tolyldiphenylmethane 
 
PhLi: Compound  20 (6.0 mg, 0.022 mmol) and  hexamethylbenzene (1.0 mg, 
0.0062 mmol) as an internal standard were dissolved in THF-d8 (0.5 mL) and added to a 
J-Young tube. PhLi(12 μL, 1.8 M in diphenyl ether, 0.022 mmol.) was added to the 
reaction and agitated for 10 minutes at room temperature. 1 H NMR was taken of the 
solution indicating addition to boron and no deprotonation of the central CH (Figure 4.6).  
 
 
 
o-tolyldiphenylmethane 
o-tolyldiphenylmethane + LiTMP 
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Figure 4.5. PhLi deprotonation experiment with compound 20 
 
tBuLi:  Compound  20 (6.0 mg, 0.022 mmol) and  hexamethylbenzene (1.0 mg, 
0.0062 mmol) as an internal standard were dissolved in THF-d8 (0.5 mL) and added to a 
J-Young tube. tBuLi(14 μL, 1.6 M in THF, 0.022 mmol.) was added to the reaction and 
agitated for 10 minutes at room temperature. 1 H NMR was taken of the solution showing  
a complex mixture of products (Figure 4.7).  
THF 
Diphenyl 
ether 
20 + PhLi 
20 
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Figure 4.6. Tert-butyl lithium deprotonation experiment with compound 20 
 
4.7. Bridge from Chapter IV to Chapter V 
Chapter IV of this dissertation explored the protection free method to synthesize a 
variety of 1,2-azaborines.  BN-triphenylmethane mimics were synthesized and gave 
unexpected results.  Chapter V explores one of the first pharmaceutical mimics made 
using 1,2-azaborines. The synthesis resulted in a novel deprotection route that is specific 
for amides.  The reaction mechanism and toxicology will be discussed.  
THF 
20 + tBuLi 
20 
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CHAPTER V 
1,2-DIHYDRO-1,2-AZABORINE  SILYL-DEPROTECTION USING AMIDE 
FUNCTIONALITY: TOWARD BN-ACETANALIDE 
 
5.1. General Overview 
This chapter describes unpublished work.  The synthesis, mechanism and 
toxicology of BN-acetanilide will be discussed.  I performed all of the lab work.  Jennifer 
Fox from The Oregon Translational Research and Drug Development Institute (OTRADI) 
provided the toxicology data. Lev Zakharov performed the X-ray crystallography and 
Shih-Yuan Liu provided scientific guidance and editorial assistance for all the material in 
this chapter.   
 
5.2. Introduction 
Acetanilide (1) is an arene containing compound that was accidentally found to 
have antipyretic and analgesic properties.1 For many years, it was used as an alternative 
to morphine for relief of “mild” pain.1 The pain relieving properties arise from the 
metabolism of acetanilide into acetaminophen (e.g. Tylenol®) which has since replaced 
acetanilide as the top-selling over the counter pain reliever in the world.1,2 Our group 
focuses on 1,2-dihydro-1,2-azaborine (herein referred to as 1,2- azaborine), a benzene 
mimic in which a CC bond is replaced with an isoelectronic BN bond (Scheme 5.1).3  
After the pioneering work of Dewar4 and White5 in the 1950’s and 1960’s the chemistry 
of 1,2-azaborines remained fallow until Ashe,6 Piers,7 Paetzold,8 Yamaguchi,9 
Perepichka10 and our group11 reinvigorated the field.  As a benzene mimic, 1,2-
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azaborines have the potential to replace arenes in biologically relevant molecules such as 
acetanilide. We recently demonstrated that 1,2-azaborines bind in an engineered T4 
lysozyme in the same manner as their all carbon analogs.12 We hypothesize that replacing 
the phenyl ring in acetanilide with a 1,2-azaborine could provide similar properties 
(antipyretic and analgesic), due to their isosterism.  To further expand our understanding 
of how 1,2-azaborines behave in a biological system we synthesized BN-acetanilide 2 and 
found a novel deprotection method. In this chapter we report the synthesis of a 1,2-
azaborine with an amide functionality and a novel deprotection route that this substitution 
pattern enables. BN-acetanilide 2 is one of the first pharmaceutical mimics made using 
1,2-azaborine, and its preliminary cytotoxicity against liver cells is also reported.   
 
Scheme 5.1. Isosterism between arene motifs and 1,2-azaborine 
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5.3. Synthesis, Deprotection, Crystal Structure and Toxicity of BN-Acetanilide  
 Scheme 5.2 shows the retrosynthetic analysis for BN-acetanilide 2. As in 
previously reported syntheses, we envisioned utilizing chromium to activate our substrate 
for removal of the nitrogen protecting group to give compound A.13 Intermediate B 
would be generated from tris(acetonitrile)tricarbonylchromium(0) and compound C, 
which would be accessible from the nucleophilic substitution at boron from nitrogen 
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protected 3. We chose tert-butyldimethylsilyl as our protecting group because of previous 
work performed in our lab.13 Our initial attempt to substitute compound 3 with acetamide 
4 and triethylamine in DMF gave crystalline compound 2 directly in 13% yield. To our 
delight, we were able to circumvent the chromium complexation completely, as the 
installation of the acetamide group under the reaction conditions also resulted in the 
removal of the silyl protecting group.  To our knowledge this is the first reported 
substitution/deprotection with a 1,2-azaborine in a single synthetic step, as well as the 
only deprotection of 1,2-azaborine that does not involve fluoride.13, 14 
   
Scheme 5.2. Retrosynthetic analysis 
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Scheme 5.3. Synthesis of BN-acetanilide 2 
 
Further investigation into the reaction conditions revealed that the transformation 
produces the desired product even in the absence of triethylamine (Table 5.1, entry 2). A 
survey of solvents revealed that acetonitrile (entry 6) is the solvent of choice, where 
several solvents did not produce the desired product (entry 3-5).   
 
Table 5.1. Optimization survey 
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Scheme 5.4 depicts two possible mechanisms for the substitution/deprotection 
reaction.  We propose that both mechanisms proceed through intermediate D, (observed 
by NMR spectroscopy and by high resolution mass spectrometry) via nucleophilic attack 
of the boron by acetamide. In Mechanism 1, attack at the silicon from the carbonyl 
oxygen of the amide creates a penta-coordinate silicon intermediate,15 which could 
undergo a silyl migration from the nitrogen to oxygen and subsequently react with HCl 
(or vice versa) to give the compound 2. Alternatively, a simple proton-assisted cleavage 
of the silicon-protecting group could lead directly to the target compound 2 (Mechanism 
2).  
 
Scheme 5.4. Proposed mechanisms 
 
 
We monitored the reaction by 29Si NMR and found that tert-butyldimethylsilyl 
chloride (TBSCl) is produced (δ 37.1 ppm). To test if this reaction is specific for 
acetamide 4, N-methyl acetamide 5 was reacted with 3, providing 1,2-azaborine 6 in 56% 
isolated yield (Scheme 5.5). The conversion to compound 6 occurred over the course of 
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48 hours while the reaction to form compound 2 was more rapid (3 hours), presumably 
due to steric interactions imposed by the N-Me group. To determine if the N-silyl 
deprotection will proceed for other boron substituents with similar directing ability as 
acetamide, acetic acid was added to 1,2-azaborine 3.  However, N-silyl deprotection did 
not occur.  Instead, the simple addition adduct 8 was observed. This implies that the one 
pot substitution/deprotection is specific to amides and that the N–TBS group is unreactive 
toward B-acetate-mediated N-silicon removal.   
 
Scheme 5.5. Synthesis with: a.) N-methyl acetamide 5 b.) acetic acid 7 
 
 
If Mechanism 2 is operating then HCl should cause deprotection of the silyl 
group. Therefore, additional HCl was added to compound 8 but only starting material 
was observed. The donating ability of nitrogen on the amide may cause the unique 
deprotection. To test this theory, compound 3 and potassium diphenylamine 9 were 
combined to yield compound 10 in 58% (Scheme 5.6).  Upon the addition of HCl to 
amine substituted 1,2-azaborine 10, compound 3 is reformed.  These experimental results 
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demonstrate that the amide functionality is essential for this transformation, with a strong 
neighboring group-effect. Mechanism 2 is not consistent with our control experiments. 
Future computational studies may provide further insight into the most likely mechanism.   
 
Scheme 5.6. Synthesis of amine substitute 1,2-azaborine 10  
 
 
BN-acetanilide can be used as an intermediate in the synthesis of more complex 
molecules. Upon the addition of 4 equivalents of n-butanol, compound 11 was isolated in 
90% yield (Scheme 5.7).  We recently have shown that compound 11 is a useful synthon 
for a variety of substituted 1,2-azaborines.17 This alternative route may provide a more 
cost efficient synthesis of substituted 1,2-azaborines.g  
 
Scheme 5.7.  Synthesis of the useful synthon 11 
 
 
We were able to obtain X-ray quality crystals of compound 2 (Figure 5.1). The 
comparative geometrical parameters of acetanilide 1 and BN-acetanilide 2  is shown in 
                                                
g The use of Schrock’s catalyst can be avoided.  
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Table 5.2. We determined compound 2 is much more planar than carbonaceous 
acetanilide 1,18 with a torsional angle of 4.7(2) vs. 20.0 for 1.  The dihedral angle 
between the plane of the amide and the ring are 5.91(8) and 17.10 respectively.  We 
hypothesize that the hydrogen bonding from NH on the 1,2-azaborine, to the carbonyl 
oxygen helps to induce the observed planarity.  The carbon–oxygen bond is slightly 
lengthened in 2 relative to 1 (1.236 Å and 1.219 Å, respectively).  
 
Figure 5.1. ORTEP illustration of BN-acetanilide 2, with thermal ellipsoids drawn at the 
35% level 
 
 
Table 5.2. Select angles, planarity and H-bonding for BN-acetanilide 2 and acetanilide 1  
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Understanding the manner in which 1,2-azaborines behave in biological systems 
is of fundamental importance. As one of the first therapeutic mimics to be made using a 
1,2-azaborine, further testing was performed with BN acetanilide 2. Acetaminophen, the 
oxidative metabolite of acetanilide, toxicity manifests in the liver.19 To determine the 
toxicity of BN-acetanilide 2, we probed its cytotoxicity against HepG2 liver cells.  We 
tested acetanilide 1, BN-acetanilide 2, Tamoxifen, a known liver toxin, and also ran a 
control reaction with simply the solvent (Figure 5.2) to establish relative toxicity. After 
24 h and 48 h, compound 2 had no effect on the growth of HepG2, which is the same as 
1. In contrast, Tamoxifen clearly caused necrosis at high concentrations. It is important to 
note that 2 is nontoxic at this concentration to this line of cells. BN-acetanilide 2 and 
acetanilide 1 behave similarly in biological assays.  Further work will be directed at 
determining the analgesic effects of our mimic, as well as developing assays that provide 
a distinction between the liver toxicity of our BN mimic and the natural acetanilide 1.  
 
5.4. Conclusion  
In conclusion, we have shown a direct synthetic route to BN-acetanilide 2 from 3 
and propose a reasonable mechanism for this transformation.  The crystal structure shows 
a very planar compound most likely due to the H-bonding of the NH in the 1,2-azaborine 
ring to the carbonyl oxygen, which is distinct from the solid-state structure of acetanilide 
1.  We also demonstrated the first toxicity studies on a 1,2-azaborine and found that our 
compound shows similar hepatotoxicity as acetanilide. This promising study could lead 
to future 1,2-azaborine pharmaceuticals.  
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Figure 5.2. Toxicology studies of BN-Acetanilide 2  
 
 
5.5. Experimental 
General 
All oxygen- and moisture-sensitive manipulations were carried out under an inert 
atmosphere using either standard Schlenk techniques or a glove box. 
THF, Et2O, CH2Cl2, toluene and pentane were purified by passing through a neutral 
alumina column under argon. 
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1,2-Dihydro-1,2-azaborine 3 was prepared according to a previously reported 
procedure. All other chemicals and solvents were purchased (Aldrich, Acros, TCI or 
Strem) and used as received. 
Silica gel (230-400 mesh) was heated under vacuum in a 175 °C oil bath for 12 
hours. Flash chromatography was performed with this silica gel under an inert 
atmosphere. Preparative TLC (1000 µm thickness) plates were purchased from Silicycle 
and heated to 120° C for 18 h in an oven before usage under inert conditions. 
11B NMR spectra were recorded on a Varian Unity/Inova 300 spectrometer at 
ambient temperature. 1H NMR spectra were recorded on a Varian Unity/Inova 300 or 
Varian Unity/Inova 500 spectrometer. 13C NMR spectra were recorded on a Varian 
Unity/Inova 300 or Varian Unity/Inova 500 spectrometer. All chemical shifts are 
externally referenced: 11B NMR to BF3•Et2O (δ 0). 
IR spectra were recorded on a Nicolet Magna 550 FT-IR instrument with OMNIC 
software. 
High-resolution mass spectroscopy data were obtained at the Mass Spectroscopy 
Facilities and Services Core of the Environmental Health Sciences Center at Oregon State 
University. Financial support for this facility has been furnished in part by the National 
Institute of Environmental Health Sciences, NIH (P30 ES00210). 
 
Optimization Survey (Table 5.1) 
Yields in Table 5.1 were determined by NMR analysis of the reaction mixture 
versus hexamethylbenzene as an internal standard.  
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General Procedure:  In a glove box, a J-Young Tube was charged with a 
solution of 3, solvent and hexamethylbenzene.  Acetamide 4 was added to the vessel and 
the progress of the reaction was monitored by NMR.  
 
Entry 1: The general procedure was followed, using 3 (19 mg, 0.083 mmol), 4 
(5.4 mg, 0.092 mmol), DMF-d7 (0.3 mL), triethylamine (12 μL, 0.092 mmol) and 
hexamethylbenzene (1 mg). NMR analysis indicated the formation of 2 in 52% yield.  
 
Entry 2: The general procedure was followed, using 3 (26 mg, 0.115 mmol), 4 
(7.5 mg, 0.127 mmol), DMF-d7 (0.3 mL) and hexamethylbenzene (1 mg). NMR analysis 
indicated the formation of 2 in 78% yield.  
 
Entry 3: The general procedure was followed, using 3 (28 mg, 0.124 mmol), 4 
(8.1 mg, 0.136 mmol), THF-d8 (0.3 mL) and hexamethylbenzene (1 mg). NMR analysis 
indicated no reaction occurred.  
 
Entry 4: The general procedure was followed, using 3 (20 mg, 0.086 mmol), 4 
(5.6 mg, 0.094 mmol), DMSO-d6 (0.3 mL) and hexamethylbenzene (1 mg). NMR 
analysis indicated that product 2 was not formed.  
 
Entry 5: The general procedure was followed, using 3 (21 mg, 0.091 mmol), 4 
(5.9 mg, 0.100 mmol), acetone-d6 (0.3 mL) and hexamethylbenzene (1 mg). NMR 
analysis indicated that product 2 was not formed.  
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Entry 6: The general procedure was followed, using 3 (21 mg, 0.091 mmol), 4 
(5.8 mg, 0.099 mmol), MeCN-d3 (0.3 mL) and hexamethylbenzene (1 mg). The NMR 
tube was heated to 80 °C. NMR analysis indicated the formation of 2 in 98% yield.  
 
Synthesis of Compound 2 
Compound 2:  In a glove box, a flask was charged with a solution of 3 and 
acetonitrile.  Acetamide 4 was added to the vessel and heated for 3 hours at 80 °C. The 
reaction was cooled to room temperature. Acetonitrile was removed with reduced 
pressure.  The resulting mixture was dissolved in Et2O followed by filtration through an 
acrosdisc.  Recrystallization from pentane yielded crystalline 2 in 62% yield.  
1H NMR (300 MHz, C6D6): δ 10.01 (br s, 1H), 7.56 (dd, 3JHH =  6.8, 3.4 Hz, 1H), 6.56 (t, 
3JHH = 6.8 Hz, 1H), 6.19 (d, 3JHH =11.2 Hz, 1H), 5.93 (t, 3JHH = 6.4 Hz, 1H), 5.55 (br s, 
1H), 1.53 (s, 3H). 13C NMR (125 MHz, C6D6): δ 175.7, 146.0, 133.9, 122 (br), 108.9, 
25.6. 11B NMR (96.3 MHz, C6D6): δ 27.4. FTIR (thin film) 3362, 3023, 2929, 2857, 
1665, 1613, 1513, 1455, 1411, 1368, 1282, 1227, 1176, 1148, 1084, 988, 825, 791, 741, 
685 cm–1. HRMS (EI) calcd for C7H10BNO (M+) 137.08863, found 137.08886. 
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Synthesis of Intermediate D  
Scheme 5.8. Intermediate D synthesis 
 
 
Compound 12:  In a glovebox, a solution of 3 (0.223 g, 0.98 mmol in 5.0 mL 
benzene) was added dropwise to a stirring suspension of AgOTf (0.302 g, 1.18 mmol in 
10.0 mL benzene). The reaction was stirred at rt for 8 h, whereupon the solvent was 
removed under reduced pressure and redissolved in pentane, filtered through an acros 
disc. which yielded light pink crytals  (0.314 g, 94%). 
1H NMR (300 MHz, CD3CN): δ , 7.91 (dd, 3JHH =  6.4, 3.4 Hz, 1H), 7.43 (d, 3JHH = 7.8 
Hz, 1H), 6.75 (d, 3JHH =11.2 Hz, 1H), 6.53 (t, 3JHH = 6.4 Hz, 1H), 0.97 (s, 9H), 0.53 (s, 
6H). 11B NMR (96.3 MHz, C6D6): δ 30.1.  
 
Intermediate D: In a glovebox, a solution of 12 (0.026 g, 0.076 mmol in 1.0 mL 
THF) was added to acetamide 4 (0.005 g, 0.08 mmol in 1 mL THF). The reaction was 
stirred at rt for 8 h, whereupon the solvent was removed under reduced pressure and 
redissolved in pentane, filtered through an acros disc. which yielded a mixture of 
intermediate D (48% by NMR) and compound 2h.  
1H NMR (300 MHz, CD3CN): δ 7.47 (dd, 3JHH =  6.4, 3.4 Hz, 1H), 7.12 (d, 3JHH = 7.8 Hz, 
1H), 6.17 (d, 3JHH =12.3 Hz, 1H), 6.00 (t, 3JHH = 6.7 Hz, 1H), 0.95 (s, 9H), 0.47 (s, 6H). 
                                                
h Triflates have been shown to deprotect TBS20   
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11B NMR (96.3 MHz, CD3CN): δ 30.0. HRMS (EI) calcd for C7H12BN2O (M+), 251.1751 
found 251.1756. 
 
Mechanism Elucidation:  
Si NMR: In a glove box, a J-Young tube was charged with a solution of 3 (0.105 
g, 0.461 mmols in 0.3 mL of acetonitrile).  Acetamide 4 (0.030 g, 0.507 mmols) was 
added to the vessel and heated for 3 hours at 80 °C. The reaction was monitored by Si 
NMR.  
29Si NMR (99 MHz, CD3CN): δ37.1. 
 
Compound 6:  In a glove box, a flask was charged with a solution of 3 and 
acetonitrile.  N-methylacetamide 5 was added to the vessel and heated for 6 hours at 80 
°C. The reaction was allowed to cool to room temperature. Acetonitrile was removed and 
dissolved in Et2O followed by filtration through an acrosdisc.  Recrystallization from 
pentane yielded crystalline 6 in 56% yield.  
1H NMR (300 MHz, CD3CN): δ10.69 (br s, 1H), 7.71 (dd, 3JHH =  6.4, 3.4 Hz, 1H), 7.37 
(t, 3JHH = 7.8 Hz, 1H), 6.54 (d, 3JHH =11.2 Hz, 1H), 6.21 (t, 3JHH = 6.4 Hz, 1H), 3.20 (s, 
3H), 2.24 (s, 3H). 11B NMR (96.3 MHz, C6D6): δ 28.2. HRMS (EI) calcd for C7H12BN2O 
(M+), 151.1043 found 151.1049. 
 
Compound 8:  In a glove box, a flask was charged with a solution of 3 (0.023 g, 
0.102 mmols) and acetonitrile 1 mL.  Acetic acid 7  (6.3 μL, 0.113 mmols) was added to 
the vessel and heated for 3 hours at 80 °C. The reaction was allowed to cool to room 
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temperature. The solvent was removed via reduced pressure and the reaction mixture was 
dissolved in pentane followed by filtration through an acrosdisc yielding the colorless 
liquid 8 in 51% yield.  
1H NMR (300 MHz, CD2Cl2): δ  7.65 (dd, 3JHH =  6.8, 3.4 Hz, 1H), 7.19 (t, 3JHH = 6.8 Hz, 
1H), 6.69 (d, 3JHH =11.2 Hz, 1H), 6.24 (t, 3JHH = 6.4 Hz, 1H), 2.21 (s, 3H), 0.97 (s, 9H), 
0.50 (s, 6H). 11B NMR (96.3 MHz, CD2Cl2): δ 31.0. FTIR (thin film) cm–1. HRMS (EI) 
calcd for C12H23BNO2 (M+) 252.1291, found 252.1593.  
 
Addition of HCl to Compound 8: In a glove box, a J-Young tube was charged 
with a solution of 8 (21 mg, 0.083 mmol) in 0.3 mL MeCN-d3.  HCl (2.0 M in Et2O, 42 
μL 0.083 mmol) was added to the tube and heated for 3 hours at 80 °C. The progress of 
the reaction was monitored by NMR which indicated that the deprotected 1,2-azaborines 
was not formed.  
 
Compound 10: In a glove box, a flask was charged with a solution of  
diphenylamine (0.100 g, 0.59 mmols in 10 mL THF) and  KH (0.0.30 g, 0.75 mmols) and 
reacted for four hours.  In a separate vial a solution of  3 (0.052 g, 0.23  mmols) and THF 
were cooled to -30 °C. The potassium diphenylamine 9 was slowly added to the cooled 
solution of  3 and reacted for 16 hours. The solvent was removed under reduced pressure. 
The reaction mixture was dissolved in pentane and filtered through an acrosdisc yielding 
the yellow liquid 10 in 58% yield.  
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1H NMR (300 MHz, CD3CN): 7.12 (m, 5H), 5.05 (d, 3JHH = 7.7 Hz, 2H), 6.94 (m, 5H), 
5.92 (d, 3JHH = 11.2 Hz, 1H), 5.78 (d, 3JHH = 6.4 Hz, 1H), 0.83 (s, 9H), 0.46 (s, 6H).. 11B 
NMR (96.3 MHz, CD3CN): δ 31.4.  
 
Addition of HCl to Compound 10: In a glove box, a J-Young tube was charged 
with a solution of 10 (21 mg, 0.083 mmol) in 0.3 mL MeCN-d3.  HCl (2.0 M in Et2O, 42 
μL 0.083 mmol) was added to the tube.  The progress of the reaction was monitored by 
NMR which indicated that the compound 3 was produced.  
1H NMR (300 MHz, CD3CN): δ 7.64 (dd, 3JHH =  6.8, 3.6 Hz, 1H), 7.43 (t, 3JHH = 7.1 Hz, 
1H), 6.64 (d, 3JHH =11.2 Hz, 1H), 6.43 (t, 3JHH = 6.4 Hz, 1H), 1.00 (s, 9H), 0.63 (s, 6H). 
11B NMR (96.3 MHz, CD3CN): δ 35.2.  
 
Compound 11:  In a glove box, a vial was charged with a solution of 2 (51.4 mg, 
0.378 mmols) and 2 mL THF.  Butanol  (112 mg, 0.1.54 mmols) was added to the vessel 
and stirred at room temperature for 4 hours.  The solvent was removed under reduced 
pressure and the crude product was purified with a short plug of silica (3:1 pentane/Et2O) 
to afford 9 (90%) as light yellow liquid. 
1H NMR (500 MHz, CD2Cl2): δ 7.54, (m, 1H), 7.05 (t 3JHH = 7.6 Hz, 1H), 6.89 (s br, 1H), 
6.29 (d 3JHH = 11.7 Hz, 1H), 5.91 (d 3JHH = 7.0 Hz, 1H), 3.95 (t 3JHH = 6.7 Hz, 2H), 1.65 
(m, 2H), 1.43 (m, 2H), 0.95 (m, 3H). 11B NMR (96.3 MHz, CD2Cl2) δ 29.1. FTIR (thin 
film) HRMS (EI) calcd. for C8H14NBO (M+) 151.11685, found 151.11686. 
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Cytotoxicity Protocol Using HepG2 Cells 
 
Dose-Response Curves for Chemicals to Determine Level of Cytotoxicity to Human 
Liver Cells 
Always check volumes of media and cells to make sure enough is prepared to 
complete each experiment.  Volumes in this protocol are for testing 1 human cell line 
(HepG2) with 6 different compounds 
 
Chemicals to be Tested for Cytotoxicity: 
Positive Controls:  Cyclohexamide, Tamoxifen, Vancomycin 
Negative Control:  DMSO 
Exp. Chemicals:   BN acetanilide & all-carbon acetanilide 
 
Human Cell Line to be Tested: HepG2 (ATCC# HB-8065), Human 
hepatocarcinoma (liver cancer) cells 
 
Experimental set-up in 96-well plates: 
GOAL: Chemicals to be tested are assayed for dose-responsive cytotoxicity activity at 
concentrations ranging from 2nM to 200mM (1:3 dilution).   
 
The cytotoxicity assay used at OTRADI is based on the standard mammalian cytotoxicity 
regiment used by the National Cancer Institute to evaluate possible toxicity of novel 
compounds.  The protocol and references can be found at: 
http://dtp.nci.nih.gov/docs/compare/compare_methodology.html 
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Negative control wells are left untreated with chemicals, and positive control wells are 
treated with known anti-bacterial and/or cytotoxic drugs (cyclohexamide, tamoxifen & 
vancomycin).  At 72-hours post-chemical treatment, a microplate reader is used to 
quantify number of cells alive in each well, by measuring fluorescence with a xenon flash 
at excitation 540nm and emission 590nm (fluorescence of live cells).  Wells treated with 
test chemicals that are cytotoxic to HepG2 cells will exhibit a fewer number of live cells 
as shown by markedly lower level of fluorescence, as will the positive control wells.  
Wells treated with chemicals that are not cytotoxic will show essentially no difference in 
fluorescence from the negative (untreated) control wells.  
 
Day 1: 
1) Thaw out chemicals to be tested, check to make sure enough media is made to 
perform experiment, draw plate maps for experiment and calculate timing of each 
step. 
2) In the AM, harvest HepG2 cells from a 75cm2 flask by resuspending trypsinized cells 
in 15mL of MEM media.  Count cells using a hemacytometer: 
a) Aliquot 20uL of resuspended cells into a disposable hemacytometer. 
b) Use microscope to count number of cells within 5 separate squares. 
c) Add up the total number of cells in 5 squares.  Multiply this number by 100 to 
calculate the average number of cells per 100uL (e.g., 88,000 cells/100uL).     
3) Using the starting number of cells/100uL determined above, calculate a dilution 
factor to give a final cell density of 10,000 cells/150uL in the appropriate volume to 
complete experiment.  For example, we need to prepare enough cells at 10,000 
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cells/150uL density to aliquot 150uL/well into three 96-well plates.  To do this, we 
need to prepare 100mL of cells at 10,000 cells/150uL density by diluting our starting 
resuspended cells as follows:  
a) 88,000/100uL = x/150uL (in this case, x=132,000) 
b) 132,000/10,000 = dilution factor of 1:13.2 
c) We need 100mL cells, so divide 100mL by dilution factor to calculate volume of 
resuspended cells to add.  100mL/13.2 = approximately 7.6mL cells. 
d) Add 7.6mL of cells to 92.4mL (100mL-7.6mL) media to obtain 100mL of cells 
diluted to density of 10,000 cells/150uL.   
4) Place the 100mL of diluted cells into a reservoir to be used to add 150uL/well to all 
wells of three 96-well plates using the Caliper robot. 
5) Label 3 tissue culture treated 96-well plates to use as your cell assay plates; set aside. 
6) Steps A-C are carried out using the Caliper robot: 
a) Step A: Bring the following items to the Caliper robot and place them in their 
proper spots (see map of area for where to place each item): reservoir with 100mL 
of diluted cells, empty labeled assay plates stacked in correct order with lids 
removed (set lids aside). 
b) Step B: Place empty labeled assay plates in rack 1 of pods (make sure to note that 
the plates are in the proper orientation), place reservoir containing cells in slot B2 
on deck.  Make sure that empty red tip box holders are in slots A4 & B3 on 
deck. 
c) Step C: Open iLinkPro, select program entitled “96 well Liquid Handling 
_Master”.  “Initialize” and push “Run”.  Now open Maestro window, under tab 
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called “Add cells or medium only” answer questions about volume to be 
transferred (150uL) and # of plates (3).  After filling in this information, run 
program, which does the following: 
• Empty assay plates are transferred to the deck and 150mL of cells diluted in 
media is added to each well. 
• Treated cell assay plates are carried to and deposited in rack 3 of pods. 
7)  Gently remove treated cell assay plates from rack, replace matching lids on each 
assay plate and incubate in appropriate cell incubator for four hours to allow the cells 
to recover and adhere to plates. 
8) Remove reservoir with diluted cells from deck, wash out at sink and place in 
biohazard bin.   
9) Prepare “mother” plate of chemicals to be tested.  The “mother” plate is used to 
deliver chemicals to the “daughter” plates or assay plates.  Refer to mother plate map 
to see placement of each chemical in mother plate columns.  To prepare mother plate 
of chemicals, first use the multi-channel pipetman to add 88mL of MEM media to 
each column of the mother plate.  Next, add 12mL of [10mM] chemical to be tested 
to each of the first four wells of column #1 of mother plate.  Repeat down this column 
and across with other chemicals to be tested (see plate map entitled mother plate for 
proper chemical placement).  This results in a [12X] of chemicals in mother plate = 
[1.2mM]. 
10)  Prepare reservoir of media to be used for experiment.  Add 150mL of MEM 
media to a reservoir, and set aside for experiment.   
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11)  Prepare and label assay plates for experiment.  For each column of chemicals 
tested, prepare 1 non-treated assay plate (e.g., if testing 3 columns of chemicals in 
mother plate then prepare 3 assay plates).  Label top left corner of assay plate and lid 
with plate number.  Set labeled assay plates aside for experiment.   
12)  Steps A-C are carried out using the Caliper robot: 
a) Step A: Bring the following items to the Caliper robot and place them in their 
proper spots (see map of area for where to place each item): reservoir with 150mL 
MEM media (in slot B2), mother plate with chemicals (lid removed) (in rack 2), 
empty labeled assay plates stacked in correct order with lids removed (in rack 1) 
(set lids aside). 
b) Step B: Place empty labeled assay plates in rack 1 of pods (make sure to note that 
the plates are in the proper orientation), place mother plate with chemicals in rack 
2 of pods (make sure to note that the plate is in the proper orientation), and place 
media reservoir in slot C2 on deck.  Make sure that empty red tip box holders are 
in slots A4 & B3 on deck. 
c) Step C: Open iLinkPro, select program entitled “96 Well Liquid 
Handling_Master”.  “Initialize” and push “Run”.  Now open Maestro window, 
under tab called “drug dilutions only” answer questions about # of drug plates 
(mother plates), columns, 100uL final volume, 50uL transfer from mother 
plate, etc.  After filling in this information, run program, which does the 
following: 
• Empty assay plates are transferred to the deck and 100mL of media is added 
to each well. 
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• 50mL from each of the mother plate columns is transferred to the last column 
of each assay plate. 
• Starting with the last column of each assay plate, a mixing step is followed by 
transfer of 100mL from each well of a column to the column immediately to 
the left (1:3 dilution across the plate moving from the right to the left side).  
This results in a 1:3 dilution across the plate with all concentrations being at 
[4X].  Note: column #1 is not treated with chemicals and serves as untreated 
negative control for experiment.   
• Treated assay plates are carried to and deposited in rack 3 of pods. 
13)  Gently remove treated assay plates from rack, replace matching lids on each assay 
plate and set plates aside to be used later. 
14)  Remove mother plate of chemicals from rack, replace lid and place in biohazard 
waste can.  Remove media reservoir from deck, wash out at sink and place in dirty 
dishes bin.   
15)  After cell plates have incubated for 4 hours, the following steps are carried out 
using the Caliper robot: 
a) Step A: Bring the following items to the Caliper robot and place them in their 
proper spots (see map of area for where to place each item): chemical assay plates 
that are labeled and stacked in correct order with lids removed (set lids aside) and 
cell plates that are labeled and stacked in correct order with lids removed (set lids 
aside). 
b) Step B: Place drug dilution plates in rack 6 of pods (make sure to note that the 
plates are in the right order).  Place cell plates in rack 1 of pods (make sure to note 
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that the plates are in the proper orientation).  Make sure that empty red tip box 
holders are in slots A4 & B3 on deck. 
c) Step C: Open iLinkPro, select program entitled “96Well Drug Transfer.mth”.  
IMPORTANT: before running the program, enter the correct “# of runs” at top of 
sheet (= the # of plates to transfer to “3”).  “Initialize” and push “Run”.  Now 
open Maestro window, under “transfer drug interface” enter volume to transfer 
(50uL).  After filling in this information, run program, which does the 
following: 
• Each chemical assay plate and cell assay plate are transferred to the deck. 
• 50mL from each well of chemical assay plate is transferred to each well of 
corresponding cell assay plate (final volume will be 200uL total). 
• Treated cell/assay plates are carried to and deposited in rack 3 of pods. 
16)  Gently remove treated cell/assay plates from rack, replace matching lids on each 
plate and incubate in appropriate cell incubator for 72 hours to allow the cells to be 
exposed to chemical during growth. 
17)  Remove chemical assay plates and place in biohazard bin. 
 
Day 4: 
18)  After 72 hours of incubation post-treatment, add 10X solution of Alamar Blue 
indicator solution to each well of plates, using the Caliper robot: 
a) Step A: Bring the following items to the Caliper robot and place them in their 
proper spots (see map of area for where to place each item): cell/assay plates that 
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are labeled and stacked in correct order with lids removed (set lids aside) and 
reservoir containing 150mL of 10X Alamar Blue solution. 
b) Step B: Place cell/assay plates in rack 1 of pods (make sure to note that the plates 
are in the proper orientation).  Place reservoir containing Alamar Blue in slot B2 
on deck.  Make sure that empty red tip box holders are in slots A4 & B3 on deck. 
c) Step C: Open iLinkPro, select program entitled “96 Well Liquid 
Handling_Master”.  “Initialize” and push “Run”.  Now open Maestro window, 
under tab “add cells of medium only” answer questions about # of plates, etc.  
After filling in this information, run program, which does the following: 
• Each cell/assay is transferred to the deck. 
• 20mL of Alamar Blue is transferred from reservoir to each well of plates.   
• Alamar Blue-treated cell/assay plates are carried to and deposited in rack 3 of 
pods. 
19)  Gently remove treated cell/assay plates from rack, replace matching lids on each 
plate and incubate in appropriate cell incubator for 4-6 hours to allow the Alamar 
Blue to react with cells/media and change colors to indicate amount of cell growth. 
20)  Remove Alamar Blue reservoir, pour out contents and place in biohazard bin. 
21)  After 4-6 hours of incubation read the fluorescence of each well of all treated 
cell/assay plates.  Steps are to be carried out using the Caliper robot and BioTek 
microplate reader: 
a) Step A:  Take treated cell/assay plates from incubator, remove lids, and stack in 
correct order.  Place these plates in rack 1 of pods before starting to run program. 
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b) Step B:  Open iLinkPro, folder entitled “Plate Read”, file entitled 
“PlateRead_Main”.  At top of this page, check to make sure the “# of runs” is 
correct (i.e., for measuring 3 assay plates, be sure # of runs is set to 3). 
c) Step C:  Click “Run”.  Open Excel window and load protocol “Cytotoxicity”.  
Now RUN program, which does the following: 
• Assay plates are transferred, one at a time, from rack 1 of pods to the BioTek 
plate reader.  Each well is measured by the BioTek reader using the following 
parameters (xenon flash (no filter wheel), 540nm excitation, 590nm emission, 
70% sensitivity) to determine the amount of fluorescence per well, which 
corresponds to the # cells remaining in each well.  After reading, each assay 
plate is placed in rack 3 of pods. 
d) Step D: After program has completed reading all plates, prepare data to be 
exported and analyzed: 
• Go to desktop folder “Shortcuts to Everything” and open folder “Plate 
Reader Output”.  Look for file/files with today’s date and time.   
• Click file to open, select all the plates from today’s run (i.e., 3 plates), 
right click, file export 
• Under My Documents, open OD600 Output, create new folder named with 
today’s date, click to save all files (save # plates). 
• Go to your folder where you have saved your “Plate Template” file that 
you created the day before. 
• Double check that all data is correctly filled in.  Save this file again after 
all data is filled in. 
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• Go to desktop folder called “Analysis Software”, click on “Dose Response 
Analysis” file.  Load “Plate Template” from today’s folder, load data (all 
plates) from today’s folder.  Click “Build Report” and “Generate 
Summary”.   
• Save this “Summary Report” file to folder with today’s date created above 
and save onto server in your folder.  The “Summary Report” is an Excel 
spreadsheet with each drug against strains tested and tabs for graphs and 
IC50 values.   
NOTE: If you change things in Prism data table and you want to re-analyze the data, 
go back to the “Dose Response Analysis” file, and choose the Prism file you were 
working with/altered.      
22)  When ready to analyze data and prepare graphs, open Prism file on your computer 
(from server).  Make sure graphs are correct, label graphs, calculate results, determine 
dose-response curves, check the data tables to see calculated IC50 values, add these 
values for each chemical tested to each graph.  Note: if IC50 value is above 200uM or 
below 200nM, do not report the calculated value, report these as >200uM or <200nM, 
respectively.   
 
Data Analysis: Each experiment tests chemicals (in quadruplicate repeats) at 11 
concentrations ranging from 3nM to 200mM; results from each well are averaged to 
obtain values and statistical information.  Dose response curves are calculated using non-
linear regression analysis.  The IC50 of each chemical ([chemical] that inhibits 50% of 
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HepG2 human cell growth) is then calculated from each dose response curve.  Results are 
represented as graphs showing dose-responsive inhibition of human HepG2 cell growth.   
 
 5.6. Bridge from Chapter V to Chapter VI  
 Chapter V of this dissertation explored one of the first pharmaceutical 
mimics made using 1,2-azaborines. The synthesis resulted in a novel deprotection route 
that is specific for amides. Chapter VI summarizes miscellaneous contributions from 
three different publications which discuss the basic properties of 1,2-azaborines.  
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CHAPTER VI 
MISCELLANEOUS CONTRIBUTIONS 
 
6.1. General Overview 
This chapter will discuss the UV-photoelectron spectrum of 1,2-dihydro-1,2-
azaborine.  This chapter contains published material: Chrostowska, A.; Xu, S.; Lamm, A. 
N.; Mazière, A.; Weber, C. D.; Dargelos, A.; Baylère, P.; Graciaa, A.; Liu, S.-Y. J. Am. 
Chem. Soc.  Manuscript Accepted. I synthesized the 1,2-dihydro-1,2-azaborine. Senmiao 
Xu synthesized the NMe protected 1,2- and 1,3-azaborines.  Professor Anna 
Chrostowska, Audrey Mazière, Alain Dargelos, Patrick Baylère, and Alain Graciaa 
performed the UV-photoelectron spectrum experiments and the associated calculations.  
Christopher D. Weber performed the electrochemistry experiments.  
This chapter will also discuss the photoisomerization of 1,2-dihydro-1,2-
azaborine.  This chapter contains material submitted for publication:  Brough, S. A.; 
Lamm, A. N.; Liu, S.-Y. Bettinger, H. F. Manuscript Submitted. I synthesized the 1,2-
dihydro-1,2-azaborine, Sarah Brough and Professor Holger Bettinger performed the 
photoisomerization experiments.  
Lastly, this chapter discusses the effect of 1,2-azaborine incorporation on the 
resulting optoelectronic properties of diphenylacetylene derivatives. This material has 
been previously published: Marwitz, A. J. V.; Lamm, A. N.; Zakharov, L. N.; Vasiliu, 
M.; Dixon, D. A.; Liu, S.-Y. Chemical Science 2012, 3, 825–829.  Adam Marwitz 
performed the majority of the lab work.  I re-synthesized BN-Tolan, Bis-BN-Tolan and 
performed additional UV-vis, fluorescence and IR measurements on these compounds.  
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Lev Zakharov performed X-Ray crystallography.  Monica Vasiliu, David A. Dixon 
provided computational data and Shih-Yuan Liu provided editorial assistance and 
scientific guidance for the entire chapter.   
 
6.2. Introduction 
 Benzene is one of the most fundamentally important small molecules.1  The study 
of benzene has introduced concepts such as aromaticity and delocalization in the 
chemical community.2  Benzene and its derivatives (arenes) are ubiquitous in chemical 
research with applications ranging from material science to biomedical research.3  
Recently, the isoelectronic and isostructural BN-containing analog, 1,2-dihydro-1,2-
azaborine, was isolated 50 years after the initial attempt (Figure 6.1).4  While the 
chemistry of polycyclic boron-nitrogen heterocycles is well understood,5 relatively little 
work has been performed on monocyclic derivatives.  Dewar6 pioneered the chemistry of 
1,2-azaborines and this field has seen a recent revitalization, notably from the Ashe,7 
Piers8 and Liu9 groups.  We have recently provided experimental and computational 
evidence for the aromatic character of 1,2-azaborines.10  This chapter expands on the 
basic science of 1,2-dihydro-1,2-azaborines and describes the UV-photoelectron11 
spectrum and photoisomerization reaction12 of 1,2-dihydro-1,2-azaborine. Finally, a study 
will be presented on incorporating 1,2-azaborines into a known carbon scaffold.13   
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Figure 6.1. The isomerism between benzene and 1 
6.3. UV-Photoelectron Spectrum for 1,2- and 1,3-Azaborines 
 The UV-PES technique allows the determination of  accurate values of ionization 
energies for electronic structure characterization of molecules and ions.
14  Simply put, 
UV-PES is the
 
experimental technique for determining the energies of
 
occupied 
molecular orbitals. In collaboration with the Chrostowska group BN-heterocycles 1-3 and 
the corresponding arenes (Figure 6.2) were subjected to UV-PES conditions with 
simultaneous monitoring via mass spectrometry.  
 
Figure 6.2. UV-PES spectra of (a) benzene and (b) 1,2-dihydro-1,2-azaborine 1. The 
complete list of compounds tested in this study is shown on the right side.   
 
 
 
Figure 1.  UV-PE spectra of (a) benzene and (b) 1,2-dihydro-1,2-azaborine 1, (c) toluene, (d) N-Me-1,2-BN-toluene 2, and (e) N-Me-
1,3-BN-toluene 3. The y-axis is defined as the negative value of the experimentally determined ionization energy (-IE). The top seven 
occupied molecular orbitals associated with the corresponding energy levels for each of the molecules are also depicted 
As can be seen from the comparison between Figure 1a and 
Figure 1b, the replacement of two adjacent carbon atoms in 
benzene by nitrogen and boron as in 1,2-dihydro-1,2-
azaborine 1 causes a significant change in the electronic 
structure. In heterocycle 1, the degeneracy found in benzene is 
lifted and results in a 0.65 eV destabilization of the HOMO 
and 1.05 eV stabilization of the HOMO-1 (vs. benzene’s 
degenerate HOMO level at -9.25 eV). This lifting of 
degeneracy is also observed for HOMO-2 and HOMO-3 of 
1,2-azaborine 1, which leads to a 0.43 eV destabilization and a 
0.47 eV stabilization vs. benzene’s degenerate σ MOs at -11.53 
eV, respectively. The fifth MO in 1 is stabilized by 0.32 eV 
compared to the corresponding π3 MO of the benzene 
molecule. 
A comparison of Figure 1c (toluene) vs. Figure 1a 
(benzene) shows that the presence of a methyl substituent on 
the six-membered ring leads to a more electron rich system 
than the parent benzene molecule. A lifting of degeneracy of 
orbitals is also observed. The HOMO is found at -8.83 eV, 
0.42 eV higher than the corresponding HOMO π2 in benzene 
at -9.25 eV, whereas the HOMO-1 (corresponding to π1 in 
benzene) is stabilized by 0.11 eV. The toluene MO associated 
with the totally symmetrical π3 MO of benzene is also 
destabilized by 0.4 eV.  
Figure 1c-e illustrates the changes in the electronic 
structure associated with the two different variants of BN/CC 
isosterism of toluene, i.e., 1,2- and the 1,3-isosteres. In N-Me-
1,2-BN-toluene 2, the HOMO is destabilized by 0.38 eV 
compared to toluene. In N-Me-1,3-BN-toluene 3, the 
destabilization of HOMO is even more pronounced, with the 
HOMO energy level difference between 3 and toluene being 
0.83 eV. On the other hand, a stabilization of the HOMO-1 
and π3-type π-symmetry orbitals is observed for the BN 
toluenes. Relative to toluene, the HOMO-1 is stabilized by 
0.49 eV and 0.39 eV for 2 and 3, respectively. Similarly, the 
π3-type orbitals for BN toluenes 2 and 3 are lowered in energy 
compared to toluene by 0.52 and 0.72 eV, respectively. 
Interestingly, the HOMO is of π1-type symmetry for 1,2-
azaborines (see Figure 1b and Figure 1d) whereas it is of π2-
type symmetry for toluene and 1,3-azaborines (see Figure 1c 
and Figure 1e).  
Additional Computational Results.  We have also 
computationally investigated the ground-state dipole 
moments of the five arenes. As can be seen from Table 1,  
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1,2-Azaborine shows a significant deviation in the electronic structure from 
benzene, by just replacing a CC bond with a BN bond. In this study, the HOMO energies 
(via UV-PES; highest to lowest), the dipole moment (strongest to weakest), the UV-Vis 
(longest to shortest wavelength) and the aniodic peak in the CV all follow the trend: N- 
Me-1,3-BN-toluene 3 > N-Me-1,2-BN-toluene 2  > 1,2-dihydro-1,2-azaborine 1  > 
toluene  > benzene.  
6.4. Photoisomerization of 1,2-Dihydro-1,2-Azaborine 
The photoisomerization of benzene has been widely studied, with five valence 
isomers being well known.15  The first observation of Dewar benzene was reported in 
1968.16 In collaboration with the Bettinger group, the first study on the 
photoisomerization of 1,2-dihydro-1,2-azaborine which produces the Dewar isomer (4) 
was performed (Figure 6.3). The computed harmonic vibrational frequencies of 4 
compared well to the observed spectrum. No other valence isomers for 1,2-dihydro-1,2-
azaborine 1 were detected.  
  
 
 
 
Figure 6.3. Photoisomerization of 1,2-dihydro-1,2-azaborine into the BN-Dewar 4 
isomer. (a) The observed infrared difference spectrum between irradiation before and 
after, and (b) the calculated spectrum for BN-Dewar 4.  
 3
Table 2. Comparison of Vibrational Frequencies (cm-1) after 
Irradiation at 253.7nm (Ne, 4 K) and Calculated Wavenumbers (cm-1) 
for BN-Dewar, 4[a] 
Ȟexp (cm-1) Ȧtheor (cm-1)[b] Assignment 
3482.2 3615.6  Ȟ(NH) 
3117.8-2958.5 3197.0-3084.0 Ȟ(CH) 
2602.3-2566.5 
[10B] 2663.4, 
[11B] 650.4 
Ȟ(BH) 
1630.9[c] 1601.4 Ȟ(CC) 
[10B] 1392.8 
[11B] 1374.5 
[10B] 1418.0,  
[11B] 1399.1 
Ȟ(BN) 
1283.6 1298.5 į(in plane CH) 
1229.8 1253.5 į(in plane CH) 
1179.7 1201.8 į(in plane CH) 
1161.0 1175.2 į(in plane CH) 
1143.7 1164.4 į(in plane CH) 
911.1 924.1 į(out plane CH) 
861.8 877.3 į(out plane CH) 
[10B] 753.0 
[11B] 747.6 
[10B] 767.8,  
[11B] 763.1 
į(BH) 
716.6 723.9 į(out plane CH) 
582.7 590.7 į(NH) 
[a] B3LYP/6-311++G**, [b] Unscaled, [c] Tentative assignment, due to 
overlap with H2O bending frequencies 
Figure 4. Observed and calculated infrared spectra for isomers of 1. 
(a) Observed infrared difference spectrum between those observed 
before, and after, 105 minute UV irradiation (Ne, 4K), (b) A spectral 
pattern for BN-Dewar, 4, (c) A spectral pattern for BN-benzvalene, 3, 
(d) A spectral pattern for BN-fulvene, 2. 
 
 
 In the optimized (CCSD(T)/cc-pVTZ, Figure 5) structure of 
BN-Dewar, 4, the C3–C4 bridging bond distance is 1.573 Å. Th s 
compares well with the experimental electron diffraction structure of 
Dewar benzene (1.574(5) Å).[23a] The B–N bond length is 1.397 Å, 
which is typical for B-N double bonds,[24] and the carbon-carbon 
double bond is 1.344 Å (1.345 Å, Dewar benzene).[23a] The long B–
C bond (1.610 Å) and the short N–C bond length (1.472 Å) result in 
a distortion of the corresponding four-membered ring. The B-C3-C2 
angle and the N-C4-C1 angles are 115.4° and 116.1°, respectively. 
This compares well to Dewar benzene, which has a corresponding 
C-C-C bond angle of 116.7(6)°.[23a] 
Figure 5. Optimized geometrical structure of BN-Dewar, 4 
(CCSD(T)/cc-pVTZ). Bond lengths are in Å. 
 
 
In summary, an infrared spectrum of 1,2-dihydro-1,2-
azaborine, 1, in low temperature neon matrices has been obtained 
and analyzed. The observed spectrum compared well with that of 
the DFT calculation. Subsequent photolysis of 1, was found to 
produce exclusively the BN- Dewar form, 4.  
 
 
 
The first observation of Dewar benzene was reported in 
1962,[15a,25] a substituted Dewar borazine was initially reported in 
1984,[26,27] and to the best of our knowledge, it is the first time that 
the Dewar isomer (4) of 1,2-dihydro-1,2-azaborine (1) has been 
observed. Computed harmonic vibrational frequencies of 4 
compared well to that of the observed spectrum. No other valence 
isomers were detected. The development of benzene mimics, such 
as 1, is an increasingly important and emerging area of chemistry 
and the discoveries of the type of chemistry 1 can undergo is of 
fundamental interest to the scientific community. 
Experimental Section 
1,2-Dihydro-1,2-azaborine was synthesized according to Liu et al.[7] 
Matrix experiments were carried out according to standard 
techniques[28] using a SHI CKW-21A displex closed cycle helium 
cryostat. 1,2-Dihydro-1,2-azaborine was sublimed from a glass flask 
at -80 °C (EtOH/Julabo FT902 immersion cooler) and co-condensed 
with a large excess of neon 5.0 (Westfalen) or argon (Westfalen, 
99.9999%), which was dosed to 2.0 sccm by a mass flow controller 
(MKS mass flow PR400B), prior to being condensed onto a cold CsI 
window (4 K). Deposition occurred for a total of 180 minutes. Matrix 
photolysis was achieved using a low pressure mercury lamp (UVP, 
253.7 nm), and light was transmitted through a quartz window present 
in the vacuum shroud. All FT-IR spectra were measured between 
4000 and 400 cm-1 on a Bruker V 70 spectrometer using a resolution 
of 0.5 cm-1. All calculations were performed with the Gaussian 09 
program suite, using either the functional B3LYP or second order 
Møller-Plesset perturbation (MP2) theory with the implemented 6-
311++G** basis set.[29] Geometries were optimized and harmonic 
vibrational frequencies were computed for all compounds. In addition, 
the geometry of 4 was optimized employing coupled cluster theory 
with singles, doubles, and a perturbative estimate of triples excitations 
[CCSD(T)][30] (all electrons were correlated) in conjunction with the cc-
pVTZ[31] basis set using the CFOUR program.[32] 
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6.5. BN-Substituted Diphenylacetylene  
 Diphenylacetylene is one of the most fundamental building blocks in material 
science and is a sub-unit of graphyne.17 As part of our goal to develop BN-based materials 
we synthesized BN-tolan 5 and bis-BN-tolan 6 and studied their optoelectronic properties.  
 
 
  
 
 
 
 
 
Figure 6.4. Normalized emission spectra of 5, 6, and tolan in THF (10-5 M). 
 BN-tolans 5 and 6 display absorption and emission spectra that are distinct from 
their carbon analogue (Figure 6.4). Time-dependent DFT calculations show that for BN-
tolan 5, 6, and tolan, the singlet excited state transitions are dominated by the HOMO–
LUMO transition with little charge transfer character.  
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6.6. Conclusion 
 The basic science of benzene and its derivatives (such as diphenylacetylene) is 
well established.1-3, 17  The implications of replacing a C=C bond with a B-N bond is not 
well understood. Fundamental studies are revealing some of the optoelectronic properties 
of 1,2-azaborines including: 1) the UV-photoelectonic spectrum (UV-PES) which 
establishes the position of the occupied molecular orbitals, showing that azaborines have 
higher HOMOs than arenes; 2) photoisomerization can occur, giving the BN-Dewar 
isomer 4 and 3) the replacement of an arene with a 1,2-azaborine causes a distinct shift in 
the optical properties. 1,2-Azaborines are an interesting class of molecules that have thus 
far been understudied.  Future work into the basic science of 1,2-azaborines may lead to 
novel biomedical and material based applications.    
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APPENDIX A 
SUPPORTING INFORMATION FOR CHAPTER III : 
TRIMERIZATION OF 1,2-DIHYDRO-1,2-AZABORINE 
 
X-ray Crystal Structure Determination of 1 &5 
General Procedure: Diffraction intensity data for all compounds were collected 
with a Bruker Smart Apex CCD diffractometer at 173(2) K using MoK - radiation 
(0.71073 Å). The structures were solved using direct methods, completed by subsequent 
difference Fourier syntheses, and refined by full matrix least-squares procedures on F2. 
All non-H atoms were refined with anisotropic thermal parameters. H atoms were found 
on the residual density map and refined with isotropic thermal parameters except for 
those in two disordered -CH2- groups in one of two symmetrically independent 
molecules of compound 4, which were treated in the calculated positions and refined in a 
rigid group model. All software and sources scattering factors are contained in the 
SHELXTL (6.10) program package (G.Sheldrick, Bruker XRD, Madison, WI). 
Crystallographic data and some details of data collection and crystal structure refinement 
for 19 and 20 are given in the following tables. 
 
 
 
 
 
  
 
149 
 
Crystallographic data for Compound 1 (liu63). 
 
 
 
 
 
 
 
 
Table 1.  Crystal data and structure refinement for liu63. 
Identification code  liu63 
Empirical formula  C12 H12 B3 N3 
Formula weight  230.68 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 5.1474(19) Å a= 90°. 
 b = 17.134(6) Å b= 93.529(8)°. 
 c = 26.491(10) Å g = 90°. 
Volume 2331.9(15) Å3 
Z 8 
Density (calculated) 1.314 Mg/m3 
Absorption coefficient 0.077 mm-1 
F(000) 960 
Crystal size 0.42 x 0.10 x 0.08 mm3 
Theta range for data collection 1.42 to 25.00°. 
Index ranges -6<=h<=6, -20<=k<=20, -31<=l<=31 
Reflections collected 22266 
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Independent reflections 4102 [R(int) = 0.0854] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9939 and 0.9684 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4102 / 0 / 423 
Goodness-of-fit on F2 1.018 
Final R indices [I>2sigma(I)] R1 = 0.0499, wR2 = 0.0933 
R indices (all data) R1 = 0.1224, wR2 = 0.1344 
Largest diff. peak and hole 0.156 and -0.141 e.Å-3 
 
 
Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for liu63.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
N(1) 1001(5) -2848(2) 203(1) 39(1) 
B(1A) 1001(5) -2848(2) 203(1) 39(1) 
N(2) 2493(5) -3439(2) -595(1) 36(1) 
B(2A) 2493(5) -3439(2) -595(1) 36(1) 
N(3) 4524(5) -2204(2) -254(1) 38(1) 
B(3A) 4524(5) -2204(2) -254(1) 38(1) 
B(1) 771(5) -3437(2) -165(1) 38(1) 
N(1A) 771(5) -3437(2) -165(1) 38(1) 
B(2) 4371(5) -2821(2) -638(1) 38(1) 
N(2A) 4371(5) -2821(2) -638(1) 38(1) 
B(3) 2925(6) -2195(2) 165(1) 41(1) 
N(3A) 2925(6) -2195(2) 165(1) 41(1) 
C(1) -647(6) -2872(2) 621(1) 49(1) 
C(2) -2410(6) -3448(2) 663(1) 49(1) 
C(3) -2696(6) -4048(2) 296(1) 48(1) 
C(4) -1197(6) -4056(2) -107(1) 49(1) 
C(5) 2392(6) -4052(2) -961(1) 44(1) 
C(6) 4043(6) -4067(2) -1341(1) 50(1) 
C(7) 5887(6) -3463(2) -1395(1) 51(1) 
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C(8) 6072(6) -2858(2) -1067(1) 49(1) 
C(9) 6377(7) -1576(2) -288(1) 53(1) 
C(10) 6611(7) -1006(2) 60(2) 57(1) 
C(11) 5027(7) -1005(2) 481(1) 57(1) 
C(12) 3241(7) -1569(2) 538(1) 52(1) 
N(1') 4942(5) 1387(2) 2797(1) 40(1) 
B(1A') 4942(5) 1387(2) 2797(1) 40(1) 
N(2') 2699(5) 810(2) 2008(1) 39(1) 
B(2A') 2699(5) 810(2) 2008(1) 39(1) 
N(3') 1098(5) 2075(2) 2358(1) 42(1) 
B(3A') 1098(5) 2075(2) 2358(1) 42(1) 
B(1') 4732(5) 785(2) 2443(1) 37(1) 
N(1A') 4732(5) 785(2) 2443(1) 37(1) 
B(2') 938(5) 1453(2) 1988(1) 40(1) 
N(2A') 938(5) 1453(2) 1988(1) 40(1) 
B(3') 3119(5) 2058(2) 2772(1) 40(1) 
N(3A') 3119(5) 2058(2) 2772(1) 40(1) 
C(1') 6991(6) 1335(2) 3213(1) 50(1) 
C(2') 8606(6) 715(2) 3241(1) 46(1) 
C(3') 8380(6) 106(2) 2877(1) 42(1) 
C(4') 6523(6) 130(2) 2492(1) 43(1) 
C(5') 2461(6) 206(2) 1625(1) 45(1) 
C(6') 554(6) 243(2) 1248(1) 49(1) 
C(7') -1242(6) 871(2) 1219(1) 55(1) 
C(8') -1070(6) 1447(2) 1568(2) 56(1) 
C(9') -730(7) 2737(2) 2351(2) 55(1) 
C(10') -511(8) 3293(2) 2716(2) 65(1) 
C(11') 1466(7) 3267(2) 3115(2) 59(1) 
C(12') 3216(7) 2682(2) 3138(1) 50(1) 
________________________________________________________________________________
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Table 3.   Bond lengths [Å] and angles [°] for liu63. 
_____________________________________________________ 
N(1)-B(1)  1.403(4) 
N(1)-C(1)  1.435(4) 
N(1)-B(3)  1.502(4) 
N(2)-C(5)  1.427(4) 
N(2)-B(2)  1.444(4) 
N(2)-B(1)  1.485(4) 
N(3)-B(3)  1.424(4) 
N(3)-C(9)  1.445(4) 
N(3)-B(2)  1.465(4) 
B(1)-C(4)  1.482(4) 
B(2)-C(8)  1.478(4) 
B(3)-C(12)  1.459(4) 
C(1)-C(2)  1.349(4) 
C(1)-H(8)  1.02(3) 
C(2)-C(3)  1.419(4) 
C(2)-H(17)  0.98(3) 
C(3)-C(4)  1.354(4) 
C(3)-H(20)  1.01(3) 
C(4)-H(27)  0.94(3) 
C(5)-C(6)  1.358(4) 
C(5)-H(4)  1.02(3) 
C(6)-C(7)  1.417(4) 
C(6)-H(30)  1.01(3) 
C(7)-C(8)  1.351(4) 
C(7)-H(23)  0.97(3) 
C(8)-H(3)  1.00(3) 
C(9)-C(10)  1.342(5) 
C(9)-H(15)  0.98(3) 
C(10)-C(11)  1.422(5) 
C(10)-H(14)  1.03(3) 
C(11)-C(12)  1.349(4) 
C(11)-H(22)  0.98(3) 
C(12)-H(2)  0.95(3) 
N(1')-B(1')  1.393(4) 
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N(1')-C(1')  1.481(4) 
N(1')-B(3')  1.483(4) 
N(2')-B(2')  1.426(4) 
N(2')-C(5')  1.448(4) 
N(2')-B(1')  1.509(4) 
N(3')-B(2')  1.446(4) 
N(3')-B(3')  1.465(4) 
N(3')-C(9')  1.473(4) 
B(1')-C(4')  1.452(4) 
B(2')-C(8')  1.472(4) 
B(3')-C(12')  1.442(4) 
C(1')-C(2')  1.349(4) 
C(1')-H(5)  1.02(3) 
C(2')-C(3')  1.420(4) 
C(2')-H(13)  1.01(3) 
C(3')-C(4')  1.356(4) 
C(3')-H(19)  1.00(3) 
C(4')-H(12)  0.99(2) 
C(5')-C(6')  1.359(4) 
C(5')-H(9)  1.00(3) 
C(6')-C(7')  1.418(4) 
C(6')-H(6)  1.09(3) 
C(7')-C(8')  1.350(5) 
C(7')-H(29)  1.11(3) 
C(8')-H(1)  0.97(3) 
C(9')-C(10')  1.356(5) 
C(9')-H(25)  1.02(3) 
C(10')-C(11')  1.424(5) 
C(10')-H(21)  0.96(3) 
C(11')-C(12')  1.346(4) 
C(11')-H(11)  1.14(3) 
C(12')-H(10)  1.05(3) 
B(1)-N(1)-C(1) 119.1(3) 
B(1)-N(1)-B(3) 121.1(2) 
C(1)-N(1)-B(3) 119.7(3) 
C(5)-N(2)-B(2) 118.9(3) 
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C(5)-N(2)-B(1) 121.6(3) 
B(2)-N(2)-B(1) 119.5(2) 
B(3)-N(3)-C(9) 117.0(3) 
B(3)-N(3)-B(2) 122.8(2) 
C(9)-N(3)-B(2) 120.2(3) 
N(1)-B(1)-C(4) 118.1(3) 
N(1)-B(1)-N(2) 120.4(3) 
C(4)-B(1)-N(2) 121.4(3) 
N(2)-B(2)-N(3) 118.8(2) 
N(2)-B(2)-C(8) 117.4(3) 
N(3)-B(2)-C(8) 123.8(3) 
N(3)-B(3)-C(12) 119.3(3) 
N(3)-B(3)-N(1) 117.3(3) 
C(12)-B(3)-N(1) 123.3(3) 
C(2)-C(1)-N(1) 121.2(3) 
C(2)-C(1)-H(8) 122.3(16) 
N(1)-C(1)-H(8) 116.3(16) 
C(1)-C(2)-C(3) 120.9(3) 
C(1)-C(2)-H(17) 118.9(17) 
C(3)-C(2)-H(17) 120.1(17) 
C(4)-C(3)-C(2) 120.6(3) 
C(4)-C(3)-H(20) 118.6(16) 
C(2)-C(3)-H(20) 120.8(16) 
C(3)-C(4)-B(1) 120.0(3) 
C(3)-C(4)-H(27) 118.1(17) 
B(1)-C(4)-H(27) 121.8(17) 
C(6)-C(5)-N(2) 121.3(3) 
C(6)-C(5)-H(4) 121.6(16) 
N(2)-C(5)-H(4) 117.1(16) 
C(5)-C(6)-C(7) 121.0(3) 
C(5)-C(6)-H(30) 116.9(17) 
C(7)-C(6)-H(30) 122.1(17) 
C(8)-C(7)-C(6) 121.1(3) 
C(8)-C(7)-H(23) 121.0(17) 
C(6)-C(7)-H(23) 117.8(17) 
C(7)-C(8)-B(2) 120.4(3) 
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C(7)-C(8)-H(3) 124.0(17) 
B(2)-C(8)-H(3) 115.6(17) 
C(10)-C(9)-N(3) 122.2(4) 
C(10)-C(9)-H(15) 116.9(17) 
N(3)-C(9)-H(15) 120.9(17) 
C(9)-C(10)-C(11) 120.5(4) 
C(9)-C(10)-H(14) 121.8(17) 
C(11)-C(10)-H(14) 117.7(17) 
C(12)-C(11)-C(10) 120.9(4) 
C(12)-C(11)-H(22) 121.2(18) 
C(10)-C(11)-H(22) 117.6(17) 
C(11)-C(12)-B(3) 120.0(3) 
C(11)-C(12)-H(2) 118.3(17) 
B(3)-C(12)-H(2) 121.5(17) 
B(1')-N(1')-C(1') 118.6(3) 
B(1')-N(1')-B(3') 121.4(3) 
C(1')-N(1')-B(3') 119.9(3) 
B(2')-N(2')-C(5') 120.0(3) 
B(2')-N(2')-B(1') 117.4(3) 
C(5')-N(2')-B(1') 122.6(3) 
B(2')-N(3')-B(3') 120.0(3) 
B(2')-N(3')-C(9') 123.4(3) 
B(3')-N(3')-C(9') 116.6(3) 
N(1')-B(1')-C(4') 119.3(3) 
N(1')-B(1')-N(2') 120.9(2) 
C(4')-B(1')-N(2') 119.8(3) 
N(2')-B(2')-N(3') 122.3(3) 
N(2')-B(2')-C(8') 115.9(3) 
N(3')-B(2')-C(8') 121.7(3) 
C(12')-B(3')-N(3') 118.8(3) 
C(12')-B(3')-N(1') 123.3(3) 
N(3')-B(3')-N(1') 117.9(3) 
C(2')-C(1')-N(1') 119.8(3) 
C(2')-C(1')-H(5) 120.0(16) 
N(1')-C(1')-H(5) 120.1(16) 
C(1')-C(2')-C(3') 121.1(3) 
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C(1')-C(2')-H(13) 121.6(17) 
C(3')-C(2')-H(13) 117.3(16) 
C(4')-C(3')-C(2') 120.9(3) 
C(4')-C(3')-H(19) 119.7(15) 
C(2')-C(3')-H(19) 119.4(15) 
C(3')-C(4')-B(1') 120.3(3) 
C(3')-C(4')-H(12) 118.9(15) 
B(1')-C(4')-H(12) 120.7(15) 
C(6')-C(5')-N(2') 120.5(3) 
C(6')-C(5')-H(9) 117.1(16) 
N(2')-C(5')-H(9) 122.4(16) 
C(5')-C(6')-C(7') 120.9(3) 
C(5')-C(6')-H(6) 120.1(15) 
C(7')-C(6')-H(6) 118.9(15) 
C(8')-C(7')-C(6') 120.2(3) 
C(8')-C(7')-H(29) 126.8(17) 
C(6')-C(7')-H(29) 113.0(17) 
C(7')-C(8')-B(2') 122.4(3) 
C(7')-C(8')-H(1) 120.1(18) 
B(2')-C(8')-H(1) 117.5(18) 
C(10')-C(9')-N(3') 120.5(4) 
C(10')-C(9')-H(25) 122.3(19) 
N(3')-C(9')-H(25) 117.2(19) 
C(9')-C(10')-C(11') 122.1(4) 
C(9')-C(10')-H(21) 120(2) 
C(11')-C(10')-H(21) 117.8(19) 
C(12')-C(11')-C(10') 120.1(4) 
C(12')-C(11')-H(11) 119.3(18) 
C(10')-C(11')-H(11) 120.5(17) 
C(11')-C(12')-B(3') 121.8(4) 
C(11')-C(12')-H(10) 119.4(16) 
B(3')-C(12')-H(10) 118.8(16) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Table 4.   Anisotropic displacement parameters (Å2x 103)for liu63.  The anisotropic 
displacement factor exponent takes the form: -2p2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
N(1) 33(2)  46(2) 39(2)  10(1) 3(1)  7(1) 
B(1A) 33(2)  46(2) 39(2)  10(1) 3(1)  7(1) 
N(2) 29(2)  39(2) 38(2)  3(1) -1(1)  4(1) 
B(2A) 29(2)  39(2) 38(2)  3(1) -1(1)  4(1) 
N(3) 32(2)  37(2) 42(2)  8(1) -4(1)  2(1) 
B(3A) 32(2)  37(2) 42(2)  8(1) -4(1)  2(1) 
B(1) 31(2)  44(2) 39(2)  10(2) 3(1)  7(1) 
N(1A) 31(2)  44(2) 39(2)  10(2) 3(1)  7(1) 
B(2) 30(2)  44(2) 39(2)  11(2) 0(1)  3(2) 
N(2A) 30(2)  44(2) 39(2)  11(2) 0(1)  3(2) 
B(3) 37(2)  41(2) 43(2)  3(2) -4(2)  6(2) 
N(3A) 37(2)  41(2) 43(2)  3(2) -4(2)  6(2) 
C(1) 42(2)  53(2) 52(2)  7(2) 7(2)  7(2) 
C(2) 39(2)  61(2) 47(2)  11(2) 13(2)  10(2) 
C(3) 40(2)  50(2) 54(2)  15(2) 6(2)  5(2) 
C(4) 46(2)  54(2) 45(2)  7(2) 2(2)  10(2) 
C(5) 36(2)  44(2) 50(2)  1(2) 2(2)  1(2) 
C(6) 41(2)  60(2) 48(2)  -4(2) 3(2)  6(2) 
C(7) 38(2)  75(3) 41(2)  12(2) 9(2)  14(2) 
C(8) 37(2)  56(2) 53(2)  15(2) 2(2)  -2(2) 
C(9) 45(2)  61(2) 53(2)  13(2) -1(2)  7(2) 
C(10) 51(2)  48(2) 70(3)  7(2) -6(2)  -4(2) 
C(11) 50(2)  48(2) 70(3)  -12(2) -9(2)  0(2) 
C(12) 46(2)  54(2) 55(2)  -10(2) 1(2)  5(2) 
N(1') 33(2)  39(2) 50(2)  10(2) 12(2)  -2(1) 
B(1A') 33(2)  39(2) 50(2)  10(2) 12(2)  -2(1) 
N(2') 31(2)  39(2) 47(2)  7(1) 7(1)  -2(1) 
B(2A') 31(2)  39(2) 47(2)  7(1) 7(1)  -2(1) 
N(3') 33(2)  37(2) 58(2)  15(2) 14(2)  3(1) 
B(3A') 33(2)  37(2) 58(2)  15(2) 14(2)  3(1) 
B(1') 28(2)  36(2) 46(2)  10(1) 10(1)  0(1) 
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N(1A') 28(2)  36(2) 46(2)  10(1) 10(1)  0(1) 
B(2') 31(2)  38(2) 51(2)  14(2) 10(1)  0(1) 
N(2A') 31(2)  38(2) 51(2)  14(2) 10(1)  0(1) 
B(3') 35(2)  36(2) 49(2)  7(1) 13(2)  -2(1) 
N(3A') 35(2)  36(2) 49(2)  7(1) 13(2)  -2(1) 
C(1') 49(2)  45(2) 59(2)  3(2) 18(2)  -3(2) 
C(2') 38(2)  49(2) 50(2)  11(2) 3(2)  -3(2) 
C(3') 37(2)  41(2) 50(2)  7(2) 4(2)  3(2) 
C(4') 36(2)  49(2) 45(2)  6(2) 4(2)  1(2) 
C(5') 40(2)  45(2) 48(2)  2(2) 6(2)  -1(2) 
C(6') 44(2)  53(2) 49(2)  5(2) -4(2)  -8(2) 
C(7') 43(2)  60(2) 60(2)  19(2) -2(2)  -12(2) 
C(8') 36(2)  52(2) 80(3)  29(2) 12(2)  2(2) 
C(9') 44(2)  53(2) 68(3)  21(2) 13(2)  2(2) 
C(10') 62(3)  44(2) 93(3)  22(2) 39(2)  14(2) 
C(11') 67(3)  41(2) 70(3)  4(2) 27(2)  2(2) 
C(12') 54(2)  41(2) 57(2)  2(2) 18(2)  -2(2) 
______________________________________________________________________________
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Table 5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) 
for liu63. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(1) -2270(60) 1884(18) 1542(11) 67(11) 
H(2) 2120(50) -1521(16) 805(10) 49(9) 
H(3) 7350(60) -2420(16) -1089(10) 59(9) 
H(4) 1090(50) -4490(16) -914(10) 57(9) 
H(5) 7100(50) 1751(16) 3491(10) 55(9) 
H(6) 460(50) -193(17) 949(11) 68(10) 
H(8) -520(50) -2406(16) 862(10) 51(9) 
H(9) 3680(50) -249(16) 1623(10) 55(9) 
H(10) 4650(60) 2668(16) 3434(11) 65(10) 
H(11) 1530(60) 3720(20) 3428(13) 101(13) 
H(12) 6460(50) -295(15) 2237(9) 39(8) 
H(13) 10010(60) 663(16) 3520(10) 62(10) 
H(14) 7910(60) -555(18) 31(11) 69(10) 
H(15) 7500(60) -1543(16) -571(11) 56(10) 
H(17) -3570(50) -3427(16) 941(10) 57(9) 
H(19) 9560(50) -356(15) 2915(9) 43(8) 
H(20) -4080(60) -4464(17) 319(10) 60(10) 
H(21) -1770(60) 3711(19) 2718(11) 78(11) 
H(22) 5160(50) -555(17) 708(11) 59(10) 
H(23) 7030(60) -3501(16) -1671(11) 60(10) 
H(25) -2190(60) 2745(18) 2071(12) 83(12) 
H(27) -1490(50) -4453(15) -350(10) 45(9) 
H(29) -2650(60) 833(19) 888(12) 90(11) 
H(30) 3910(60) -4531(18) -1578(11) 71(11) 
________________________________________________________________________________
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Table 6.  Torsion angles [°] for liu63. 
________________________________________________________________ 
C(1)-N(1)-B(1)-C(4) 0.5(4) 
B(3)-N(1)-B(1)-C(4) -179.1(2) 
C(1)-N(1)-B(1)-N(2) -178.5(2) 
B(3)-N(1)-B(1)-N(2) 1.9(4) 
C(5)-N(2)-B(1)-N(1) 176.7(2) 
B(2)-N(2)-B(1)-N(1) -1.4(4) 
C(5)-N(2)-B(1)-C(4) -2.2(4) 
B(2)-N(2)-B(1)-C(4) 179.6(2) 
C(5)-N(2)-B(2)-N(3) -178.3(2) 
B(1)-N(2)-B(2)-N(3) 0.0(3) 
C(5)-N(2)-B(2)-C(8) 0.7(4) 
B(1)-N(2)-B(2)-C(8) 178.9(2) 
B(3)-N(3)-B(2)-N(2) 1.1(4) 
C(9)-N(3)-B(2)-N(2) -179.8(2) 
B(3)-N(3)-B(2)-C(8) -177.8(3) 
C(9)-N(3)-B(2)-C(8) 1.3(4) 
C(9)-N(3)-B(3)-C(12) -0.6(4) 
B(2)-N(3)-B(3)-C(12) 178.6(3) 
C(9)-N(3)-B(3)-N(1) -179.8(2) 
B(2)-N(3)-B(3)-N(1) -0.6(4) 
B(1)-N(1)-B(3)-N(3) -0.9(4) 
C(1)-N(1)-B(3)-N(3) 179.5(2) 
B(1)-N(1)-B(3)-C(12) 180.0(3) 
C(1)-N(1)-B(3)-C(12) 0.4(4) 
B(1)-N(1)-C(1)-C(2) -0.1(4) 
B(3)-N(1)-C(1)-C(2) 179.5(3) 
N(1)-C(1)-C(2)-C(3) -0.2(5) 
C(1)-C(2)-C(3)-C(4) 0.2(5) 
C(2)-C(3)-C(4)-B(1) 0.2(4) 
N(1)-B(1)-C(4)-C(3) -0.6(4) 
N(2)-B(1)-C(4)-C(3) 178.4(3) 
B(2)-N(2)-C(5)-C(6) 0.8(4) 
B(1)-N(2)-C(5)-C(6) -177.4(3) 
N(2)-C(5)-C(6)-C(7) -1.4(5) 
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C(5)-C(6)-C(7)-C(8) 0.5(5) 
C(6)-C(7)-C(8)-B(2) 1.0(5) 
N(2)-B(2)-C(8)-C(7) -1.6(4) 
N(3)-B(2)-C(8)-C(7) 177.3(3) 
B(3)-N(3)-C(9)-C(10) 0.2(4) 
B(2)-N(3)-C(9)-C(10) -179.0(3) 
N(3)-C(9)-C(10)-C(11) 0.5(5) 
C(9)-C(10)-C(11)-C(12) -0.8(5) 
C(10)-C(11)-C(12)-B(3) 0.4(5) 
N(3)-B(3)-C(12)-C(11) 0.3(4) 
N(1)-B(3)-C(12)-C(11) 179.4(3) 
C(1')-N(1')-B(1')-C(4') -0.2(4) 
B(3')-N(1')-B(1')-C(4') -178.4(2) 
C(1')-N(1')-B(1')-N(2') -179.3(2) 
B(3')-N(1')-B(1')-N(2') 2.5(4) 
B(2')-N(2')-B(1')-N(1') -2.9(4) 
C(5')-N(2')-B(1')-N(1') 178.4(3) 
B(2')-N(2')-B(1')-C(4') 178.0(2) 
C(5')-N(2')-B(1')-C(4') -0.8(4) 
C(5')-N(2')-B(2')-N(3') -179.5(3) 
B(1')-N(2')-B(2')-N(3') 1.7(4) 
C(5')-N(2')-B(2')-C(8') 0.6(4) 
B(1')-N(2')-B(2')-C(8') -178.2(2) 
B(3')-N(3')-B(2')-N(2') -0.2(4) 
C(9')-N(3')-B(2')-N(2') -178.7(3) 
B(3')-N(3')-B(2')-C(8') 179.7(2) 
C(9')-N(3')-B(2')-C(8') 1.2(4) 
B(2')-N(3')-B(3')-C(12') -179.4(2) 
C(9')-N(3')-B(3')-C(12') -0.8(4) 
B(2')-N(3')-B(3')-N(1') -0.3(4) 
C(9')-N(3')-B(3')-N(1') 178.3(2) 
B(1')-N(1')-B(3')-C(12') 178.2(3) 
C(1')-N(1')-B(3')-C(12') 0.0(4) 
B(1')-N(1')-B(3')-N(3') -0.8(4) 
C(1')-N(1')-B(3')-N(3') -179.0(2) 
B(1')-N(1')-C(1')-C(2') 0.1(4) 
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B(3')-N(1')-C(1')-C(2') 178.4(3) 
N(1')-C(1')-C(2')-C(3') 0.1(4) 
C(1')-C(2')-C(3')-C(4') -0.3(5) 
C(2')-C(3')-C(4')-B(1') 0.3(4) 
N(1')-B(1')-C(4')-C(3') -0.1(4) 
N(2')-B(1')-C(4')-C(3') 179.1(3) 
B(2')-N(2')-C(5')-C(6') -0.5(4) 
B(1')-N(2')-C(5')-C(6') 178.2(3) 
N(2')-C(5')-C(6')-C(7') 0.0(5) 
C(5')-C(6')-C(7')-C(8') 0.4(5) 
C(6')-C(7')-C(8')-B(2') -0.3(5) 
N(2')-B(2')-C(8')-C(7') -0.2(4) 
N(3')-B(2')-C(8')-C(7') 179.9(3) 
B(2')-N(3')-C(9')-C(10') 178.5(3) 
B(3')-N(3')-C(9')-C(10') -0.1(4) 
N(3')-C(9')-C(10')-C(11') 0.1(5) 
C(9')-C(10')-C(11')-C(12') 0.8(5) 
C(10')-C(11')-C(12')-B(3') -1.7(5) 
N(3')-B(3')-C(12')-C(11') 1.7(4) 
N(1')-B(3')-C(12')-C(11') -177.3(3) 
________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Crystallographic data for Compound 5 (liu119) 
 
 
 
 
 
 
 
 
 
 
Table 7.  Crystal data and structure refinement for liu119. 
Identification code  liu119 
Empirical formula  C15 H24 B3 Cr N3 O3 
Formula weight  378.80 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.7468(11) Å a= 70.900(2)°. 
 b = 10.4017(15) Å b= 82.487(2)°. 
 c = 10.4245(15) Å g = 83.414(2)°. 
Volume 784.63(19) Å3 
Z 2 
Density (calculated) 1.603 Mg/m3 
Absorption coefficient 0.750 mm-1 
F(000) 396 
Crystal size 0.37 x 0.08 x 0.06 mm3 
Theta range for data collection 2.08 to 27.00°. 
Index ranges -9<=h<=9, -13<=k<=13, -13<=l<=13 
Reflections collected 8746 
Independent reflections 3399 [R(int) = 0.0256] 
Completeness to theta = 27.00° 98.9 %  
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Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9564 and 0.7687 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3399 / 0 / 274 
Goodness-of-fit on F2 1.077 
Final R indices [I>2sigma(I)] R1 = 0.0385, wR2 = 0.0918 
R indices (all data) R1 = 0.0495, wR2 = 0.0989 
Largest diff. peak and hole 0.429 and -0.241 e.Å-3 
 
 
Table 8.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for liu119.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
Cr(1) 2242(1) 2710(1) 5877(1) 19(1) 
O(1) 2735(2) 4506(2) 2982(2) 34(1) 
O(2) 5923(2) 1509(2) 5611(2) 42(1) 
O(3) 3440(3) 5008(2) 6590(2) 54(1) 
N(1) 924(2) 1640(2) 7935(2) 20(1) 
N(2) 2481(2) -671(2) 8312(2) 22(1) 
N(3) 2260(2) 469(2) 10107(2) 24(1) 
B(1) 1551(3) 519(3) 7411(2) 21(1) 
B(2) 2799(3) -749(3) 9675(3) 23(1) 
B(3) 1380(3) 1680(3) 9277(3) 23(1) 
C(1) 2565(3) 3793(2) 4101(2) 23(1) 
C(2) 4511(3) 1971(2) 5733(2) 27(1) 
C(3) 2980(3) 4110(3) 6353(2) 31(1) 
C(4) -153(3) 2731(2) 7188(2) 24(1) 
C(5) -618(3) 2793(3) 5938(2) 27(1) 
C(6) 124(3) 1840(2) 5286(2) 25(1) 
C(7) 1247(3) 746(2) 5939(2) 24(1) 
C(8) 2993(3) -1791(2) 7868(3) 28(1) 
C(9) 3761(3) -2958(3) 8655(3) 35(1) 
C(10) 4094(3) -3097(3) 10006(3) 36(1) 
C(11) 3665(3) -2074(3) 10544(2) 30(1) 
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C(12) 2631(3) 450(3) 11382(2) 30(1) 
C(13) 2217(3) 1509(3) 11855(3) 34(1) 
C(14) 1381(4) 2739(3) 11057(3) 37(1) 
C(15) 937(3) 2879(3) 9793(3) 32(1) 
 
Table 9.   Bond lengths [Å] and angles [°] for liu119. 
_____________________________________________________ 
Cr(1)-C(1)  1.827(2) 
Cr(1)-C(2)  1.843(2) 
Cr(1)-C(3)  1.853(2) 
Cr(1)-C(4)  2.158(2) 
Cr(1)-C(5)  2.201(2) 
Cr(1)-C(6)  2.204(2) 
Cr(1)-N(1)  2.2380(18) 
Cr(1)-C(7)  2.243(2) 
Cr(1)-B(1)  2.389(2) 
O(1)-C(1)  1.159(3) 
O(2)-C(2)  1.152(3) 
O(3)-C(3)  1.145(3) 
N(1)-C(4)  1.402(3) 
N(1)-B(1)  1.453(3) 
N(1)-B(3)  1.501(3) 
N(2)-C(8)  1.388(3) 
N(2)-B(2)  1.449(3) 
N(2)-B(1)  1.464(3) 
N(3)-C(12)  1.390(3) 
N(3)-B(3)  1.430(3) 
N(3)-B(2)  1.479(3) 
B(1)-C(7)  1.520(3) 
B(2)-C(11)  1.517(3) 
B(3)-C(15)  1.503(3) 
C(4)-C(5)  1.376(3) 
C(4)-H(4)  0.88(2) 
C(5)-C(6)  1.408(3) 
C(5)-H(5)  0.83(3) 
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C(6)-C(7)  1.391(3) 
C(6)-H(6)  0.90(2) 
C(7)-H(7)  0.89(2) 
C(8)-C(9)  1.346(3) 
C(8)-H(8)  0.91(3) 
C(9)-C(10)  1.423(4) 
C(9)-H(9)  0.96(3) 
C(10)-C(11)  1.349(4) 
C(10)-H(10)  0.87(3) 
C(11)-H(11)  0.97(3) 
C(12)-C(13)  1.339(4) 
C(12)-H(12)  0.87(2) 
C(13)-C(14)  1.415(4) 
C(13)-H(13)  0.92(3) 
C(14)-C(15)  1.362(4) 
C(14)-H(14)  0.90(3) 
C(15)-H(15)  0.94(3) 
C(1)-Cr(1)-C(2) 89.38(10) 
C(1)-Cr(1)-C(3) 87.28(10) 
C(2)-Cr(1)-C(3) 90.67(11) 
C(1)-Cr(1)-C(4) 124.32(9) 
C(2)-Cr(1)-C(4) 146.29(9) 
C(3)-Cr(1)-C(4) 90.31(10) 
C(1)-Cr(1)-C(5) 94.99(9) 
C(2)-Cr(1)-C(5) 156.46(10) 
C(3)-Cr(1)-C(5) 112.60(10) 
C(4)-Cr(1)-C(5) 36.77(9) 
C(1)-Cr(1)-C(6) 87.57(9) 
C(2)-Cr(1)-C(6) 120.21(10) 
C(3)-Cr(1)-C(6) 148.61(10) 
C(4)-Cr(1)-C(6) 67.52(9) 
C(5)-Cr(1)-C(6) 37.28(9) 
C(1)-Cr(1)-N(1) 160.83(8) 
C(2)-Cr(1)-N(1) 109.37(8) 
C(3)-Cr(1)-N(1) 96.19(9) 
C(4)-Cr(1)-N(1) 37.13(7) 
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C(5)-Cr(1)-N(1) 66.25(8) 
C(6)-Cr(1)-N(1) 79.65(8) 
C(1)-Cr(1)-C(7) 108.82(9) 
C(2)-Cr(1)-C(7) 90.35(9) 
C(3)-Cr(1)-C(7) 163.87(9) 
C(4)-Cr(1)-C(7) 80.01(9) 
C(5)-Cr(1)-C(7) 66.34(9) 
C(6)-Cr(1)-C(7) 36.45(8) 
N(1)-Cr(1)-C(7) 68.34(7) 
C(1)-Cr(1)-B(1) 146.63(9) 
C(2)-Cr(1)-B(1) 86.81(9) 
C(3)-Cr(1)-B(1) 125.87(10) 
C(4)-Cr(1)-B(1) 65.71(8) 
C(5)-Cr(1)-B(1) 76.86(9) 
C(6)-Cr(1)-B(1) 66.21(8) 
N(1)-Cr(1)-B(1) 36.42(7) 
C(7)-Cr(1)-B(1) 38.16(8) 
C(4)-N(1)-B(1) 120.16(18) 
C(4)-N(1)-B(3) 117.64(18) 
B(1)-N(1)-B(3) 122.20(18) 
C(4)-N(1)-Cr(1) 68.35(12) 
B(1)-N(1)-Cr(1) 77.45(12) 
B(3)-N(1)-Cr(1) 126.05(14) 
C(8)-N(2)-B(2) 118.92(19) 
C(8)-N(2)-B(1) 118.66(19) 
B(2)-N(2)-B(1) 122.33(19) 
C(12)-N(3)-B(3) 117.8(2) 
C(12)-N(3)-B(2) 118.8(2) 
B(3)-N(3)-B(2) 123.45(19) 
N(1)-B(1)-N(2) 117.62(19) 
N(1)-B(1)-C(7) 115.6(2) 
N(2)-B(1)-C(7) 126.7(2) 
N(1)-B(1)-Cr(1) 66.12(11) 
N(2)-B(1)-Cr(1) 137.07(15) 
C(7)-B(1)-Cr(1) 65.73(12) 
N(2)-B(2)-N(3) 117.5(2) 
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N(2)-B(2)-C(11) 117.3(2) 
N(3)-B(2)-C(11) 125.2(2) 
N(3)-B(3)-N(1) 116.3(2) 
N(3)-B(3)-C(15) 119.3(2) 
N(1)-B(3)-C(15) 124.3(2) 
O(1)-C(1)-Cr(1) 178.2(2) 
O(2)-C(2)-Cr(1) 178.3(2) 
O(3)-C(3)-Cr(1) 177.1(2) 
C(5)-C(4)-N(1) 121.7(2) 
C(5)-C(4)-Cr(1) 73.30(14) 
N(1)-C(4)-Cr(1) 74.52(12) 
C(5)-C(4)-H(4) 121.7(15) 
N(1)-C(4)-H(4) 116.6(15) 
Cr(1)-C(4)-H(4) 126.7(15) 
C(4)-C(5)-C(6) 121.2(2) 
C(4)-C(5)-Cr(1) 69.93(13) 
C(6)-C(5)-Cr(1) 71.49(13) 
C(4)-C(5)-H(5) 113.6(18) 
C(6)-C(5)-H(5) 124.8(18) 
Cr(1)-C(5)-H(5) 125.3(18) 
C(7)-C(6)-C(5) 120.6(2) 
C(7)-C(6)-Cr(1) 73.30(13) 
C(5)-C(6)-Cr(1) 71.23(13) 
C(7)-C(6)-H(6) 121.1(15) 
C(5)-C(6)-H(6) 118.2(15) 
Cr(1)-C(6)-H(6) 123.9(15) 
C(6)-C(7)-B(1) 119.3(2) 
C(6)-C(7)-Cr(1) 70.25(13) 
B(1)-C(7)-Cr(1) 76.12(13) 
C(6)-C(7)-H(7) 117.7(14) 
B(1)-C(7)-H(7) 123.0(14) 
Cr(1)-C(7)-H(7) 124.8(15) 
C(9)-C(8)-N(2) 122.9(2) 
C(9)-C(8)-H(8) 120.4(16) 
N(2)-C(8)-H(8) 116.8(16) 
C(8)-C(9)-C(10) 120.7(2) 
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C(8)-C(9)-H(9) 118.0(16) 
C(10)-C(9)-H(9) 121.2(16) 
C(11)-C(10)-C(9) 121.7(2) 
C(11)-C(10)-H(10) 119(2) 
C(9)-C(10)-H(10) 119(2) 
C(10)-C(11)-B(2) 118.4(2) 
C(10)-C(11)-H(11) 120.8(16) 
B(2)-C(11)-H(11) 120.8(16) 
C(13)-C(12)-N(3) 123.2(2) 
C(13)-C(12)-H(12) 122.7(16) 
N(3)-C(12)-H(12) 114.1(16) 
C(12)-C(13)-C(14) 121.0(2) 
C(12)-C(13)-H(13) 121.3(19) 
C(14)-C(13)-H(13) 117.4(19) 
C(15)-C(14)-C(13) 121.3(2) 
C(15)-C(14)-H(14) 119.7(19) 
C(13)-C(14)-H(14) 118.9(19) 
C(14)-C(15)-B(3) 117.4(2) 
C(14)-C(15)-H(15) 117.6(17) 
B(3)-C(15)-H(15) 125.0(17) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Table 10.   Anisotropic displacement parameters (Å2x 103)for liu119.  The anisotropic 
displacement factor exponent takes the form: -2p2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
Cr(1) 19(1)  21(1) 18(1)  -5(1) -4(1)  -3(1) 
O(1) 42(1)  31(1) 24(1)  -3(1) -1(1)  -1(1) 
O(2) 24(1)  57(1) 40(1)  -11(1) -5(1)  7(1) 
O(3) 73(2)  46(1) 56(1)  -25(1) -13(1)  -24(1) 
N(1) 20(1)  22(1) 19(1)  -5(1) -2(1)  -1(1) 
N(2) 24(1)  20(1) 22(1)  -5(1) -1(1)  -1(1) 
N(3) 23(1)  29(1) 19(1)  -7(1) -1(1)  -5(1) 
B(1) 18(1)  22(1) 22(1)  -7(1) 0(1)  -5(1) 
B(2) 19(1)  27(1) 20(1)  -4(1) 1(1)  -3(1) 
B(3) 21(1)  26(1) 22(1)  -9(1) 1(1)  -3(1) 
C(1) 22(1)  22(1) 26(1)  -10(1) -4(1)  0(1) 
C(2) 28(1)  29(1) 23(1)  -4(1) -4(1)  -5(1) 
C(3) 35(1)  33(1) 23(1)  -6(1) -5(1)  -8(1) 
C(4) 23(1)  23(1) 26(1)  -9(1) -1(1)  1(1) 
C(5) 19(1)  29(1) 30(1)  -5(1) -6(1)  1(1) 
C(6) 23(1)  32(1) 22(1)  -6(1) -6(1)  -8(1) 
C(7) 25(1)  23(1) 25(1)  -9(1) -2(1)  -5(1) 
C(8) 32(1)  26(1) 26(1)  -10(1) -2(1)  -1(1) 
C(9) 40(1)  24(1) 38(1)  -10(1) 3(1)  4(1) 
C(10) 35(1)  28(1) 33(1)  1(1) -1(1)  7(1) 
C(11) 28(1)  35(1) 22(1)  -2(1) -2(1)  1(1) 
C(12) 31(1)  36(1) 19(1)  -5(1) -4(1)  -7(1) 
C(13) 35(1)  47(2) 22(1)  -13(1) -2(1)  -10(1) 
C(14) 44(2)  42(2) 35(1)  -25(1) 0(1)  -5(1) 
C(15) 35(1)  32(1) 31(1)  -14(1) -3(1)  1(1) 
______________________________________________________________________________
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Table 11.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) 
for liu119. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(4) -550(30) 3360(20) 7570(20) 20(6) 
H(5) -1250(30) 3480(30) 5590(30) 30(7) 
H(6) -80(30) 1990(20) 4420(20) 19(6) 
H(7) 1760(30) 200(20) 5460(20) 17(6) 
H(8) 2780(30) -1710(30) 7000(30) 32(7) 
H(9) 4110(40) -3670(30) 8270(30) 37(7) 
H(10) 4600(40) -3860(30) 10500(30) 45(8) 
H(11) 3890(30) -2190(30) 11470(30) 37(7) 
H(12) 3150(30) -310(30) 11850(20) 25(7) 
H(13) 2540(40) 1490(30) 12680(30) 51(9) 
H(14) 1120(40) 3430(30) 11400(30) 46(8) 
H(15) 410(40) 3720(30) 9300(30) 40(8) 
 
 
Table 12.  Torsion angles [°] for liu119. 
________________________________________________________________ 
C(1)-Cr(1)-N(1)-C(4) -17.3(3) 
C(2)-Cr(1)-N(1)-C(4) 175.20(14) 
C(3)-Cr(1)-N(1)-C(4) 82.30(14) 
C(5)-Cr(1)-N(1)-C(4) -29.70(13) 
C(6)-Cr(1)-N(1)-C(4) -66.25(13) 
C(7)-Cr(1)-N(1)-C(4) -102.42(14) 
B(1)-Cr(1)-N(1)-C(4) -129.95(18) 
C(1)-Cr(1)-N(1)-B(1) 112.7(3) 
C(2)-Cr(1)-N(1)-B(1) -54.85(14) 
C(3)-Cr(1)-N(1)-B(1) -147.75(14) 
C(4)-Cr(1)-N(1)-B(1) 129.95(18) 
C(5)-Cr(1)-N(1)-B(1) 100.25(14) 
C(6)-Cr(1)-N(1)-B(1) 63.70(13) 
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C(7)-Cr(1)-N(1)-B(1) 27.53(12) 
C(1)-Cr(1)-N(1)-B(3) -126.5(3) 
C(2)-Cr(1)-N(1)-B(3) 66.03(19) 
C(3)-Cr(1)-N(1)-B(3) -26.87(19) 
C(4)-Cr(1)-N(1)-B(3) -109.2(2) 
C(5)-Cr(1)-N(1)-B(3) -138.87(19) 
C(6)-Cr(1)-N(1)-B(3) -175.42(19) 
C(7)-Cr(1)-N(1)-B(3) 148.41(19) 
B(1)-Cr(1)-N(1)-B(3) 120.9(2) 
C(4)-N(1)-B(1)-N(2) -172.28(18) 
B(3)-N(1)-B(1)-N(2) 7.3(3) 
Cr(1)-N(1)-B(1)-N(2) 132.23(19) 
C(4)-N(1)-B(1)-C(7) 10.8(3) 
B(3)-N(1)-B(1)-C(7) -169.58(19) 
Cr(1)-N(1)-B(1)-C(7) -44.67(17) 
C(4)-N(1)-B(1)-Cr(1) 55.49(17) 
B(3)-N(1)-B(1)-Cr(1) -124.91(19) 
C(8)-N(2)-B(1)-N(1) 175.88(19) 
B(2)-N(2)-B(1)-N(1) -0.7(3) 
C(8)-N(2)-B(1)-C(7) -7.6(3) 
B(2)-N(2)-B(1)-C(7) 175.9(2) 
C(8)-N(2)-B(1)-Cr(1) -100.3(3) 
B(2)-N(2)-B(1)-Cr(1) 83.1(3) 
C(1)-Cr(1)-B(1)-N(1) -146.57(15) 
C(2)-Cr(1)-B(1)-N(1) 129.42(13) 
C(3)-Cr(1)-B(1)-N(1) 40.89(17) 
C(4)-Cr(1)-B(1)-N(1) -30.51(11) 
C(5)-Cr(1)-B(1)-N(1) -67.66(12) 
C(6)-Cr(1)-B(1)-N(1) -105.47(13) 
C(7)-Cr(1)-B(1)-N(1) -135.95(18) 
C(1)-Cr(1)-B(1)-N(2) 107.9(3) 
C(2)-Cr(1)-B(1)-N(2) 23.8(2) 
C(3)-Cr(1)-B(1)-N(2) -64.7(3) 
C(4)-Cr(1)-B(1)-N(2) -136.1(3) 
C(5)-Cr(1)-B(1)-N(2) -173.2(3) 
C(6)-Cr(1)-B(1)-N(2) 149.0(3) 
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N(1)-Cr(1)-B(1)-N(2) -105.6(3) 
C(7)-Cr(1)-B(1)-N(2) 118.5(3) 
C(1)-Cr(1)-B(1)-C(7) -10.6(2) 
C(2)-Cr(1)-B(1)-C(7) -94.63(14) 
C(3)-Cr(1)-B(1)-C(7) 176.84(14) 
C(4)-Cr(1)-B(1)-C(7) 105.44(14) 
C(5)-Cr(1)-B(1)-C(7) 68.29(14) 
C(6)-Cr(1)-B(1)-C(7) 30.48(13) 
N(1)-Cr(1)-B(1)-C(7) 135.95(18) 
C(8)-N(2)-B(2)-N(3) 179.14(19) 
B(1)-N(2)-B(2)-N(3) -4.3(3) 
C(8)-N(2)-B(2)-C(11) -0.6(3) 
B(1)-N(2)-B(2)-C(11) 175.88(19) 
C(12)-N(3)-B(2)-N(2) -176.65(19) 
B(3)-N(3)-B(2)-N(2) 2.9(3) 
C(12)-N(3)-B(2)-C(11) 3.1(3) 
B(3)-N(3)-B(2)-C(11) -177.3(2) 
C(12)-N(3)-B(3)-N(1) -177.18(19) 
B(2)-N(3)-B(3)-N(1) 3.2(3) 
C(12)-N(3)-B(3)-C(15) 1.5(3) 
B(2)-N(3)-B(3)-C(15) -178.1(2) 
C(4)-N(1)-B(3)-N(3) 171.07(19) 
B(1)-N(1)-B(3)-N(3) -8.5(3) 
Cr(1)-N(1)-B(3)-N(3) -106.6(2) 
C(4)-N(1)-B(3)-C(15) -7.5(3) 
B(1)-N(1)-B(3)-C(15) 172.9(2) 
Cr(1)-N(1)-B(3)-C(15) 74.8(3) 
C(2)-Cr(1)-C(1)-O(1) -153(6) 
C(3)-Cr(1)-C(1)-O(1) -62(6) 
C(4)-Cr(1)-C(1)-O(1) 26(6) 
C(5)-Cr(1)-C(1)-O(1) 50(6) 
C(6)-Cr(1)-C(1)-O(1) 87(6) 
N(1)-Cr(1)-C(1)-O(1) 39(6) 
C(7)-Cr(1)-C(1)-O(1) 117(6) 
B(1)-Cr(1)-C(1)-O(1) 124(6) 
C(1)-Cr(1)-C(2)-O(2) -42(7) 
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C(3)-Cr(1)-C(2)-O(2) -129(7) 
C(4)-Cr(1)-C(2)-O(2) 139(7) 
C(5)-Cr(1)-C(2)-O(2) 59(8) 
C(6)-Cr(1)-C(2)-O(2) 45(7) 
N(1)-Cr(1)-C(2)-O(2) 134(7) 
C(7)-Cr(1)-C(2)-O(2) 67(7) 
B(1)-Cr(1)-C(2)-O(2) 105(7) 
C(1)-Cr(1)-C(3)-O(3) 3(5) 
C(2)-Cr(1)-C(3)-O(3) 93(5) 
C(4)-Cr(1)-C(3)-O(3) -121(5) 
C(5)-Cr(1)-C(3)-O(3) -91(5) 
C(6)-Cr(1)-C(3)-O(3) -78(5) 
N(1)-Cr(1)-C(3)-O(3) -158(5) 
C(7)-Cr(1)-C(3)-O(3) -174(5) 
B(1)-Cr(1)-C(3)-O(3) 179(100) 
B(1)-N(1)-C(4)-C(5) -1.4(3) 
B(3)-N(1)-C(4)-C(5) 179.0(2) 
Cr(1)-N(1)-C(4)-C(5) 58.6(2) 
B(1)-N(1)-C(4)-Cr(1) -59.93(17) 
B(3)-N(1)-C(4)-Cr(1) 120.45(17) 
C(1)-Cr(1)-C(4)-C(5) 42.47(18) 
C(2)-Cr(1)-C(4)-C(5) -138.93(19) 
C(3)-Cr(1)-C(4)-C(5) 129.39(16) 
C(6)-Cr(1)-C(4)-C(5) -27.78(14) 
N(1)-Cr(1)-C(4)-C(5) -130.7(2) 
C(7)-Cr(1)-C(4)-C(5) -63.58(15) 
B(1)-Cr(1)-C(4)-C(5) -100.79(16) 
C(1)-Cr(1)-C(4)-N(1) 173.21(12) 
C(2)-Cr(1)-C(4)-N(1) -8.2(2) 
C(3)-Cr(1)-C(4)-N(1) -99.86(13) 
C(5)-Cr(1)-C(4)-N(1) 130.7(2) 
C(6)-Cr(1)-C(4)-N(1) 102.97(14) 
C(7)-Cr(1)-C(4)-N(1) 67.17(12) 
B(1)-Cr(1)-C(4)-N(1) 29.96(12) 
N(1)-C(4)-C(5)-C(6) -7.1(4) 
Cr(1)-C(4)-C(5)-C(6) 52.0(2) 
  
 
175 
N(1)-C(4)-C(5)-Cr(1) -59.14(19) 
C(1)-Cr(1)-C(5)-C(4) -145.96(15) 
C(2)-Cr(1)-C(5)-C(4) 114.1(2) 
C(3)-Cr(1)-C(5)-C(4) -56.84(17) 
C(6)-Cr(1)-C(5)-C(4) 134.7(2) 
N(1)-Cr(1)-C(5)-C(4) 29.98(13) 
C(7)-Cr(1)-C(5)-C(4) 105.65(16) 
B(1)-Cr(1)-C(5)-C(4) 66.85(15) 
C(1)-Cr(1)-C(5)-C(6) 79.35(15) 
C(2)-Cr(1)-C(5)-C(6) -20.6(3) 
C(3)-Cr(1)-C(5)-C(6) 168.48(14) 
C(4)-Cr(1)-C(5)-C(6) -134.7(2) 
N(1)-Cr(1)-C(5)-C(6) -104.71(15) 
C(7)-Cr(1)-C(5)-C(6) -29.04(13) 
B(1)-Cr(1)-C(5)-C(6) -67.84(14) 
C(4)-C(5)-C(6)-C(7) 5.1(3) 
Cr(1)-C(5)-C(6)-C(7) 56.38(19) 
C(4)-C(5)-C(6)-Cr(1) -51.3(2) 
C(1)-Cr(1)-C(6)-C(7) 126.94(15) 
C(2)-Cr(1)-C(6)-C(7) 39.08(17) 
C(3)-Cr(1)-C(6)-C(7) -152.30(18) 
C(4)-Cr(1)-C(6)-C(7) -104.13(15) 
C(5)-Cr(1)-C(6)-C(7) -131.6(2) 
N(1)-Cr(1)-C(6)-C(7) -67.41(14) 
B(1)-Cr(1)-C(6)-C(7) -31.84(13) 
C(1)-Cr(1)-C(6)-C(5) -101.50(15) 
C(2)-Cr(1)-C(6)-C(5) 170.64(14) 
C(3)-Cr(1)-C(6)-C(5) -20.7(2) 
C(4)-Cr(1)-C(6)-C(5) 27.43(14) 
N(1)-Cr(1)-C(6)-C(5) 64.15(14) 
C(7)-Cr(1)-C(6)-C(5) 131.6(2) 
B(1)-Cr(1)-C(6)-C(5) 99.72(15) 
C(5)-C(6)-C(7)-B(1) 5.0(3) 
Cr(1)-C(6)-C(7)-B(1) 60.41(18) 
C(5)-C(6)-C(7)-Cr(1) -55.40(19) 
N(1)-B(1)-C(7)-C(6) -12.6(3) 
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N(2)-B(1)-C(7)-C(6) 170.8(2) 
Cr(1)-B(1)-C(7)-C(6) -57.47(18) 
N(1)-B(1)-C(7)-Cr(1) 44.85(17) 
N(2)-B(1)-C(7)-Cr(1) -131.7(2) 
C(1)-Cr(1)-C(7)-C(6) -57.53(16) 
C(2)-Cr(1)-C(7)-C(6) -146.99(15) 
C(3)-Cr(1)-C(7)-C(6) 119.4(4) 
C(4)-Cr(1)-C(7)-C(6) 65.48(14) 
C(5)-Cr(1)-C(7)-C(6) 29.66(14) 
N(1)-Cr(1)-C(7)-C(6) 102.25(15) 
B(1)-Cr(1)-C(7)-C(6) 128.6(2) 
C(1)-Cr(1)-C(7)-B(1) 173.85(13) 
C(2)-Cr(1)-C(7)-B(1) 84.39(14) 
C(3)-Cr(1)-C(7)-B(1) -9.3(4) 
C(4)-Cr(1)-C(7)-B(1) -63.14(13) 
C(5)-Cr(1)-C(7)-B(1) -98.96(14) 
C(6)-Cr(1)-C(7)-B(1) -128.6(2) 
N(1)-Cr(1)-C(7)-B(1) -26.37(12) 
B(2)-N(2)-C(8)-C(9) 0.7(3) 
B(1)-N(2)-C(8)-C(9) -176.0(2) 
N(2)-C(8)-C(9)-C(10) -0.2(4) 
C(8)-C(9)-C(10)-C(11) -0.3(4) 
C(9)-C(10)-C(11)-B(2) 0.2(4) 
N(2)-B(2)-C(11)-C(10) 0.2(3) 
N(3)-B(2)-C(11)-C(10) -179.5(2) 
B(3)-N(3)-C(12)-C(13) -0.5(3) 
B(2)-N(3)-C(12)-C(13) 179.1(2) 
N(3)-C(12)-C(13)-C(14) -0.9(4) 
C(12)-C(13)-C(14)-C(15) 1.4(4) 
C(13)-C(14)-C(15)-B(3) -0.4(4) 
N(3)-B(3)-C(15)-C(14) -1.0(4) 
N(1)-B(3)-C(15)-C(14) 177.5(2) 
________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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APPENDIX B 
SUPPORTING INFORMATION FOR CHAPTER IV : 
NOVEL SYNHETIC ROUTE TO 1,2-DIHYDRO-1,2-AZABORINES 
 
X-ray Crystal Structure Determination of 19 &20. 
General Procedure: Diffraction intensity data for all compounds were collected 
with a Bruker Smart Apex CCD diffractometer at 173(2) K using MoK - radiation 
(0.71073 Å). The structures were solved using direct methods, completed by subsequent 
difference Fourier syntheses, and refined by full matrix least-squares procedures on F2. 
All non-H atoms were refined with anisotropic thermal parameters. H atoms were found 
on the residual density map and refined with isotropic thermal parameters except for 
those in two disordered -CH2- groups in one of two symmetrically independent 
molecules of compound 4, which were treated in the calculated positions and refined in a 
rigid group model. All software and sources scattering factors are contained in the 
SHELXTL (6.10) program package (G.Sheldrick, Bruker XRD, Madison, WI). 
Crystallographic data and some details of data collection and crystal structure refinement 
for 19 and 20 are given in the following tables. 
Crystallographic data for Compound 19 (liu127a):  
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Table 1.  Crystal data and structure refinement for liu127a. 
Identification code  liu127a 
Empirical formula  C12 H12 B N O2 
Formula weight  213.04 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pccn 
Unit cell dimensions a = 17.083(2) Å a= 90°. 
 b = 18.098(3) Å b= 90°. 
 c = 7.4267(11) Å g = 90°. 
Volume 2296.2(6) Å3 
Z 8 
Density (calculated) 1.232 Mg/m3 
Absorption coefficient 0.082 mm-1 
F(000) 896 
Crystal size 0.26 x 0.18 x 0.02 mm3 
Theta range for data collection 1.64 to 25.00°. 
Index ranges -20<=h<=20, -21<=k<=20, -8<=l<=8 
Reflections collected 13541 
Independent reflections 2024 [R(int) = 0.0543] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9984 and 0.9789 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2024 / 0 / 193 
Goodness-of-fit on F2 1.053 
Final R indices [I>2sigma(I)] R1 = 0.0431, wR2 = 0.0867 
R indices (all data) R1 = 0.0736, wR2 = 0.1016 
Largest diff. peak and hole 0.150 and -0.136 e.Å-3 
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 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for liu127a.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 681(1) 3301(1) 5247(2) 39(1) 
O(2) -70(1) 4242(1) 6180(2) 45(1) 
N(1) 1071(1) 4408(1) 3459(2) 31(1) 
B(1) 1096(1) 3642(1) 3814(3) 31(1) 
C(1) 1486(1) 4716(1) 2077(3) 38(1) 
C(2) 1945(1) 4302(1) 1001(3) 44(1) 
C(3) 1998(1) 3528(1) 1271(3) 42(1) 
C(4) 1605(1) 3184(1) 2611(3) 37(1) 
C(5) 152(1) 3613(1) 6333(2) 35(1) 
C(6) -119(2) 3074(1) 7744(3) 50(1) 
C(7) -667(1) 3385(1) 9126(2) 34(1) 
C(8) -1444(1) 3168(1) 9198(3) 43(1) 
C(9) -1942(1) 3450(1) 10488(3) 51(1) 
C(10) -1670(1) 3949(1) 11731(3) 49(1) 
C(11) -899(1) 4164(1) 11682(3) 45(1) 
C(12) -399(1) 3886(1) 10392(3) 38(1) 
 
Table 3.   Bond lengths [Å] and angles [°] for  liu127a. 
_____________________________________________________  
O(1)-C(5)  1.337(2) 
O(1)-B(1)  1.420(2) 
O(2)-C(5)  1.204(2) 
N(1)-C(1)  1.367(2) 
N(1)-B(1)  1.412(3) 
N(1)-H(1N)  0.89(2) 
B(1)-C(4)  1.496(3) 
C(1)-C(2)  1.347(3) 
C(1)-H(1)  0.98(2) 
C(2)-C(3)  1.418(3) 
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C(2)-H(2)  1.00(2) 
C(3)-C(4)  1.353(3) 
C(3)-H(3)  0.98(2) 
C(4)-H(4)  0.95(2) 
C(5)-C(6)  1.504(3) 
C(6)-C(7)  1.499(3) 
C(6)-H(6A)  0.98(3) 
C(6)-H(6B)  0.97(2) 
C(7)-C(12)  1.384(3) 
C(7)-C(8)  1.385(3) 
C(8)-C(9)  1.380(3) 
C(8)-H(8)  0.94(2) 
C(9)-C(10)  1.372(3) 
C(9)-H(9)  0.98(2) 
C(10)-C(11)  1.375(3) 
C(10)-H(10)  0.98(2) 
C(11)-C(12)  1.378(3) 
C(11)-H(11)  0.98(2) 
C(12)-H(12)  0.99(2) 
C(5)-O(1)-B(1) 127.39(15) 
C(1)-N(1)-B(1) 121.66(18) 
C(1)-N(1)-H(1N) 118.1(13) 
B(1)-N(1)-H(1N) 120.1(13) 
N(1)-B(1)-O(1) 123.39(17) 
N(1)-B(1)-C(4) 116.76(18) 
O(1)-B(1)-C(4) 119.85(18) 
C(2)-C(1)-N(1) 121.3(2) 
C(2)-C(1)-H(1) 123.2(11) 
N(1)-C(1)-H(1) 115.5(11) 
C(1)-C(2)-C(3) 120.2(2) 
C(1)-C(2)-H(2) 118.4(12) 
C(3)-C(2)-H(2) 121.3(12) 
C(4)-C(3)-C(2) 121.7(2) 
C(4)-C(3)-H(3) 123.6(11) 
C(2)-C(3)-H(3) 114.7(11) 
C(3)-C(4)-B(1) 118.3(2) 
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C(3)-C(4)-H(4) 119.3(12) 
B(1)-C(4)-H(4) 122.5(12) 
O(2)-C(5)-O(1) 123.70(17) 
O(2)-C(5)-C(6) 125.57(18) 
O(1)-C(5)-C(6) 110.73(16) 
C(7)-C(6)-C(5) 115.23(18) 
C(7)-C(6)-H(6A) 110.9(16) 
C(5)-C(6)-H(6A) 104.2(16) 
C(7)-C(6)-H(6B) 109.0(14) 
C(5)-C(6)-H(6B) 103.2(14) 
H(6A)-C(6)-H(6B) 114(2) 
C(12)-C(7)-C(8) 118.46(19) 
C(12)-C(7)-C(6) 120.3(2) 
C(8)-C(7)-C(6) 121.3(2) 
C(9)-C(8)-C(7) 120.8(2) 
C(9)-C(8)-H(8) 119.8(13) 
C(7)-C(8)-H(8) 119.3(13) 
C(10)-C(9)-C(8) 120.2(2) 
C(10)-C(9)-H(9) 116.8(13) 
C(8)-C(9)-H(9) 123.0(13) 
C(9)-C(10)-C(11) 119.5(2) 
C(9)-C(10)-H(10) 119.4(14) 
C(11)-C(10)-H(10) 121.0(14) 
C(10)-C(11)-C(12) 120.6(2) 
C(10)-C(11)-H(11) 120.4(13) 
C(12)-C(11)-H(11) 119.0(13) 
C(11)-C(12)-C(7) 120.4(2) 
C(11)-C(12)-H(12) 120.5(12) 
C(7)-C(12)-H(12) 119.0(12) 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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Table 4.   Anisotropic displacement parameters  (Å2x 103) for liu127a.  The anisotropic 
displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 51(1)  26(1) 39(1)  1(1) 12(1)  9(1) 
O(2) 61(1)  28(1) 45(1)  6(1) 16(1)  13(1) 
N(1) 33(1)  27(1) 35(1)  -1(1) 1(1)  3(1) 
B(1) 30(1)  31(1) 32(1)  -1(1) -3(1)  1(1) 
C(1) 36(1)  32(1) 47(1)  7(1) 2(1)  0(1) 
C(2) 38(1)  46(1) 49(1)  9(1) 9(1)  -1(1) 
C(3) 37(1)  45(1) 44(1)  -4(1) 9(1)  4(1) 
C(4) 36(1)  32(1) 44(1)  -3(1) 1(1)  4(1) 
C(5) 45(1)  27(1) 33(1)  -2(1) 2(1)  5(1) 
C(6) 74(2)  34(1) 43(1)  5(1) 20(1)  11(1) 
C(7) 46(1)  27(1) 30(1)  8(1) 2(1)  5(1) 
C(8) 55(2)  36(1) 39(1)  5(1) -9(1)  -10(1) 
C(9) 38(1)  56(2) 58(2)  18(1) 6(1)  -4(1) 
C(10) 54(2)  50(2) 44(1)  7(1) 16(1)  13(1) 
C(11) 60(2)  44(1) 33(1)  -5(1) -1(1)  -1(1) 
C(12) 36(1)  42(1) 36(1)  3(1) -2(1)  1(1) 
______________________________________________________________________________  
 
 
Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for liu127a. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1) 1420(11) 5252(12) 1920(30) 46(6) 
H(1N) 749(12) 4698(11) 4080(30) 48(6) 
H(2) 2237(12) 4551(12) 10(30) 58(7) 
H(3) 2335(12) 3269(10) 410(30) 47(6) 
H(4) 1658(10) 2666(12) 2750(30) 46(6) 
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H(6A) -372(14) 2677(15) 7050(40) 94(10) 
H(6B) 363(13) 2929(13) 8330(30) 70(8) 
H(8) -1636(12) 2839(12) 8330(30) 61(7) 
H(9) -2496(15) 3319(11) 10560(30) 63(7) 
H(10) -2031(13) 4147(12) 12640(30) 67(7) 
H(11) -698(12) 4523(12) 12550(30) 57(7) 
H(12) 152(12) 4048(10) 10340(30) 47(6) 
________________________________________________________________________________  
 
 Table 6.  Torsion angles [°] for liu127a. 
________________________________________________________________  
C(1)-N(1)-B(1)-O(1) 179.26(17) 
C(1)-N(1)-B(1)-C(4) 0.4(3) 
C(5)-O(1)-B(1)-N(1) 7.7(3) 
C(5)-O(1)-B(1)-C(4) -173.40(18) 
B(1)-N(1)-C(1)-C(2) -0.6(3) 
N(1)-C(1)-C(2)-C(3) 0.8(3) 
C(1)-C(2)-C(3)-C(4) -0.8(3) 
C(2)-C(3)-C(4)-B(1) 0.6(3) 
N(1)-B(1)-C(4)-C(3) -0.4(3) 
O(1)-B(1)-C(4)-C(3) -179.34(18) 
B(1)-O(1)-C(5)-O(2) 3.1(3) 
B(1)-O(1)-C(5)-C(6) -176.87(19) 
O(2)-C(5)-C(6)-C(7) -4.6(4) 
O(1)-C(5)-C(6)-C(7) 175.4(2) 
C(5)-C(6)-C(7)-C(12) -69.9(3) 
C(5)-C(6)-C(7)-C(8) 111.5(2) 
C(12)-C(7)-C(8)-C(9) 0.7(3) 
C(6)-C(7)-C(8)-C(9) 179.29(19) 
C(7)-C(8)-C(9)-C(10) -0.5(3) 
C(8)-C(9)-C(10)-C(11) -0.1(3) 
C(9)-C(10)-C(11)-C(12) 0.4(3) 
C(10)-C(11)-C(12)-C(7) -0.2(3) 
C(8)-C(7)-C(12)-C(11) -0.3(3) 
C(6)-C(7)-C(12)-C(11) -178.96(19) 
________________________________________________________________  
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Symmetry transformations used to generate equivalent atoms:  
  
 Table 7.  Hydrogen bonds for liu127a  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 N(1)-H(1N)...O(2) 0.89(2) 2.25(2) 2.823(2) 121.9(16) 
 N(1)-H(1N)...O(2)#1 0.89(2) 2.25(2) 2.995(2) 140.8(17) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms: #1 -x,-y+1,-z+1      
 
 
Crystallographic data for Compound 20 (liu158): 
 
 
 
 
 
 
 
 
 
Table 8.  Crystal data and structure refinement for liu158. 
Identification code  liu158 
Empirical formula  C18 H18 B N 
Formula weight  259.14 
Temperature  203(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 29.5015(15) Å a= 90°. 
 b = 7.4179(4) Å b= 112.7280(10)°. 
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 c = 28.8636(14) Å g = 90°. 
Volume 5826.0(5) Å3 
Z 16 
Density (calculated) 1.182 Mg/m3 
Absorption coefficient 0.067 mm-1 
F(000) 2208 
Crystal size 0.24 x 0.17 x 0.08 mm3 
Theta range for data collection 1.50 to 25.00°. 
Index ranges -34<=h<=34, -8<=k<=8, -34<=l<=34 
Reflections collected 26923 
Independent reflections 5128 [R(int) = 0.0427] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9946 and 0.9841 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5128 / 0 / 481 
Goodness-of-fit on F2 1.080 
Final R indices [I>2sigma(I)] R1 = 0.0499, wR2 = 0.1203 
R indices (all data) R1 = 0.0732, wR2 = 0.1347 
Largest diff. peak and hole 0.255 and -0.274 e.Å-3 
 
 
Table 9.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for liu158.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
N(1) 1760(1) -2449(2) 4350(1) 36(1) 
B(1) 1458(1) -874(3) 4301(1) 34(1) 
C(1) 1906(1) -3483(3) 4774(1) 44(1) 
C(2) 1771(1) -3128(3) 5163(1) 49(1) 
C(3) 1465(1) -1652(3) 5142(1) 48(1) 
C(4) 1302(1) -548(3) 4729(1) 42(1) 
C(5) 1930(1) -3045(3) 3958(1) 49(1) 
C(6) 1344(1) 390(3) 3819(1) 33(1) 
C(7) 949(1) 1813(3) 3744(1) 33(1) 
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C(8) 501(1) 1721(3) 3341(1) 41(1) 
C(9) 147(1) 3049(3) 3257(1) 49(1) 
C(10) 234(1) 4488(3) 3580(1) 50(1) 
C(11) 676(1) 4597(3) 3987(1) 48(1) 
C(12) 1029(1) 3273(3) 4067(1) 41(1) 
C(13) 1808(1) 1293(3) 3817(1) 32(1) 
C(14) 1852(1) 1707(3) 3368(1) 41(1) 
C(15) 2257(1) 2625(3) 3360(1) 50(1) 
C(16) 2631(1) 3123(3) 3801(1) 49(1) 
C(17) 2605(1) 2675(3) 4254(1) 46(1) 
C(18) 2196(1) 1770(3) 4261(1) 39(1) 
N(1') 1294(1) -2385(2) 6412(1) 37(1) 
B(1') 1334(1) -780(3) 6702(1) 33(1) 
C(1') 1702(1) -3387(3) 6464(1) 44(1) 
C(2') 2158(1) -2940(3) 6794(1) 49(1) 
C(3') 2228(1) -1420(3) 7103(1) 48(1) 
C(4') 1839(1) -354(3) 7070(1) 41(1) 
C(5') 818(1) -3075(3) 6052(1) 53(1) 
C(6') 848(1) 383(3) 6597(1) 35(1) 
C(7') 900(1) 1813(3) 6995(1) 34(1) 
C(8') 653(1) 1655(3) 7316(1) 40(1) 
C(9') 689(1) 2968(3) 7670(1) 47(1) 
C(10') 976(1) 4476(3) 7712(1) 46(1) 
C(11') 1225(1) 4652(3) 7397(1) 47(1) 
C(12') 1188(1) 3341(3) 7044(1) 43(1) 
C(13') 651(1) 1241(3) 6073(1) 34(1) 
C(14') 152(1) 1394(3) 5795(1) 44(1) 
C(15') -22(1) 2187(4) 5325(1) 56(1) 
C(16') 297(1) 2830(3) 5121(1) 50(1) 
C(17') 795(1) 2689(3) 5388(1) 44(1) 
C(18') 970(1) 1896(3) 5860(1) 41(1) 
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Table 10.   Bond lengths [Å] and angles [°] for liu158. 
_____________________________________________________ 
N(1)-C(1)  1.366(3) 
N(1)-B(1)  1.443(3) 
N(1)-C(5)  1.470(3) 
B(1)-C(4)  1.498(3) 
B(1)-C(6)  1.600(3) 
C(1)-C(2)  1.351(3) 
C(1)-H(1)  1.03(2) 
C(2)-C(3)  1.407(3) 
C(2)-H(2)  0.94(2) 
C(3)-C(4)  1.371(3) 
C(3)-H(3)  1.06(2) 
C(4)-H(4)  0.96(2) 
C(5)-H(5A)  0.9700 
C(5)-H(5B)  0.9700 
C(5)-H(5C)  0.9700 
C(6)-C(7)  1.525(3) 
C(6)-C(13)  1.527(3) 
C(6)-H(6)  0.98(2) 
C(7)-C(8)  1.385(3) 
C(7)-C(12)  1.388(3) 
C(8)-C(9)  1.386(3) 
C(8)-H(8)  0.98(2) 
C(9)-C(10)  1.375(4) 
C(9)-H(9)  0.96(2) 
C(10)-C(11)  1.381(4) 
C(10)-H(10)  0.95(3) 
C(11)-C(12)  1.382(3) 
C(11)-H(11)  0.95(3) 
C(12)-H(12)  0.98(2) 
C(13)-C(14)  1.385(3) 
C(13)-C(18)  1.396(3) 
C(14)-C(15)  1.382(3) 
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C(14)-H(14)  1.03(2) 
C(15)-C(16)  1.375(3) 
C(15)-H(15)  0.97(3) 
C(16)-C(17)  1.379(3) 
C(16)-H(16)  0.96(2) 
C(17)-C(18)  1.388(3) 
C(17)-H(17)  0.98(3) 
C(18)-H(18)  0.95(2) 
N(1')-C(1')  1.373(3) 
N(1')-B(1')  1.435(3) 
N(1')-C(5')  1.479(3) 
B(1')-C(4')  1.492(3) 
B(1')-C(6')  1.599(3) 
C(1')-C(2')  1.355(3) 
C(1')-H(1')  0.96(2) 
C(2')-C(3')  1.404(4) 
C(2')-H(2')  0.93(3) 
C(3')-C(4')  1.367(3) 
C(3')-H(3')  1.03(2) 
C(4')-H(4')  0.97(2) 
C(5')-H(5'A)  0.9700 
C(5')-H(5'B)  0.9700 
C(5')-H(5'C)  0.9700 
C(6')-C(7')  1.526(3) 
C(6')-C(13')  1.535(3) 
C(6')-H(6')  0.98(2) 
C(7')-C(8')  1.388(3) 
C(7')-C(12')  1.389(3) 
C(8')-C(9')  1.386(3) 
C(8')-H(8')  0.96(2) 
C(9')-C(10')  1.379(3) 
C(9')-H(9')  1.02(2) 
C(10')-C(11')  1.380(3) 
C(10')-H(10')  0.97(2) 
C(11')-C(12')  1.381(3) 
C(11')-H(11')  0.93(3) 
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C(12')-H(12')  0.97(2) 
C(13')-C(14')  1.383(3) 
C(13')-C(18')  1.396(3) 
C(14')-C(15')  1.382(3) 
C(14')-H(14')  1.130(16) 
C(15')-C(16')  1.374(4) 
C(15')-H(15')  0.99(3) 
C(16')-C(17')  1.374(3) 
C(16')-H(16')  0.95(2) 
C(17')-C(18')  1.386(3) 
C(17')-H(17')  0.95(2) 
C(18')-H(18')  1.00(2) 
C(1)-N(1)-B(1) 120.72(19) 
C(1)-N(1)-C(5) 116.00(18) 
B(1)-N(1)-C(5) 123.28(18) 
N(1)-B(1)-C(4) 115.14(19) 
N(1)-B(1)-C(6) 118.36(18) 
C(4)-B(1)-C(6) 126.43(19) 
C(2)-C(1)-N(1) 122.9(2) 
C(2)-C(1)-H(1) 121.4(12) 
N(1)-C(1)-H(1) 115.6(12) 
C(1)-C(2)-C(3) 120.4(2) 
C(1)-C(2)-H(2) 118.1(14) 
C(3)-C(2)-H(2) 121.5(14) 
C(4)-C(3)-C(2) 120.4(2) 
C(4)-C(3)-H(3) 117.8(14) 
C(2)-C(3)-H(3) 121.7(14) 
C(3)-C(4)-B(1) 120.3(2) 
C(3)-C(4)-H(4) 117.5(13) 
B(1)-C(4)-H(4) 122.2(13) 
N(1)-C(5)-H(5A) 109.5 
N(1)-C(5)-H(5B) 109.5 
H(5A)-C(5)-H(5B) 109.5 
N(1)-C(5)-H(5C) 109.5 
H(5A)-C(5)-H(5C) 109.5 
H(5B)-C(5)-H(5C) 109.5 
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C(7)-C(6)-C(13) 109.47(15) 
C(7)-C(6)-B(1) 114.94(17) 
C(13)-C(6)-B(1) 111.87(16) 
C(7)-C(6)-H(6) 104.3(12) 
C(13)-C(6)-H(6) 105.8(11) 
B(1)-C(6)-H(6) 109.8(12) 
C(8)-C(7)-C(12) 117.51(19) 
C(8)-C(7)-C(6) 120.91(18) 
C(12)-C(7)-C(6) 121.55(18) 
C(7)-C(8)-C(9) 121.4(2) 
C(7)-C(8)-H(8) 117.9(13) 
C(9)-C(8)-H(8) 120.7(13) 
C(10)-C(9)-C(8) 120.2(2) 
C(10)-C(9)-H(9) 121.6(15) 
C(8)-C(9)-H(9) 118.2(15) 
C(9)-C(10)-C(11) 119.3(2) 
C(9)-C(10)-H(10) 120.5(15) 
C(11)-C(10)-H(10) 120.1(15) 
C(10)-C(11)-C(12) 120.2(2) 
C(10)-C(11)-H(11) 122.4(15) 
C(12)-C(11)-H(11) 117.4(15) 
C(11)-C(12)-C(7) 121.4(2) 
C(11)-C(12)-H(12) 120.0(13) 
C(7)-C(12)-H(12) 118.6(13) 
C(14)-C(13)-C(18) 117.55(19) 
C(14)-C(13)-C(6) 120.72(19) 
C(18)-C(13)-C(6) 121.71(18) 
C(15)-C(14)-C(13) 121.3(2) 
C(15)-C(14)-H(14) 119.9(11) 
C(13)-C(14)-H(14) 118.8(11) 
C(16)-C(15)-C(14) 120.5(2) 
C(16)-C(15)-H(15) 119.2(15) 
C(14)-C(15)-H(15) 120.3(15) 
C(15)-C(16)-C(17) 119.5(2) 
C(15)-C(16)-H(16) 119.3(14) 
C(17)-C(16)-H(16) 121.2(14) 
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C(16)-C(17)-C(18) 119.9(2) 
C(16)-C(17)-H(17) 121.0(14) 
C(18)-C(17)-H(17) 119.0(14) 
C(17)-C(18)-C(13) 121.2(2) 
C(17)-C(18)-H(18) 120.2(12) 
C(13)-C(18)-H(18) 118.6(12) 
C(1')-N(1')-B(1') 121.01(19) 
C(1')-N(1')-C(5') 116.37(18) 
B(1')-N(1')-C(5') 122.61(18) 
N(1')-B(1')-C(4') 115.15(19) 
N(1')-B(1')-C(6') 118.21(18) 
C(4')-B(1')-C(6') 126.62(19) 
C(2')-C(1')-N(1') 122.4(2) 
C(2')-C(1')-H(1') 123.8(12) 
N(1')-C(1')-H(1') 113.8(12) 
C(1')-C(2')-C(3') 120.3(2) 
C(1')-C(2')-H(2') 118.3(15) 
C(3')-C(2')-H(2') 121.4(15) 
C(4')-C(3')-C(2') 120.5(2) 
C(4')-C(3')-H(3') 120.7(13) 
C(2')-C(3')-H(3') 118.8(13) 
C(3')-C(4')-B(1') 120.6(2) 
C(3')-C(4')-H(4') 118.8(13) 
B(1')-C(4')-H(4') 120.6(13) 
N(1')-C(5')-H(5'A) 109.5 
N(1')-C(5')-H(5'B) 109.5 
H(5'A)-C(5')-H(5'B) 109.5 
N(1')-C(5')-H(5'C) 109.5 
H(5'A)-C(5')-H(5'C) 109.5 
H(5'B)-C(5')-H(5'C) 109.5 
C(7')-C(6')-C(13') 110.09(16) 
C(7')-C(6')-B(1') 114.16(16) 
C(13')-C(6')-B(1') 112.33(17) 
C(7')-C(6')-H(6') 104.9(12) 
C(13')-C(6')-H(6') 104.5(12) 
B(1')-C(6')-H(6') 110.1(12) 
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C(8')-C(7')-C(12') 117.2(2) 
C(8')-C(7')-C(6') 121.04(19) 
C(12')-C(7')-C(6') 121.71(19) 
C(9')-C(8')-C(7') 121.5(2) 
C(9')-C(8')-H(8') 119.9(13) 
C(7')-C(8')-H(8') 118.6(13) 
C(10')-C(9')-C(8') 120.4(2) 
C(10')-C(9')-H(9') 120.8(13) 
C(8')-C(9')-H(9') 118.9(14) 
C(9')-C(10')-C(11') 118.8(2) 
C(9')-C(10')-H(10') 120.8(14) 
C(11')-C(10')-H(10') 120.4(14) 
C(10')-C(11')-C(12') 120.6(2) 
C(10')-C(11')-H(11') 118.6(16) 
C(12')-C(11')-H(11') 120.8(16) 
C(11')-C(12')-C(7') 121.5(2) 
C(11')-C(12')-H(12') 120.7(13) 
C(7')-C(12')-H(12') 117.9(13) 
C(14')-C(13')-C(18') 117.7(2) 
C(14')-C(13')-C(6') 121.19(19) 
C(18')-C(13')-C(6') 121.10(18) 
C(15')-C(14')-C(13') 120.7(2) 
C(15')-C(14')-H(14') 118.7(8) 
C(13')-C(14')-H(14') 120.4(8) 
C(16')-C(15')-C(14') 121.0(2) 
C(16')-C(15')-H(15') 120.4(15) 
C(14')-C(15')-H(15') 118.6(16) 
C(15')-C(16')-C(17') 119.5(2) 
C(15')-C(16')-H(16') 120.8(14) 
C(17')-C(16')-H(16') 119.7(14) 
C(16')-C(17')-C(18') 119.8(2) 
C(16')-C(17')-H(17') 120.2(14) 
C(18')-C(17')-H(17') 120.0(14) 
C(17')-C(18')-C(13') 121.4(2) 
C(17')-C(18')-H(18') 118.5(13) 
C(13')-C(18')-H(18') 120.1(13) 
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_____________________________________________________________ 
 
Table 11.   Anisotropic displacement parameters (Å2x 103)for liu158.  The anisotropic 
displacement factor exponent takes the form: -2p2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
N(1) 40(1)  27(1) 41(1)  2(1) 14(1)  1(1) 
B(1) 33(1)  24(1) 42(1)  -4(1) 11(1)  -5(1) 
C(1) 44(1)  31(1) 48(1)  5(1) 9(1)  2(1) 
C(2) 57(2)  39(1) 45(1)  12(1) 12(1)  -3(1) 
C(3) 58(2)  46(1) 44(1)  0(1) 24(1)  -9(1) 
C(4) 50(1)  32(1) 48(1)  0(1) 24(1)  1(1) 
C(5) 58(2)  35(1) 56(2)  -2(1) 25(1)  10(1) 
C(6) 35(1)  26(1) 35(1)  -4(1) 12(1)  2(1) 
C(7) 35(1)  28(1) 37(1)  3(1) 16(1)  1(1) 
C(8) 39(1)  39(1) 43(1)  3(1) 13(1)  1(1) 
C(9) 37(1)  49(2) 58(2)  12(1) 14(1)  5(1) 
C(10) 43(1)  38(1) 79(2)  17(1) 33(1)  12(1) 
C(11) 52(2)  32(1) 70(2)  -2(1) 32(1)  3(1) 
C(12) 40(1)  33(1) 49(1)  -2(1) 16(1)  2(1) 
C(13) 35(1)  25(1) 37(1)  3(1) 15(1)  8(1) 
C(14) 46(1)  42(1) 39(1)  0(1) 19(1)  6(1) 
C(15) 54(2)  54(2) 52(2)  8(1) 33(1)  9(1) 
C(16) 40(1)  49(1) 67(2)  11(1) 30(1)  6(1) 
C(17) 35(1)  45(1) 54(2)  4(1) 11(1)  1(1) 
C(18) 41(1)  36(1) 38(1)  6(1) 15(1)  3(1) 
N(1') 44(1)  29(1) 36(1)  3(1) 11(1)  3(1) 
B(1') 44(1)  26(1) 28(1)  6(1) 13(1)  -1(1) 
C(1') 60(2)  31(1) 43(1)  7(1) 22(1)  10(1) 
C(2') 50(2)  45(1) 55(2)  18(1) 24(1)  18(1) 
C(3') 38(1)  49(1) 49(1)  14(1) 9(1)  3(1) 
C(4') 43(1)  36(1) 41(1)  3(1) 12(1)  0(1) 
C(5') 62(2)  40(1) 52(2)  -9(1) 16(1)  -2(1) 
C(6') 37(1)  31(1) 33(1)  0(1) 10(1)  -7(1) 
C(7') 34(1)  30(1) 32(1)  2(1) 8(1)  1(1) 
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C(8') 42(1)  40(1) 40(1)  -1(1) 17(1)  -3(1) 
C(9') 48(1)  54(2) 42(1)  -2(1) 20(1)  5(1) 
C(10') 54(1)  40(1) 39(1)  -5(1) 11(1)  9(1) 
C(11') 57(2)  34(1) 45(1)  -5(1) 14(1)  -6(1) 
C(12') 53(1)  39(1) 40(1)  -3(1) 21(1)  -7(1) 
C(13') 38(1)  26(1) 35(1)  -4(1) 11(1)  2(1) 
C(14') 37(1)  47(1) 41(1)  -1(1) 8(1)  3(1) 
C(15') 43(1)  69(2) 46(2)  6(1) 5(1)  8(1) 
C(16') 63(2)  44(1) 33(1)  3(1) 9(1)  10(1) 
C(17') 57(2)  35(1) 43(1)  -1(1) 24(1)  5(1) 
C(18') 40(1)  37(1) 43(1)  -1(1) 13(1)  4(1) 
 
 
Table 12.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) 
for liu158. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(5A) 2127 -4127 4070 73 
H(5B) 2127 -2101 3895 73 
H(5C) 1649 -3300 3652 73 
H(5'A) 873 -4168 5895 80 
H(5'B) 665 -2174 5795 80 
H(5'C) 605 -3337 6228 80 
H(1) 2124(8) -4580(30) 4780(8) 48(6) 
H(2) 1889(8) -3890(30) 5443(9) 50(6) 
H(3) 1355(9) -1350(30) 5443(9) 65(7) 
H(4) 1092(8) 440(30) 4731(8) 47(6) 
H(6) 1216(7) -340(30) 3513(8) 37(5) 
H(8) 443(8) 700(30) 3110(8) 47(6) 
H(9) -154(9) 2930(30) 2970(9) 61(7) 
H(10) -4(9) 5420(40) 3520(9) 66(8) 
H(11) 749(9) 5550(40) 4228(9) 62(7) 
H(12) 1341(8) 3340(30) 4361(9) 50(6) 
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H(14) 1583(7) 1280(30) 3037(8) 36(5) 
H(15) 2287(9) 2880(30) 3044(10) 62(7) 
H(16) 2909(9) 3770(30) 3788(8) 56(7) 
H(17) 2865(9) 3020(30) 4571(9) 60(7) 
H(18) 2178(7) 1450(30) 4571(8) 39(6) 
H(1') 1632(7) -4440(30) 6253(8) 39(6) 
H(2') 2421(9) -3680(30) 6813(9) 61(7) 
H(3') 2577(8) -1140(30) 7360(8) 50(6) 
H(4') 1898(8) 700(30) 7287(8) 52(7) 
H(6') 579(8) -400(30) 6599(7) 42(6) 
H(8') 452(8) 600(30) 7288(8) 46(6) 
H(9') 504(8) 2790(30) 7899(8) 52(6) 
H(10') 1004(8) 5390(30) 7961(9) 58(7) 
H(11') 1416(9) 5680(40) 7425(9) 65(8) 
H(12') 1366(7) 3460(30) 6824(8) 42(6) 
H(14') -122(6) 810(20) 5940(6) 13(4) 
H(15') -381(10) 2250(40) 5134(10) 73(8) 
H(16') 176(8) 3340(30) 4792(9) 53(7) 
H(17') 1018(8) 3160(30) 5255(8) 50(7) 
H(18') 1333(9) 1790(30) 6046(8) 52(7) 
 
 
Table 4.13.  Torsion angles [°] for liu158. 
________________________________________________________________ 
C(1)-N(1)-B(1)-C(4) -3.0(3) 
C(5)-N(1)-B(1)-C(4) 176.90(19) 
C(1)-N(1)-B(1)-C(6) 174.12(18) 
C(5)-N(1)-B(1)-C(6) -5.9(3) 
B(1)-N(1)-C(1)-C(2) 1.2(3) 
C(5)-N(1)-C(1)-C(2) -178.7(2) 
N(1)-C(1)-C(2)-C(3) 0.6(4) 
C(1)-C(2)-C(3)-C(4) -0.4(4) 
C(2)-C(3)-C(4)-B(1) -1.6(3) 
N(1)-B(1)-C(4)-C(3) 3.2(3) 
C(6)-B(1)-C(4)-C(3) -173.7(2) 
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N(1)-B(1)-C(6)-C(7) 169.16(17) 
C(4)-B(1)-C(6)-C(7) -14.0(3) 
N(1)-B(1)-C(6)-C(13) -65.2(2) 
C(4)-B(1)-C(6)-C(13) 111.6(2) 
C(13)-C(6)-C(7)-C(8) 120.7(2) 
B(1)-C(6)-C(7)-C(8) -112.5(2) 
C(13)-C(6)-C(7)-C(12) -57.3(2) 
B(1)-C(6)-C(7)-C(12) 69.5(2) 
C(12)-C(7)-C(8)-C(9) 0.9(3) 
C(6)-C(7)-C(8)-C(9) -177.2(2) 
C(7)-C(8)-C(9)-C(10) -0.7(3) 
C(8)-C(9)-C(10)-C(11) 0.1(4) 
C(9)-C(10)-C(11)-C(12) 0.2(4) 
C(10)-C(11)-C(12)-C(7) 0.0(3) 
C(8)-C(7)-C(12)-C(11) -0.6(3) 
C(6)-C(7)-C(12)-C(11) 177.5(2) 
C(7)-C(6)-C(13)-C(14) -82.0(2) 
B(1)-C(6)-C(13)-C(14) 149.40(19) 
C(7)-C(6)-C(13)-C(18) 96.5(2) 
B(1)-C(6)-C(13)-C(18) -32.1(3) 
C(18)-C(13)-C(14)-C(15) -2.6(3) 
C(6)-C(13)-C(14)-C(15) 175.90(19) 
C(13)-C(14)-C(15)-C(16) 1.2(3) 
C(14)-C(15)-C(16)-C(17) 1.0(4) 
C(15)-C(16)-C(17)-C(18) -1.7(4) 
C(16)-C(17)-C(18)-C(13) 0.2(3) 
C(14)-C(13)-C(18)-C(17) 1.9(3) 
C(6)-C(13)-C(18)-C(17) -176.55(19) 
C(1')-N(1')-B(1')-C(4') -2.4(3) 
C(5')-N(1')-B(1')-C(4') 176.21(19) 
C(1')-N(1')-B(1')-C(6') 176.34(18) 
C(5')-N(1')-B(1')-C(6') -5.1(3) 
B(1')-N(1')-C(1')-C(2') 1.0(3) 
C(5')-N(1')-C(1')-C(2') -177.6(2) 
N(1')-C(1')-C(2')-C(3') 0.8(3) 
C(1')-C(2')-C(3')-C(4') -1.2(3) 
  
 
197 
C(2')-C(3')-C(4')-B(1') -0.3(3) 
N(1')-B(1')-C(4')-C(3') 2.0(3) 
C(6')-B(1')-C(4')-C(3') -176.6(2) 
N(1')-B(1')-C(6')-C(7') 167.39(17) 
C(4')-B(1')-C(6')-C(7') -14.1(3) 
N(1')-B(1')-C(6')-C(13') -66.4(2) 
C(4')-B(1')-C(6')-C(13') 112.2(2) 
C(13')-C(6')-C(7')-C(8') 121.5(2) 
B(1')-C(6')-C(7')-C(8') -111.1(2) 
C(13')-C(6')-C(7')-C(12') -57.1(3) 
B(1')-C(6')-C(7')-C(12') 70.3(2) 
C(12')-C(7')-C(8')-C(9') 0.3(3) 
C(6')-C(7')-C(8')-C(9') -178.34(19) 
C(7')-C(8')-C(9')-C(10') -0.2(3) 
C(8')-C(9')-C(10')-C(11') 0.1(3) 
C(9')-C(10')-C(11')-C(12') 0.0(4) 
C(10')-C(11')-C(12')-C(7') 0.0(4) 
C(8')-C(7')-C(12')-C(11') -0.2(3) 
C(6')-C(7')-C(12')-C(11') 178.4(2) 
C(7')-C(6')-C(13')-C(14') -88.4(2) 
B(1')-C(6')-C(13')-C(14') 143.2(2) 
C(7')-C(6')-C(13')-C(18') 91.5(2) 
B(1')-C(6')-C(13')-C(18') -36.9(3) 
C(18')-C(13')-C(14')-C(15') -0.6(3) 
C(6')-C(13')-C(14')-C(15') 179.3(2) 
C(13')-C(14')-C(15')-C(16') 0.5(4) 
C(14')-C(15')-C(16')-C(17') -0.3(4) 
C(15')-C(16')-C(17')-C(18') 0.2(4) 
C(16')-C(17')-C(18')-C(13') -0.4(3) 
C(14')-C(13')-C(18')-C(17') 0.6(3) 
C(6')-C(13')-C(18')-C(17') -179.33(19) 
________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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APPENDIX C 
SUPPORTING INFORMATION FOR CHAPTER V:  
1,2-DIHYDRO-1,2-AZABORINE SILYL-DEPROTECTION USING AMIDE 
FUNCTIONALITY: TOWARD BN-ACETANILIDE 
 
X-ray Crystal Structure Determination of 2 (Figure 5.1). 
General Procedure: Diffraction intensity data for all compounds were collected 
with a Bruker Smart Apex CCD diffractometer at 173(2) K using MoK - radiation 
(0.71073 Å). The structures were solved using direct methods, completed by subsequent 
difference Fourier syntheses, and refined by full matrix least-squares procedures on F2. 
All non-H atoms were refined with anisotropic thermal parameters. H atoms were found 
on the residual density map and refined with isotropic thermal parameters except for 
those in two disordered -CH2- groups in one of two symmetrically independent 
molecules of compound 4, which were treated in the calculated positions and refined in a 
rigid group model. All software and sources scattering factors are contained in the 
SHELXTL (6.10) program package (G.Sheldrick, Bruker XRD, Madison, WI). 
Crystallographic data and some details of data collection and crystal structure refinement 
for 1-5 are given in the following tables. 
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Crystallographic Data for Compound 2 (Liu 81) 
 
 
 
Table 1.  Crystal data and structure refinement for Liu 81 (BN-Acetanilide 2). 
 
Identification code  liu81 
Empirical formula  C6 H9 B N2 O 
Formula weight  135.96 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pbca 
Unit cell dimensions a = 9.5308(14) Å a= 90°. 
 b = 7.3968(11) Å b= 90°. 
 c = 20.531(3) Å g = 90°. 
Volume 1447.4(4) Å3 
Z 8 
Density (calculated) 1.248 Mg/m3 
Absorption coefficient 0.085 mm-1 
F(000) 576 
Crystal size 0.48 x 0.25 x 0.04 mm3 
Theta range for data collection 1.98 to 26.99°. 
Index ranges -12<=h<=12, -9<=k<=9, -25<=l<=26 
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Reflections collected 14502 
Independent reflections 1578 [R(int) = 0.0419] 
Completeness to theta = 26.99° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9966 and 0.9606 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1578 / 0 / 127 
Goodness-of-fit on F2 1.000 
Final R indices [I>2sigma(I)] R1 = 0.0394, wR2 = 0.0965 
R indices (all data) R1 = 0.0556, wR2 = 0.1064 
Largest diff. peak and hole 0.223 and -0.147 e.Å-3 
 
 
Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters 
(Å2x 103) for liu81.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________ 
O(1) 7557(1) 1386(1) 4784(1) 37(1) 
N(1) 8093(1) 594(2) 6076(1) 32(1) 
N(2) 9594(1) 2221(2) 5265(1) 31(1) 
B(1) 9336(2) 1583(2) 5925(1) 30(1) 
C(1) 7775(2) 40(2) 6692(1) 37(1) 
C(2) 8634(2) 400(2) 7197(1) 40(1) 
C(3) 9911(2) 1343(2) 7096(1) 40(1) 
C(4) 10299(2) 1932(2) 6495(1) 36(1) 
C(5) 8726(1) 2101(2) 4743(1) 30(1) 
C(6) 9232(2) 2904(2) 4115(1) 38(1) 
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Table 3.   Bond lengths [Å] and angles [°] for liu81. 
_____________________________________________________ 
O(1)-C(5)  1.2360(16) 
N(1)-C(1)  1.3640(19) 
N(1)-B(1)  1.4266(19) 
N(1)-H(1N)  0.898(17) 
N(2)-C(5)  1.3571(18) 
N(2)-B(1)  1.455(2) 
N(2)-H(2N)  0.856(18) 
B(1)-C(4)  1.510(2) 
C(1)-C(2)  1.348(2) 
C(1)-H(1)  0.972(17) 
C(2)-C(3)  1.418(2) 
C(2)-H(2)  0.999(17) 
C(3)-C(4)  1.359(2) 
C(3)-H(3)  0.973(18) 
C(4)-H(4)  0.970(18) 
C(5)-C(6)  1.499(2) 
C(6)-H(6A)  0.93(3) 
C(6)-H(6B)  1.00(2) 
C(6)-H(6C)  0.95(2) 
C(1)-N(1)-B(1) 122.68(13) 
C(1)-N(1)-H(1N) 117.7(10) 
B(1)-N(1)-H(1N) 119.6(10) 
C(5)-N(2)-B(1) 127.64(12) 
C(5)-N(2)-H(2N) 115.5(11) 
B(1)-N(2)-H(2N) 116.7(11) 
N(1)-B(1)-N(2) 120.59(13) 
N(1)-B(1)-C(4) 115.08(14) 
N(2)-B(1)-C(4) 124.31(13) 
C(2)-C(1)-N(1) 121.33(14) 
C(2)-C(1)-H(1) 121.6(10) 
N(1)-C(1)-H(1) 117.0(10) 
C(1)-C(2)-C(3) 120.31(15) 
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C(1)-C(2)-H(2) 119.3(9) 
C(3)-C(2)-H(2) 120.4(9) 
C(4)-C(3)-C(2) 121.65(14) 
C(4)-C(3)-H(3) 120.2(10) 
C(2)-C(3)-H(3) 118.1(10) 
C(3)-C(4)-B(1) 118.90(14) 
C(3)-C(4)-H(4) 120.1(10) 
B(1)-C(4)-H(4) 121.0(10) 
O(1)-C(5)-N(2) 121.60(13) 
O(1)-C(5)-C(6) 121.19(13) 
N(2)-C(5)-C(6) 117.21(13) 
C(5)-C(6)-H(6A) 110.5(14) 
C(5)-C(6)-H(6B) 113.0(13) 
H(6A)-C(6)-H(6B) 102.6(19) 
C(5)-C(6)-H(6C) 115.7(13) 
H(6A)-C(6)-H(6C) 112(2) 
H(6B)-C(6)-H(6C) 101.4(17) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
 
Table 4. Anisotropic displacement parameters (Å2x 103)for liu81.  The anisotropic 
Displacement factor exponent takes the form:- 2p2[ h
2
a*
2
U
11
 + ... + 2 h k a* b* U
12
 ] 
________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
________________________________________________________________________ 
O(1) 26(1)  37(1) 47(1)  -3(1) -4(1)  -3(1) 
N(1) 26(1)  29(1) 39(1)  -2(1) -3(1)  -2(1) 
N(2) 22(1)  30(1) 42(1)  -3(1) 0(1)  -2(1) 
B(1) 26(1)  22(1) 42(1)  -4(1) 1(1)  4(1) 
C(1) 36(1)  29(1) 47(1)  2(1) 3(1)  -2(1) 
C(2) 47(1)  33(1) 41(1)  5(1) -1(1)  3(1) 
C(3) 40(1)  36(1) 44(1)  -1(1) -12(1)  6(1) 
C(4) 27(1)  31(1) 49(1)  -3(1) -5(1)  1(1) 
C(5) 26(1)  25(1) 41(1)  -5(1) 0(1)  4(1) 
C(6) 36(1)  38(1) 41(1)  -2(1) 1(1)  3(1) 
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Table 5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 
103) for liu81. 
________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________ 
 
H(1N) 7464(18) 370(20) 5760(7) 40(4) 
H(2N) 10410(19) 2660(20) 5187(8) 42(5) 
H(1) 6887(18) -580(20) 6752(8) 45(4) 
H(2) 8345(16) 30(20) 7646(8) 42(4) 
H(3) 10506(18) 1580(20) 7471(9) 47(5) 
H(4) 11181(18) 2570(20) 6438(8) 44(4) 
H(6A) 8770(20) 3980(40) 4029(11) 89(7) 
H(6B) 8990(20) 2150(30) 3728(11) 81(7) 
H(6C) 10220(20) 3010(30) 4071(10) 74(6) 
 
Table 6.  Torsion angles [°] for liu81. 
________________________________________________________________ 
C(1)-N(1)-B(1)-N(2) -176.96(12) 
C(1)-N(1)-B(1)-C(4) 1.58(19) 
C(5)-N(2)-B(1)-N(1) 4.7(2) 
C(5)-N(2)-B(1)-C(4) -173.69(13) 
B(1)-N(1)-C(1)-C(2) -0.2(2) 
N(1)-C(1)-C(2)-C(3) -1.2(2) 
C(1)-C(2)-C(3)-C(4) 1.0(2) 
C(2)-C(3)-C(4)-B(1) 0.5(2) 
N(1)-B(1)-C(4)-C(3) -1.7(2) 
N(2)-B(1)-C(4)-C(3) 176.76(13) 
B(1)-N(2)-C(5)-O(1) -0.2(2) 
B(1)-N(2)-C(5)-C(6) 178.77(13) 
________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Table 7.  Hydrogen bonds for liu81 [Å and °]. 
_______________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
________________________________________________________________________ 
 N(1)-H(1N)...O(1) 0.898(17) 2.144(15) 2.7635(16) 125.5(13) 
 N(2)-H(2N)...O(1)#1 0.856(18) 2.167(18) 3.0074(16) 167.2(15) 
________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 x+1/2,-y+1/2,-z+1      
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